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Abstract
A multicentre, randomised controlled trial comparing the
clinical effectiveness and cost-effectiveness of early
nutritional support via the parenteral versus the enteral
route in critically ill patients (CALORIES)
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M Zia Sadique,2 Richard D Grieve,2 Ruth R Canter,1
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Background: Malnutrition is a common problem in critically ill patients in UK NHS critical care units.
Early nutritional support is therefore recommended to address deficiencies in nutritional state and related
disorders in metabolism. However, evidence is conflicting regarding the optimum route (parenteral or
enteral) of delivery.
Objectives: To estimate the effect of early nutritional support via the parenteral route compared with the
enteral route on mortality at 30 days and on incremental cost-effectiveness at 1 year. Secondary objectives
were to compare the route of early nutritional support on duration of organ support; infectious and
non-infectious complications; critical care unit and acute hospital length of stay; all-cause mortality at
critical care unit and acute hospital discharge, at 90 days and 1 year; survival to 90 days and 1 year;
nutritional and health-related quality of life, resource use and costs at 90 days and 1 year; and estimated
lifetime incremental cost-effectiveness.
Design: A pragmatic, open, multicentre, parallel-group randomised controlled trial with an integrated
economic evaluation.
Setting: Adult general critical care units in 33 NHS hospitals in England.
Participants: 2400 eligible patients.
Interventions: Five days of early nutritional support delivered via the parenteral (n= 1200) and enteral
(n= 1200) route.
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Main outcome measures: All-cause mortality at 30 days after randomisation and incremental net benefit
(INB) (at £20,000 per quality-adjusted life-year) at 1 year.
Results: By 30 days, 393 of 1188 (33.1%) patients assigned to receive early nutritional support via the
parenteral route and 409 of 1195 (34.2%) assigned to the enteral route had died [p= 0.57; absolute risk
reduction 1.15%, 95% confidence interval (CI) −2.65 to 4.94; relative risk 0.97 (0.86 to 1.08)]. At 1 year,
INB for the parenteral route compared with the enteral route was negative at −£1320 (95% CI −£3709 to
£1069). The probability that early nutritional support via the parenteral route is more cost-effective – given
the data – is < 20%. The proportion of patients in the parenteral group who experienced episodes of
hypoglycaemia (p= 0.006) and of vomiting (p< 0.001) was significantly lower than in the enteral group.
There were no significant differences in the 15 other secondary outcomes and no significant interactions
with pre-specified subgroups.
Limitations: Blinding of nutritional support was deemed to be impractical and, although the primary
outcome was objective, some secondary outcomes, although defined and objectively assessed, may have
been more vulnerable to observer bias.
Conclusions: There was no significant difference in all-cause mortality at 30 days for early nutritional
support via the parenteral route compared with the enteral route among adults admitted to critical care
units in England. On average, costs were higher for the parenteral route, which, combined with similar
survival and quality of life, resulted in negative INBs at 1 year.
Future work: Nutritional support is a complex combination of timing, dose, duration, delivery and type,
all of which may affect outcomes and costs. Conflicting evidence remains regarding optimum provision to
critically ill patients. There is a need to utilise rigorous consensus methods to establish future priorities for
basic and clinical research in this area.
Trial registration: Current Controlled Trials ISRCTN17386141.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 20, No. 28. See the NIHR Journals Library website
for further project information.
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Plain English summary
There are two main ways to way to feed seriously ill patients who cannot eat for themselves: eitherdirectly into the bloodstream (the intravenous or parenteral route) or into the stomach (via a tube
inserted through the mouth, nose or through the skin of the abdomen – the enteral route). It is not
known which is best, particularly during the first few days of a serious illness. The aim of this study was to
investigate which route is best for patients who have just been admitted to an intensive care unit of the
UK NHS. We also measured the costs of each method.
A total of 2400 patients from 33 NHS hospitals took part in the study. Their feeding route was chosen at
random. A total of 1200 patients were fed intravenously (the parenteral route) and 1200 patients were fed
into the stomach (the enteral route).
There was no significant difference between the groups in the number of patients who died at 1, 3 or
12 months. Patients who received nutritional support via the stomach had more vomiting and more
diarrhoea. At 12 months, the overall costs of intravenous feeding were £28,354 per patient and £26,775 for
feeding via the stomach. The additional costs of intravenous feeding were not justified by better outcomes.
The results of the study support continuing to feed seriously ill patients via the stomach when this
is possible.
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Scientific summary
Background
Malnutrition is a common problem in critically ill patients in UK NHS critical care units and early nutritional
support is therefore recommended. Evidence is conflicting regarding the optimum route of delivery.
Interpretation of meta-analyses of trials comparing delivery via the enteral and parenteral routes in critically
ill patients is complicated by small sample size; poor methodological quality; select groups of critically ill
patients studied; lack of standardised definitions for outcome measures; and interventions combining more
than one element of nutritional support.
The enteral route is the mainstay of nutritional support in critical care but is frequently associated with
gastrointestinal intolerance and underfeeding. In contrast, the parenteral route, although more invasive
and expensive, is more likely to secure delivery of intended nutrition. The parenteral route has been
associated with more risks and complications (e.g. infections) than the enteral route, but recent
improvements in the delivery, formulation and monitoring of parenteral nutrition (PN) justify further
comparison and evaluation, particularly in the early phase of critical illness. Economic evidence surrounding
the optimum route of delivery is largely based on evidence of effectiveness of questionable methodological
quality and narrow focus on upfront acquisition costs, and full economic evaluation is lacking.
In view of this, in late 2007 the National Institute for Health Research (NIHR) Health Technology
Assessment programme called for a large pragmatic randomised controlled trial to determine the optimal
route of delivery of early nutritional support in critically ill adults. The aim of the CALORIES trial was to
compare the clinical effectiveness and cost-effectiveness of early nutritional support, delivered via the
parenteral route compared with the enteral route, in critically ill patients.
Objectives
The primary objectives of the CALORIES trial were to estimate:
l the effect of early nutritional support via the parenteral compared with the enteral route on all-cause
mortality at 30 days, and
l the incremental cost-effectiveness of early nutritional support via the parenteral compared with the
enteral route at 1 year.
The secondary objectives of the CALORIES trial were to compare delivery via the parenteral and enteral
routes on:
l duration of specific and overall organ support in the critical care unit
l infectious and non-infectious complications in the critical care unit
l duration of critical care unit and acute hospital length of stay
l duration of survival at 90 days and 1 year
l mortality at discharge from the critical care unit and acute hospital
l mortality at 90 days and 1 year
l nutritional and health-related quality of life at 90 days and 1 year
l resource use and costs at 90 days and 1 year, and
l estimated lifetime incremental cost-effectiveness.
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Methods
Trial design and governance
The CALORIES trial was a pragmatic, open, multicentre, parallel-group, randomised controlled trial with
integrated economic evaluation. It was nested in the Case Mix Programme, the national clinical audit of
adult general critical care units in England, Wales and Northern Ireland, co-ordinated by the Intensive Care
National Audit & Research Centre (ICNARC). The North West London Research Ethics Committee approved
the trial. The NIHR funded the trial, and convened Trial Steering Committee and independent Data
Monitoring and Ethics Committee. The trial was sponsored by ICNARC and co-ordinated by the ICNARC
Clinical Trials Unit.
Participants: sites and patients
The trial aimed to recruit a representative sample of at least 20 adult, general critical care units from the
UK. Inclusion criteria were:
l active participation in the Case Mix Programme
l established protocols for PN and enteral nutrition, reflecting mainstream practice
l pre-existing implementation of bundles as promoted by the NHS to prevent development of
bloodstream infection and ventilator-associated pneumonia
l pre-existing prophylaxis protocol for prevention of venous thromboembolism
l pre-existing glycaemic control protocol in line with international guidelines
l agreement to incorporate the CALORIES trial into routine unit practice, including prior agreement from
all consultants to adhere to randomisation
l agreement to recruit all eligible patients and to maintain a screening log
l sign up from the clinical director, senior nurse manager, dietitian/clinical nutritionist and
pharmacist, and
l identification of a dedicated research nurse.
Patients aged ≥ 18 years were eligible if, within 36 hours of their original critical care unit admission,
they were an unplanned admission expected to receive nutritional support for ≥ 2 days, not planned to be
discharged within 3 days from the unit and did not meet any exclusion criteria.
Following informed consent from the patient or agreement from a personal/professional consultee,
patients were randomly allocated, 1 : 1, via 24-hour telephone randomisation, to early nutritional support
via either the parenteral or enteral route. Allocation was by minimisation with a random component based
on site, age, surgical status and malnutrition status (based on clinical judgement).
Treatment groups
Following randomisation, nutritional support was commenced as soon as possible. Blinding to treatment
allocation was not possible. As a pragmatic trial, the protocol did not dictate use of specific protocols/
products for delivery of nutritional support but ensured that local procedures/practices fell within
common boundaries.
Early nutritional support was delivered via either the parenteral or enteral route for 5 days (intervention
period) unless the patient transitioned to exclusive oral feeding or was discharged from the critical care
unit before this. Patients were able to start oral feeding, if clinically indicated, during the 5 days.
For patients who were randomised to the parenteral route, a central venous catheter, with a dedicated
lumen, was inserted and positioned in accordance with NHS guidelines. Patients received a standard
parenteral feed, obtained from the unit’s usual supplier, and used within the licence indication, which
contained 1365–2540 total kcal/bag and 7.2–16.0 g nitrogen/bag. Enteral ‘trickle feeding’ (‘trophic feeding’)
was not permitted for the 5-day intervention period.
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For patients randomised to the enteral route, a nasogastric or nasojejunal tube was inserted and
positioned in accordance with UK National Patient Safety Agency guidelines. Patients received a standard
enteral feed, obtained from the unit’s usual supplier, and used within the licence indication, which
contained 1365–2540 total kcal/day and 7.2–16.0 g nitrogen/day.
In both groups, unit staff aimed to feed patients to a target of 25 kcal/kg/day (based on actual body
weight) within 48–72 hours.
Data sources
A secure, dedicated data entry system enabled trial data to be entered by staff at units. Eligibility, baseline,
intervention, physiology and location of care data to hospital discharge were collected by sites. Following
linkage with the Health and Social Care Information Centre Data Linkage and Extract Service to confirm
mortality, a Health Services Questionnaire and a EuroQol 5-dimension (5-level version) questionnaire
(EQ-5D-5L) were sent to patients at 90 days and 1 year. Linkage to the Case Mix Programme Database
provided information on subsequent admission(s) to adult general critical care following discharge from
acute hospital.
Analysis principles
All analyses were by intention to treat, following a pre-specified statistical analysis plan. A p-value of
0.05 was considered statistically significant. All tests were two-sided, with no adjustment for multiple
comparisons. A sensitivity approach was taken when clinical effectiveness primary outcome data were
missing. Missing data for the cost-effectiveness analysis and for baseline data for adjusted analysis of
clinical outcomes were handled by multiple imputation using chained equations.
Outcome measures
The primary clinical effectiveness outcome was all-cause mortality at 30 days following randomisation and
the primary cost-effectiveness outcome was the incremental net benefit (INB) gained at 1 year following
randomisation, at a willingness-to-pay of £20,000 per quality-adjusted life-year (QALY).
Secondary outcomes were:
l number of days alive and free from organ support up to 30 days
l new confirmed or strongly suspected infectious complications and non-infectious complications in the
critical care unit
l duration of critical care unit and acute hospital length of stay
l duration of survival at 90 days and 1 year
l all-cause mortality at discharge from the critical care unit and acute hospital
l all-cause mortality at 90 days and 1 year
l nutritional and health-related quality of life at 90 days and 1 year
l resource use and costs at 90 days and 1 year, and
l estimated lifetime incremental cost-effectiveness.
Secondary analyses of primary outcomes included:
l adjusted analyses – adjusted for age, ICNARC Physiology Score, surgical status, degree of malnutrition
and a site-level random effect
l subgroup analyses to test for an interaction of treatment effect with pre-specified subgroups (age,
degree of malnutrition, acute severity of illness, mechanical ventilation, presence of cancer and time from
critical care unit admission to commencement of nutritional support)
l sensitivity analyses for missing data in the primary outcome, and
l adherence-adjusted analyses, using a structural mean model with an instrumental variable of
allocated treatment.
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A full cost-effectiveness analysis was undertaken to assess which route of delivery was most cost-effective.
The cost-effectiveness analysis was reported for three time periods: to 90 days; to 1 year; and lifetime.
For each time period, the analysis took a health and personal health services perspective, using information
on health-related quality of life at 90 days and 1 year, combined with information on vital status to report
QALYs, valued using the National Institute for Health and Care Excellence recommended threshold of
willingness-to-pay for a QALY gain (£20,000). The main assumptions were subjected to extensive
sensitivity analyses.
Results
Sites and patients
Overall, 11,108 patients were screened at 34 sites, with 2400 enrolled between 17 June 2011 and
2 March 2014. Twelve patients requested complete withdrawal, resulting in 2388 for initial analysis
(1191 parenteral, 1197 enteral). Five patients were lost to follow-up before 30 days, resulting in 2383 for
analysis of the primary outcome (1188 parenteral, 1195 enteral). Groups were well matched at baseline.
Adherence to protocol
Adherence to delivery of nutritional support during the intervention period was high. Ninety-seven per cent
of patients received nutritional support via the assigned route. Any non-adherence to the protocol was
reported for 150 (12.6%) patients in the parenteral group and 127 (10.6%) patients in the enteral group.
Delivery of care by treatment group
The median times to initiation of nutritional support were within 24 hours of critical care unit admission
(parenteral 23.5 hours, enteral 21.8 hours). The mean daily caloric intake during the intervention period was
higher in patients who were assigned to the parenteral (21.3 kcal/kg/day) than in those assigned to the
enteral (18.5 kcal/kg/day) route. In the majority of patients, the targeted delivery of 25 kcal/kg/day was not
achieved irrespective of route. The mean total protein was similar in the two groups (parenteral
0.7 g/kg/day, enteral 0.6 g/kg/day).
Primary outcome: clinical effectiveness
At 30 days, 393 (33.1%) patients in the parenteral group had died compared with 409 (34.2%) patients in
the enteral group, corresponding to an absolute risk reduction of 1.15 percentage points [95% confidence
interval (CI) −2.65 to 4.94; p= 0.57] and a relative risk of 0.97 (95% CI 0.86 to 1.08). This difference
remained non-significant after adjustment for baseline characteristics (odds ratio 0.95, 95% CI 0.79 to
1.13; p= 0.55).
Secondary outcomes: clinical effectiveness
The proportions of patients in the parenteral group who experienced episodes of hypoglycaemia
(p= 0.006) and vomiting (p< 0.001) were significantly lower than for patients in the enteral group.
There were no significant differences between groups for any of the 15 other secondary outcomes.
Subgroup and secondary analyses
There was no statistically significant interaction between the effect of treatment group on 30-day mortality
and any of the pre-specified subgroups. Sensitivity analyses for missing data and adherence-adjusted
analyses were consistent with the primary analysis.
Cost-effectiveness analysis
At 90 days, the parenteral group had higher mean total costs per patient compared with the enteral group
(£24,458 vs. £23,164). Health state profiles on the EQ-5D-5L were similar and resulted in similar mean
EQ-5D-5L utility scores for survivors (parenteral 0.655, enteral 0.654) and QALYs (parenteral 0.051,
enteral 0.050). The INB for the parenteral route compared with the enteral route was negative at −£1263
(95% CI −£2952 to £426).
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At 1 year, the mean total costs per patient were £28,354 for the parenteral group and £26,775 for the
enteral group. The mean EQ-5D-5L utility scores were similar between groups (parenteral group 0.684,
enteral group 0.683). At 1 year, a slightly higher proportion of patients in the parenteral group were alive
but the difference was not statistically significant and the 1-year QALYs were similar (parenteral group
0.348, enteral group 0.335). The INB for the parenteral group compared with the enteral group was
negative at −£1320 (95% CI −£3709 to £1069). At 1 year, the probability that early nutritional support
via the parenteral route is more cost-effective than via the enteral route – given the data – is < 20% at
the £20,000 willingness-to-pay threshold. When extrapolated to the lifetime, INB was positive (£440) but
with a wide 95% CI that included zero (−£3586 to £4466). The estimated INBs were similar across all
scenarios considered in the sensitivity analyses.
Conclusions
Among adults with an unplanned critical care unit admission, for whom early nutritional support could be
provided through either route (parenteral or enteral), there was no significant difference in mortality at
30 days according to route of delivery. In addition, there was no significant interaction on the basis of age,
degree of malnutrition, severity of illness, or timing of the initiation of nutritional support. The enteral
route was associated with significantly more episodes of hypoglycaemia and vomiting, but there were no
significant differences between groups in the duration of organ support, infectious complications, critical
care unit or hospital length of stay, or duration of survival up to 1 year. The energy target of 25 kcal/kg/day
was not reached in a majority of patients in each group.
Providing nutritional support to critically ill adult patients via the parenteral route compared with
the enteral route is unlikely to be cost-effective. At 1 year, on average, early nutritional support via the
parenteral route had higher intervention and morbidity costs, similar QALYs and a negative INB than
the enteral route. Cost-effectiveness results for the pre-specified subgroups were similar to the overall
results, and sensitivity analyses indicated that the conclusions were robust to alternative assumptions to
those in the base-case analysis. The lifetime analysis indicated that early nutritional support via the
parenteral route had higher mean lifetime QALY at higher additional mean costs, leading to a positive INB.
Implications for health care
The results of the CALORIES trial support the continuation of current, widespread practice in NHS critical
care units of delivering early nutritional support via the enteral route as both clinically effective and
cost-effective. However, they also challenge concerns about possible harm from delivering early nutritional
support via the parenteral route when such delivery is clinically indicated.
Recommendations for research
Recommendation 1
Evaluation of the longer-term outcomes for patients in the CALORIES trial should be extended beyond
1 year.
Recommendation 2
Following evaluation of the route for delivery of early nutritional support (CALORIES), a study utilising
rigorous consensus methods is required to establish future priorities for research on optimal nutritional
support for all/groups of critically ill patients.
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This trial is registered as ISRCTN17386141.
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Chapter 1 Introduction
Background and rationale
Malnutrition is a common problem in critically ill patients in UK NHS critical care units.1 The consequences
of malnutrition include vulnerability to complications, such as infection, which can lead to delays in
recovery. Early nutritional support is therefore recommended for critically ill patients to address both
deficiencies in nutritional state and related disorders in metabolism.
However, evidence is conflicting regarding the optimum route (parenteral or enteral) of delivery.2–4
Meta-analyses of the trials comparing nutritional support via the enteral and parenteral route in critically ill
patients have been published, but interpretation of their results is complicated by small sample size, poor
methodological quality, select groups of critically ill patients studied, lack of standardised definitions for
outcome measures and interventions combining more than one element of nutritional support, for
example timing and route.
In 2003, Heyland et al.2 reported no difference in mortality between patients given parenteral and enteral
nutritional support, but enteral was associated with a significant reduction in infections. Safety, cost and
feasibility led them to recommend enteral over parenteral in the critically ill adult patient. In 2004,
Gramlich et al.3 also found no difference in mortality but a significant reduction in infections with enteral
nutrition (EN).3 In addition, they reported no difference in length of unit stay or days on ventilation, but
indicated that there were insufficient data to analyse these statistically. Using a different methodological
approach to assessing quality of included studies (one less biased towards including the poorer-quality
studies), Simpson and Doig,4 in 2005, found a significant reduction in mortality but a significant increase
in infections with parenteral nutritional support compared with the enteral nutritional support. However,
the significant mortality benefit with parenteral nutrition (PN) appeared to exist when compared with the
provision of delayed, rather than early enteral nutritional support and thus this was not a like-for-like
comparison. Similar time-based analyses for infections were not possible as a result of insufficient data.
All of the meta-analyses highlighted the problems of combining data from poor-quality studies conducted
on heterogeneous patient populations (all were on select subgroups, such as head trauma, acute
pancreatitis, etc.) plus variation in the timing of measurement of mortality and, perhaps more importantly,
the nature and definitions for infections included and pooled (pneumonia, urinary tract, bacteraemia,
wound, line sepsis, etc.). Owing to incomplete reporting, it was not possible to classify and combine
infections based on risk of outcome (e.g. severe infection, moderate infection, subclinical infection).
The enteral route is the mainstay of nutritional support in critical care2,5,6 but it is frequently associated with
gastrointestinal intolerance and underfeeding.7,8 In contrast, the parenteral route though more invasive
and expensive is more likely to secure delivery of the intended nutrition.7 Historically, nutritional support via
the parenteral route has been associated with more risks and complications (e.g. infectious complications)
compared with the enteral route2–4 but recent improvements in the delivery, formulation and monitoring of
PN justify further comparison and evaluation of these routes of nutritional support, particularly in the early
phase of the illness.9,10 Economic evidence surrounding the optimum route of delivery of nutritional
support is largely based on evidence of effectiveness of questionable methodological quality and narrow
focus on upfront acquisition costs, and full economic evaluation is lacking.11
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In view of this, in late 2007, the National Institute for Health Research (NIHR) Health Technology
Assessment programme put out a call for a large pragmatic randomised controlled trial to be conducted to
determine the optimal route of delivery of early nutritional support in critically ill adults. In response to this
call, in 2008, we updated the most recent systematic review by Simpson and Doig (see Figure 1). Highly
sensitive search criteria identified a further 570 potentially relevant studies since May 2003. Following
detailed review of these studies, one additional randomised controlled trial comparing PN and EN was
identified.12 This paper reported the full results of a trial previously identified by Simpson and Doig as
having only interim results reported,13 but was excluded from their meta-analysis, as the enteral nutritional
support arm included immune-enhancing supplements. As the use of immune-enhancing supplements
was to be permitted in our study, we repeated the meta-analysis to include studies with supplementation
of either arm. This resulted in the inclusion of this trial and one additional randomised controlled trial
excluded from the Simpson and Doig meta-analysis on this criterion.14 The results of the updated
meta-analysis, including a total of 13 studies,12,14–25 indicated a non-significant survival benefit for
parenteral support [relative risk 0.82, 95% confidence interval (CI) 0.60 to 1.11] but an increased risk of
infection (relative risk 1.77, 95% CI 1.19 to 2.63) compared with enteral nutritional support (Figure 1).
Consequently, parenteral nutritional support in the critical care unit remained controversial and no clear
evidence existed as to the optimum route for delivery of early nutritional support to critically ill patients.
Aim
The aim of the CALORIES trial was to compare the clinical effectiveness and cost-effectiveness of early
nutritional support in critically ill patients, delivered via the parenteral compared with the enteral route.
Objectives
Primary
The primary objectives of the CALORIES trial were to estimate the:
l effect of early (defined as within 36 hours of the date/time of original critical care unit admission)
nutritional support via the parenteral route compared with early nutritional support via the enteral
route on all-cause mortality at 30 days, and
l incremental cost-effectiveness of early nutritional support via the parenteral route compared with early
nutritional support via the enteral route at 1 year.
Secondary
The secondary objectives of the CALORIES trial were to compare early nutritional support via the parenteral
and enteral routes for:
l duration of specific and overall organ support in the critical care unit
l infectious and non-infectious complications in the critical care unit
l duration of critical care unit and acute hospital length of stay
l duration of survival at 90 days and at 1 year
l mortality at discharge from the critical care unit and from acute hospital
l mortality at 90 days and at 1 year
l nutritional and health-related quality of life at 90 days and at 1 year
l resource use and costs at 90 days and at 1 year, and
l estimated lifetime incremental cost-effectiveness.
INTRODUCTION
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Chapter 2 Methods
Trial design
The CALORIES trial was a pragmatic, open, multicentre, parallel-group, randomised controlled trial with an
integrated economic evaluation.
The trial was nested in the Case Mix Programme, the national clinical audit of adult general critical care
units in England, Wales and Northern Ireland, established in 1995 and co-ordinated by Intensive Care
National Audit & Research Centre (ICNARC) (Scotland has its own separate national clinical audit).26
The Case Mix Programme is listed in the Department of Health’s ‘Quality Accounts’ for 2013–14 as
a recognised national audit by the National Advisory Group for Clinical Audit and Enquiries.
Nesting the CALORIES trial in the Case Mix Programme ensured an efficient design (with respect to
participating units and data collection) and facilitated efficient management of the study, including
monitoring recruitment.
Research governance
The trial was sponsored by ICNARC and co-ordinated by the ICNARC Clinical Trials Unit (CTU).
An ethics application was submitted to the North West London Research Ethics Committee on 28 October
2010 and the CALORIES trial received a favourable opinion on 16 December 2010 (reference number:
10/H0722/78). The protocol is available via www.nets.nihr.ac.uk/.
To ensure transparency, the trial was registered with the International Standard Randomised Controlled
Trial Number (ISRCTN) Registry on 25 March 2009. Registration was confirmed on 9 April 2009
(ISRCTN17386141).
The NIHR Clinical Research Network (CRN) Portfolio details high-quality clinical research studies that are
eligible for support from the NIHR CRN in England. The trial was adopted on to the NIHR CRN Portfolio on
24 March 2011 and was issued the NIHR CRN Portfolio number 10098.
Global NHS permissions were obtained from Central and East London Comprehensive Local Research
Network (CLRN) on 10 March 2011 and local NHS permissions were obtained from each participating NHS
trust. A clinical trial site agreement, based on the model agreement for non-commercial research in the
health service, was signed by each participating NHS trust and the sponsor (ICNARC).
Following guidelines from the NIHR, a Trial Steering Committee (TSC), with a majority of independent
members, was convened to oversee the trial on behalf of the funder (NIHR) and the sponsor (ICNARC).
The TSC met at least annually during the trial and comprised an independent chairperson; independent lay
members (representing patient perspectives); independent clinicians (specialising in critical care medicine);
the chief investigator (KR); and the lead clinical investigator (MM) representing the Trial Management
Group (TMG).
Additionally, an independent Data Monitoring and Ethics Committee (DMEC) was convened to monitor
trial data and ensure the safety of trial participants. The DMEC met at least annually during the trial;
it comprised two expert clinicians specialising in critical care medicine and was chaired by an
experienced statistician.
DOI: 10.3310/hta20280 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 28
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harvey et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5
Management of the trial
The trial manager was responsible for day-to-day management of the trial with support from the data
manager, trial statistician and research assistant. The TMG, chaired by the ICNARC CTU manager (SH), was
responsible for overseeing day-to-day management of the trial and comprised the chief investigator (KR),
trial dietitians (DB, ES) and co-investigators (GB, RB, DH, RL and MM). The TMG met regularly throughout
the trial to ensure adherence to the trial protocol and monitor the conduct and progress of the trial.
Network support
To maintain the profile of the trial, regular updates on trial progress were provided at quarterly meetings
of the NIHR CRN Critical Care Specialty Group and at local CLRN meetings. In addition, updates were
provided at national meetings, such as the Annual Meeting of the Case Mix Programme and the UK
Critical Care Research Forum.
Design and development of the protocol
Clinicians – including doctors, nurses and dietitians, from NHS critical care units across the UK – were
invited to a meeting in May 2010 to discuss the trial protocol. The purpose of the meeting was to provide
a forum for clinicians who had expressed an interest in taking part in the trial to discuss the trial protocol
in detail with the trial investigators. Following the meeting, minor changes were made to the trial
protocol to ensure clarity.
Amendments to the trial protocol
Following receipt of a favourable opinion of the trial protocol from the Research Ethics Committee on
16 December 2010, four substantial amendments were submitted and received favourable opinion.
In summary, these were:
l Amendment 1 (13 May 2011) – the personal/professional consultee consent form was replaced with a
personal/professional consultee agreement form to clarify that consultees were being asked for
agreement (not consent) for patients to participate in the trial according to the Mental Capacity Act
(2005)27 and the National Research Ethics Service Guidance for Researchers & Reviewers. The patient
information sheets (prospective and retrospective for the patient and for the personal/professional
consultee) and consent forms (patient consent form and retrospective patient consent form) had minor
administrative changes. A personal/professional consultee telephone agreement form was produced
to ensure that, in the situation that a personal/professional consultee was contacted via the telephone
for their opinion, this contact was documented. The trial protocol was amended to clarify the aim
of the trial – to compare early nutritional support delivered via the parenteral with early nutritional
support delivered via the enteral route – and to incorporate the most up-to-date version of the
EuroQoL 5-dimension (5-level version) questionnaire (EQ-5D-5L) to evaluate health-related quality of
life at 90 days and at 1 year.
l Amendment 2 (19 December 2011) – the letter to the patient’s general practitioner (GP) informing
them of the patient’s participation in the trial was amended for use in cases when the patient was
known to have died. The patient follow-up letters were amended to be specific to the follow-up time
point, that is 90 days and 1 year post-randomisation, and minor semantic changes were made to the
patient information sheets and consent/agreement forms.
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l Amendment 3 (4 October 2012) – following requests from research teams at sites, a CALORIES trial
information leaflet for family and friends was produced. The leaflet was placed in the critical care
unit relatives’ room, with the aim of providing relatives/friends of patients in critical care with a brief
overview of the trial. The exclusion criterion ‘known to be participating in an interventional study’ was
removed following review by the TMG; it was agreed that patients could be co-enrolled into two
interventional studies if, after careful consideration, there were no concerns about patient safety, risk of
biological interaction or the scientific integrity of the trial. Local principal investigators (PIs) were advised
to contact the ICNARC CTU on a case-by-case basis to discuss co-enrolment of patients. In addition,
minor semantic changes were made to the trial protocol and consent/consultee agreement forms.
l Amendment 4 (23 October 2013) – a patient newsletter was added to the follow-up questionnaire
pack that was sent to each patient at 90 days and 1 year post recruitment into the CALORIES trial.
NHS support costs
Trials in critical care are challenging and expensive to conduct. Unlike other areas of health care, such as
oncology, recruitment cannot take place solely within usual office hours. Resources are needed to enable
screening and recruitment 24 hours per day, 7 days per week. Patients with a critical illness can be admitted
to the critical care unit at any time of day or night, including weekends. Another challenge of critical care
research is the informed consent process, which often has to be completed within a short time frame,
as treatments are often time limited. Furthermore, critically ill patients usually lack the mental capacity to be
able to provide informed consent prior to randomisation, in which case it is necessary to involve a personal
or professional consultee in accordance with the Mental Capacity Act.27 Senior, experienced staff are
needed to be able to assess the patient’s mental capacity and to be able to effectively communicate
information about the trial to the patient and/or their relatives in a stressful situation.
To this end, resources equivalent to 0.5 whole-time equivalent (WTE) band 7 research nurse, 0.1 WTE
critical care consultant, 0.1 WTE band 7 dietitian and 1.4 hours per week of a band 6 pharmacist were
successfully agreed with the lead CLRN on 21 June 2011.
Resources were based on an estimated 175 eligible admissions per unit per year, of whom approximately
60 would be recruited and 30 randomised to receive early nutritional support via the parenteral route.
Using these recommendations, participating sites, assisted by the TMG, negotiated resources required
locally for the trial with their respective research and development departments and CLRNs.
Patient and public involvement
Engagement with patients was vital to the successful conduct of the trial. The original study proposal was
reviewed and endorsed by Patients on Intravenous and Nasogastric Nutritional Therapy support group.
Two former critical care patients were independent members of the TSC and they provided input into the
conduct of the trial, including reviewing literature to be given to patients and their families (e.g. patient
information sheets and patient newsletters).
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Participants: sites
The trial aimed to recruit a representative sample of at least 20 adult, general critical care units from the
UK. Adult, general critical care units were defined as intensive care units (ICUs) or combined intensive
care/high-dependency units. Stand-alone high-dependency units and specialist critical care units
(e.g. neurosciences, cardiothoracic, etc.) were not eligible for participation in the trial. The criteria for
inclusion were:
l active participation in the Case Mix Programme – defined as submission of data no later than 6 weeks
after the end of each quarter and returning corrected data validation reports no later than
6 weeks after receipt
l pre-existing, established protocols for PN and EN reflecting mainstream practice (reviewed and
approved by the TMG)
l pre-existing implementation of bundles as promoted by the NHS (NHS Saving Lives: reducing infection,
delivering clean and safe care – ‘High Impact Intervention No. 1: Central venous catheter’ and ‘High
Impact Intervention No. 5: Ventilator’) to prevent the development of bloodstream infection and
ventilator-associated pneumonia28,29
l pre-existing prophylaxis protocol for the prevention of venous thromboembolism
l glycaemic control protocol in line with international guidelines30
l agreement to incorporate the CALORIES trial into routine unit practice, including prior agreement –
from all consultants in the unit – to adhere to the patient’s randomly allocated route (parenteral or
enteral route) for delivery of early nutritional support
l agreement to recruit all eligible patients into the CALORIES trial and to maintain a screening log of
eligible patients who were not randomised, and patients who fulfilled the inclusion criteria but met
one or more of the exclusion criteria
l sign up from the unit clinical director, senior nurse manager, dietitian/clinical nutritionist and
pharmacist, and
l identification of a dedicated CALORIES trial research nurse.
All of the units actively participating in the Case Mix Programme were invited for expressions of interest
to take part in the trial. In addition, the trial was promoted through presentations at relevant national
meetings of professional organisations, such as the Intensive Care Society and at the UK Critical Care
Research Forum.
A PI, who was responsible for the conduct of the trial locally, was identified at each participating site.
Site initiation
Site teams from all participating sites attended a site initiation meeting prior to the commencement of
patient screening. Two site initiation meetings were held in London on 11 May 2011 and 8 June 2011,
attended by staff from 22 critical care units. The purpose of these meetings was to present the
background and rationale for the CALORIES trial and to discuss delivery of the protocol, including
screening and recruiting patients, delivery of early nutritional support via the parenteral and enteral routes,
data collection and validation, and safety monitoring. The operational challenges of conducting the trial
at sites were discussed in detail, including strategies for ensuring effective communication within the
critical care unit. The PI from each participating site was required to attend the meeting. If key research
staff were unable to attend the meeting, or new staff came into post, additional site initiation meetings
were conducted as required, either at sites or via teleconference. A standardised slide set from the site
initiation meetings was circulated to facilitate internal training within a participating site.
METHODS
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Investigator site file
An investigator site file was provided to all participating sites. This contained all essential documents for
the conduct of the trial and included the approved trial protocol; all relevant approvals (e.g. local NHS
permissions); a signed copy of the clinical trial site agreement; the delegation of trial duties log; copies of
the approved patient information sheets, patient consent form and personal/professional consultee
agreement forms; and all standard operating procedures, for example for screening participants, for
obtaining informed consent or consultee agreement, for randomising patients, for delivery of the
intervention, and for collecting and entering data onto the secure, dedicated, electronic case report form.
The site PI was responsible for maintaining the investigator site file. Responsible staff at sites were
authorised to carry out trial duties (e.g. consenting, delivering the intervention) by the site PI on the
delegation of trial duties log. This included a confirmation that the individual had been adequately training
to carry out the specific duty.
Site management
Communication
The trial manager, with support from the data manager and research assistant, maintained close contact
with the PI and trial team at participating sites by e-mail and telephone throughout the trial.
Teleconferences were held, initially every month then every 2 months, with trial teams at participating
sites. The purpose of these was to provide updates on trial progress and to provide a forum for site
teams to ask questions, discuss local barriers and challenges to the conduct of the trial, delivery of the
intervention and to share successes and best practice. Notes, including ‘hints and tips’, from the
teleconferences were distributed to all participating sites. The ICNARC CTU team facilitated further direct
communication between sites via an e-mail forum for research nurses.
Teleconferences were also held with individual site teams, as required, to address site-specific issues in the
conduct of the trial and/or to support training new staff.
Site monitoring visits
At least one routine monitoring visit was conducted at all participating sites during the trial. During the site
visit, the investigator site file was checked for completeness, that is, that all essential documents were
present; the patient consent forms and personal/professional consultee agreement forms were checked to
ensure that the relevant correctly completed form was present for every patient recruited into the trial; and
a random sample of patient case report forms were checked against the source data for accuracy and
completeness. After the visit, the PI and site team were provided with a report summarising the documents
that had been reviewed and actions required by the site team. The site PI was responsible for addressing
the actions and reporting back to the ICNARC CTU. Additional visits were conducted on a risk-based
approach, using recruitment rates, data quality and adherence to the protocol as central monitoring triggers.
Maintenance and motivation
During the trial, an e-mail was sent each month to site teams with an update on patient recruitment, and
a newsletter was sent every quarter. These provided an opportunity to clarify any issues related to the
conduct of the trial and to share ideas for maximising recruitment, as well as maintaining motivation and
involvement through regular updates on progress.
To maintain the profile of the trial at participating sites, posters were displayed in staff areas and at
relevant locations within the critical care unit, for example by the bedside or in EN and PN storage areas;
pocket cards (summarising the eligibility criteria) and branded pens were distributed to staff; and
certificates were given to clinical staff in recognition of their contribution to the trial.
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Support
A 24 hours per day, 7 days per week, telephone support service was available to site teams for advice on
screening and recruitment of patients and on delivery of the intervention. This ensured access to clinicians
and dietitians for answering any queries on delivery of the intervention.
Collaborators’ meeting
A collaborators’ meeting was held on 17 January 2013 to provide an update on trial progress, provide a
forum for site teams and investigators to discuss operational challenges to the trial and identify possible
solutions, and to share successes and best practice.
Participants: patients
The trial procedures for recruitment and follow-up of patients are summarised in Figure 2.
Eligibility met with 36 hours of ICU presentation
Screening
Via 24-hour central telephone randomisation
Randomisation
Primary clinical outcome – mortality
Follow-up: 30 days
• If a patient lacked mental capacity, agreement
   sought from personal/professional consultee
• Retrospective consent obtained from patient
   once mental capacity regained
Informed consent
(n = 1200)
Early nutritional support
via parenteral route
(n = 1200)
Early nutritional support
via enteral route
• Mortality
• Health-related quality of life, resource use
   and costs
Follow-up: 90 days
• Mortality
• Health-related quality of life, resource use
   and costs
Follow-up: 1 year
FIGURE 2 Summary of trial procedures for recruitment and follow-up of patients.
METHODS
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Eligibility
Patients were eligible for inclusion in the trial who, on admission (but within a time frame to obtain patient
consent/consultee agreement, randomise and start nutritional support within 36 hours of the date/time of
original critical care unit admission), were:
l an adult (defined as age ≥ 18 years)
l an unplanned admission (including planned admissions becoming unplanned, e.g. unexpected
postoperative complications)
l expected to receive nutritional support for ≥ 2 days in the critical care unit, and
l not planned to be discharged within 3 days (defined by clinical judgement) from the critical care unit.
Patients were excluded from the trial if they met any of the following criteria:
l had been in a critical care unit for > 36 hours (i.e. from the date/time of original critical care
unit admission)
l had been previously randomised into the CALORIES trial
l had pre-existing contraindications to PN or EN
l had received PN or EN within the 7 days prior to admission to the critical care unit
l had been admitted with a percutaneous endoscopic gastrostomy, percutaneous endoscopic
jejunostomy, needle/surgical jejunostomy or nasojejunal tube in situ
l had been admitted to the critical care unit for treatment of thermal injury (burns)
l had been admitted to the critical care unit for palliative care
l their expected stay in the UK was < 6 months, or
l known to be pregnant.
During the trial, on the advice of the Research Ethics Committee, patients who were known to have a
pre-existing condition, such as dementia, which would have precluded them from providing informed
consent at any point during the trial, were also excluded.
Screening and recruitment
Following attendance at a site initiation meeting, screening and recruitment was commenced at
participating units once the clinical trial site agreement had been signed and all of the necessary approvals
were in place.
To promote awareness of the trial and facilitate recruitment, posters providing information about the
CALORIES trial were displayed in the critical care unit and in family/visitor waiting rooms.
Potentially eligible patients were identified and approached by authorised members of staff about taking
part in the trial. Information about the trial was provided to the patient, which included the purpose of the
trial, the consequences of taking part or not, data security and funding of the trial. This information was
also provided in a patient information sheet (see Appendix 1), along with the name and contact details of
the local PI, which was given to the patient to read before making their decision to take part, or not, in
the trial.
If the patient lacked mental capacity (because of their acute illness) to understand the information about
the trial then, in accordance with the Mental Capacity Act,27 a personal consultee, who could be a relative
or close friend, was identified with whom to discuss the patient’s participation in the trial. If there was no
personal consultee available then the patient was provided with a professional consultee, for example an
independent mental capacity advocate appointed by the NHS hospital trust, with whom to discuss the
patient’s participation in the trial. The personal/professional consultee was provided with the same
information as for patients (see Appendix 1) along with an explanation that they were being asked for
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their agreement for the patient to take part in the trial. Patients and personal/professional consultees were
provided with an opportunity to ask questions before being invited to sign the consent form or personal/
professional consultee agreement form, as appropriate.
Informed consent
Staff members, who had received training on the background, rationale and purpose of the CALORIES
trial, and on the principles of the International Conference on Harmonisation Good Clinical Practice
guidelines, were authorised by the PI to take informed consent from patients or informed agreement from
a personal/professional consultee.
Once the staff member who was taking informed patient consent or consultee agreement was satisfied
that the patient or personal/professional consultee had read and understood the patient information sheet,
and that all of his/her questions about the trial had been answered, the patient or personal/professional
consultee was invited to sign the patient consent form or personal/professional consultee agreement form,
as appropriate.
For patients who had lacked mental capacity prior to randomisation, informed consent to continue
participating in the trial was sought as soon as possible after the patient had regained mental capacity.
If a patient did not regain mental capacity then, if possible, for patients entered via professional consultee
agreement, agreement from a personal consultee was obtained for the patient to continue participating in
the trial.
Randomisation and allocation procedure
Following informed consent from the patient or informed agreement from a personal/professional
consultee, eligible patients were randomised via a central 24 hours per day, 7 days per week, telephone
randomisation service hosted by Sealed Envelope Ltd. Patients were allocated, 1 : 1, to early nutritional
support via either the parenteral route or the enteral route, by minimisation with a random component
(each patient being allocated with 80% probability to the treatment group that would minimise
imbalance). Minimisation was based on the following factors: site; age (< 65 years or ≥ 65 years); surgical
status (surgery within 24 hours prior to unit admission or not); and malnutrition status (based on clinical
judgement) (yes or no). A manual randomisation list (using permuted blocks, with block lengths of 4,
6 and 8) was prepared in advance of the trial by the trial statistician for use if the central telephone
randomisation service was not available for any reason. Staff at participating sites were advised to call
the 24 hours per day, 7 days per week, telephone support service if they experienced any problems with
the central telephone randomisation service. Manual randomisation was carried out, as required,
by the on-call member of the TMG. Details of any patients manually randomised were passed to the
randomisation service for inclusion in the minimisation algorithm for subsequent allocations.
Screening log
To enable full and transparent reporting for the trial, brief details of all patients who met eligibility criteria
or who met all of the inclusion criteria plus one or more of the exclusion criteria were recorded in the
screening log. The reasons for eligible patients not being recruited were recorded, which included the
patient declining the invitation to take part, the patient being excluded by the treating clinician, logistical
reasons, etc. No patient identifiers were recorded in the screening log.
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Treatment groups
As a pragmatic trial, the CALORIES trial did not dictate the use of specific nutritional products or protocols
for delivery of nutritional support via the parenteral and enteral routes. However, existing established
protocols for delivery of PN and EN at participating units were reviewed and approved by the TMG to
ensure that they fell within common boundaries.
Early nutritional support was delivered via either the parenteral or enteral route for the 5-day (120 hours)
intervention period, unless the patient transitioned to exclusive oral feeding or was discharged from the
critical care unit before this time. Patients were able to start oral feeding if clinically indicated during
the 5 days.
Early nutritional support via the parenteral route
For patients who were randomised to early nutritional support via the parenteral route, a central venous
catheter, with a dedicated lumen, was inserted and positioned in accordance with NHS guidelines.28
Patients received a standard parenteral feed, obtained from the unit’s usual supplier and used within the
licence indication, which contained between 1365 and 2540 total kcal/bag and between 7.2 and 16.0 g of
nitrogen/bag. Unit staff aimed to feed patients to a target of 25 kcal/kg/day (based on actual body weight)
within 48–72 hours of starting the feed. There was no specific target for the amount of nitrogen to be
given. Enteral ‘trickle feeding’ (‘trophic feeding’) was not permitted for the 5-day (120 hours)
intervention period.
Local unit policy and practice was followed for delivery of nutritional support via the parenteral route and
included provision for:
l ensuring that the patient received a nutritionally complete feed
l inclusion of additional micronutrients (made under appropriate pharmaceutically controlled
environmental conditions) if clinically indicated, and as prescribed by the clinician and/or dietitian in
accordance with National Institute for Health and Care Excellence (NICE) guidelines1
l adjustment of total volume according to the patient’s fluid balance requirements
l monitoring for specific nutritional-related complications
l regular review of the patient for their ongoing nutritional support needs, and
l energy requirements for patients with extremes of body mass index (BMI) (e.g. < 18.5 kg/m2 and
> 30 kg/m2).
Early nutritional support via the enteral route
For patients who were randomised to early nutritional support via the enteral route, a nasogastric or
nasojejunal tube was inserted and positioned in accordance with UK National Patient Safety Agency
guidelines.31,32 Patients received a standard enteral feed, obtained from the unit’s usual supplier, and used
within the licence indication, which contained between 1365 and 2540 total kcal/day and between 7.2
and 16.0 g of nitrogen/day. There was no specific target for the amount of nitrogen to be given. Unit staff
aimed to feed patients to a target of 25 kcal/kg/day (based on actual body weight) within 48–72 hours of
starting the feed.
Local unit policy and practice was followed for delivery of nutritional support via the enteral route and
included provision for:
l ensuring that the patient received a nutritionally complete feed
l adjustment of total volume according to the patient’s fluid balance requirements
l monitoring for specific nutritional-related complications
l regular review of patients for their ongoing nutritional support needs, and
l energy requirements for patients with extremes of BMI (e.g. < 18.5 kg/m2 and > 30 kg/m2).
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Outcome measures
The primary clinical effectiveness outcome was all-cause mortality at 30 days following randomisation and
the primary cost-effectiveness outcome was the incremental net benefit (INB) gained at 1 year following
randomisation, at a willingness-to-pay of £20,000 per quality-adjusted life-year (QALY).
The secondary outcomes were:
l number of days alive and free from advanced respiratory support, advanced cardiovascular support,
renal support, neurological support and gastrointestinal support up to 30 days following randomisation
l number of new, treated, confirmed or strongly suspected infectious complications, classified according
to clinical diagnosis, which occurred in the critical care unit
l non-infectious complications of episodes of hypoglycaemia, elevated levels of liver enzymes, nausea
requiring treatment, abdominal distension and vomiting, collected through adverse event reporting up
to 30 days following randomisation, and new or significantly worsened pressure ulcers while in the
critical care unit
l duration of critical care unit stay (from dates and times) and acute hospital length of stay (in whole days)
following randomisation
l duration of survival at 90 days and at 1 year following randomisation
l all-cause mortality at discharge from the critical care unit and from the acute hospital
l all-cause mortality at 90 days and at 1 year following randomisation
l nutritional and health-related quality of life at 90 days and at 1 year following randomisation
l resource use and costs at 90 days and at 1 year following randomisation, and
l estimated lifetime incremental cost-effectiveness (INB).
Safety monitoring
Patients were monitored for adverse events occurring between randomisation and 30 days following
randomisation. Specified adverse events were defined as follows:
l abdominal distension was defined as any new, clinically significant change in appearance; abdominal
distension was considered severe if there was an acute obstruction
l abdominal pain was defined as any new episode of abdominal pain, localised to the abdomen and
requiring more than just simple analgesia; abdominal pain was considered severe if it was not
controlled with opiates
l episodes of electrolyte disturbance were defined as any new, clinically significant electrolyte disturbance
requiring active monitoring or treatment
l haemopneumothorax was defined as any new haemopneumothorax requiring insertion of a chest drain
l hepatomegaly was defined as any new or increased hepatomegaly on clinical examination
l hyperosmolar syndrome was defined as any new, clinically significant osmolar gap requiring active
monitoring or treatment
l hypersensitivity reaction (anaphylactic reaction) was defined as any new anaphylactic reaction
l episodes of hypoglycaemia were defined as any new episode of clinically significant hypoglycaemia
requiring active monitoring or treatment
l ischaemic bowel was defined as any new episode of ischaemic bowel inferred on radiology or
diagnosed visually, for example during surgery or by endoscopy
l jaundice was defined as any new, clinically significant jaundice requiring active monitoring or treatment
l nausea requiring treatment was defined as any new episode of nausea requiring treatment with
anti-emetic drugs
l pneumothorax was defined as any new pneumothorax requiring insertion of a chest drain
l raised levels of liver enzymes were defined as any new, clinically significant rise in liver enzyme levels
requiring active monitoring or treatment
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l regurgitation/aspiration was defined as any episode of regurgitation/aspiration
l vascular catheter-related infection was defined as any new vascular catheter-related infection for which
a vascular catheter, such as a central venous catheter, was identified as the primary source of infection
and associated with signs and symptoms of infection requiring antimicrobial drugs and/or removal of
catheter, and
l vomiting was identified as any episode of vomiting.
Unspecified adverse events were defined as an unfavourable symptom or disease that was temporally
associated with the use of the trial treatments, whether or not it was related to the trial treatment,
which was not deemed to be a direct result of the patient’s medical condition and/or standard critical
care treatment.
All adverse events were recorded in the electronic case report form and reported, as part of routine
reporting throughout the trial, to the DMEC and research ethics committee. Adverse events that were
assessed to be serious (i.e. prolonging hospitalisation or resulting in persistent or significant disability/
incapacity), life-threatening or fatal – collectively termed serious adverse events – were reported to the
ICNARC CTU and reviewed by a clinical member of the TMG. Serious adverse events that were unspecified
and considered to be possibly, probably or definitely related to the trial treatment were reported to the
research ethics committee within 15 calendar days of the event being reported.
Data collection
A secure, dedicated electronic case report form, hosted by ICNARC, was set up to enable trial data to be
entered by staff at participating sites. The electronic case report form was accessible only to authorised
users and access was approved centrally by the trial manager, data manager or research assistant (after
cross-checking the site delegation of trial duties log). Each individual was provided with a unique username
and password and had access to data only for patients recruited at their site.
The data set for the CALORIES trial included the minimum data required to confirm patient eligibility, to
describe the patient population, to monitor and describe delivery of the intervention, to assess primary and
secondary outcomes and to enable linkage to the ICNARC Case Mix Programme (see Appendix 2).26
Randomisation
Data were collected to enable the patient to be randomised, and included confirmation that the patient
met all of the inclusion criteria and none of the exclusion criteria (see Appendix 2).
Baseline
The following data were collected at baseline to enable follow-up and to describe the patient population:
l full name and address of the patient and their GP
l date of birth
l gender, and
l raw physiology data to enable calculation of the Sequential Organ Failure Assessment (SOFA) score
(see Appendix 3).33
Raw physiology data, to enable calculation of the Acute Physiology and Chronic Health Evaluation version
II (APACHE II) and ICNARC scores and predicted risks of hospital death (see Appendix 3), were obtained
from the Case Mix Programme Database.34,35
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Intervention period
Data were collected daily throughout the 5-day (120-hour) intervention period to monitor adherence
to treatment allocation (early nutritional support via parenteral route or early nutritional support via enteral
route) and to describe and cost delivery of early nutritional support via the parenteral and enteral routes.
The data collected included:
l nutritional support delivered during each calendar day, including mode of delivery of nutritional
support, site of central venous catheter, site of enteral tube (nasogastric or nasojejunal), nutritional
product type, volume of nutritional support delivered and any change to delivery of nutritional support
l physiology, for example arterial oxygen pressure (PaO2), fraction of inspired oxygen (FiO2), blood
pressure, Glasgow Coma Scale (GCS) score, blood glucose, urine output, and
l interventions, for example mechanical ventilation, vasoactive drugs, systemic antibacterial drugs and/or
antifungal drugs.
At critical care unit discharge
At the time of discharge from the critical care unit, the following data were collected:
l route(s) of delivery of nutritional support in the critical care unit from day 7 following randomisation
l interventions delivered in the critical care unit from day 7 following randomisation
l new strongly suspected or confirmed infectious episodes, classified according to clinical diagnosis,
which occurred in the critical care unit following randomisation
¢ strongly suspected infection was defined as strongly suggestive evidence, for example evidence of
gross purulence or evidence from radiological or other imaging techniques, and the commencement
of antibacterials or antifungals for a suspected infection; strongly suggested evidence must have
been documented in the case notes
¢ confirmed infection was defined as laboratory/microbiological confirmation, including cultures,
Gram stains and roentgenograms
l organ support, as defined by the UK Department of Health Critical Care Minimum Dataset (CCMDS)36
(see Appendix 4) during the critical care unit stay, and
l date and time of discharge from, or death in, the critical care unit.
At acute hospital discharge
At the time of discharge from the acute hospital, the following data were collected:
l the locations of care during the patient’s stay in the acute hospital, for example critical care unit, ward
l date that exclusive oral feeding commenced (if applicable) following the patient’s discharge from the
critical care unit
l date of discharge from, or death in, the acute hospital, and
l discharge location, for example home, nursing home, other hospital.
At 30 days
All patients were followed up at 30 days following randomisation for the primary clinical effectiveness
outcome (all-cause mortality) via the Health and Social Care Information Centre (HSCIC) Data Linkage and
Extract Service.
Longer-term follow-up
Following randomisation, a letter was sent to the patient’s GP informing them of the patient’s participation
in the trial and a request for assistance with follow-up, if required. All patients who survived to leave
hospital were followed up at 90 days for the secondary outcomes (all-cause mortality, duration of survival,
health-related quality of life and resource use), and at 1 year for secondary outcomes (all-cause mortality,
duration of survival, health-related quality of life and resource use) and to calculate the primary
cost-effectiveness outcome (INB).
METHODS
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Data linkage with death registration
Follow-up of patients was carefully monitored to prevent any potential distress to those who care for
the patient receiving a letter addressed to a deceased relative, partner or friend. The follow-up process
started at 75 days for the 90-day follow-up and at 350 days for the 1-year follow-up to allow for the
administrative processes. Each week a list of all patients who had been discharged alive from hospital and
who were either 75 days or 350 days post-randomisation was sent to the HSCIC Data Linkage and Extract
Service to confirm their mortality status. Patients indicated as having died were logged and the follow-up
process ended.
Follow-up procedure
Patients identified by the HSCIC Data Linkage and Extract Service as not having died started the follow-up
process summarised in Figure 3. A questionnaire pack was sent from the ICNARC CTU, by post, to the
patient. Following evidence-based practice for maximising responses to postal surveys,37 the questionnaire
pack included a cover letter (see Appendix 5); the patient information sheet (see Appendix 1) or patient
newsletter (which replaced the patient information sheet in November 2013); two questionnaires – the
Health Questionnaire and the Health Services Questionnaire (see Appendix 6); a stamped-addressed return
envelope; and a pen. The Health Questionnaire (see Appendix 6) included the required questions from
the EQ-5D-5L to evaluate health-related quality of life38 and the Satisfaction with Food-related Life
Questionnaire to evaluate the patient’s nutritional quality of life.39 It is a measure of satisfaction developed
by Grunert and the Food in Later Life team. The five items exhibit good reliability (as measured by
Cronbach’s alpha), good temporal stability, convergent validity with two related measures, and construct
validity as indicated by relationships with other indicators of quality of life.39 The Health Services
Questionnaire (see Appendix 6) included questions about the patient’s use of health services following
discharge from the acute hospital and was used to cost subsequent use of health services. The cover of the
questionnaires included a ‘do not wish to participate’ tick box.
Letter sent to GP
First questionnaire pack
sent to patient
If no response after 2 weeks,
patient telephoned, if possible
HSCIC Data Linkage and 
Extract Service identified
patient was not dead
Not 
confirmed
Yes
Questionnaire pack returned,
e.g. ‘not known at this 
address’ – patient’s contact 
details checked
GP/recruiting
site contacted 
for confirmation
If no response after 
2 weeks, second questionnaire
pack sent to patient
FIGURE 3 Patient follow-up process at 90 days and at 1 year.
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If no response was received after 2 weeks, a reminder letter was sent with another questionnaire pack.
If no response was received after a further 2 weeks, the patient was telephoned, if contact details were
available. Telephone calls were made at various times from Monday to Friday between 08.30 and 20.30 to
maximise the chances of contacting the patient. Patients who were successfully contacted by telephone
were asked if they had received the questionnaire pack and were invited to complete the questionnaires
over the telephone, if it was convenient. In addition, patients were reminded about completing the
questionnaire when they attended hospital follow-up appointments.
Follow-up ended on receipt of a completed (or blank) questionnaire; a questionnaire with a ticked ‘do not
wish to participate’ box; notification to the ICNARC CTU by telephone or e-mail that the patient wished
to withdraw from the trial; or if there was no response to telephone follow-up. For questionnaire packs
returned indicating that the recipient was not known at the address, the contact details for the patient
were checked with the recruiting hospital and/or GP.
For patients who were identified as either being a hospital inpatient, or resident in a care home or
rehabilitation centre, the relevant institution was contacted to establish the status of the patient and the
most appropriate way to proceed with follow-up. If the patient had mental capacity to consent but
required assistance in reading and/or completing the questionnaire then health-care professionals usually
assisted the patient. For patients who lacked mental capacity to consent, institutions advised on the most
appropriate person to contact to complete the questionnaires.
If patients were identified as having no fixed abode but were registered with a GP or had regular contact
with a homeless shelter then the questionnaire pack was sent to be passed (when appropriate) to them at
their next appointment or visit.
Data linkage with the Case Mix Programme
Linkage of patient identifiable trial data to the Case Mix Programme Database provided information on the
baseline characteristics of patients and subsequent admission to the critical care unit following discharge
from the critical care unit.
Data for the Case Mix Programme are collected by trained data collectors to precise rules and definitions.
The data then undergo extensive local and central validation for completeness, illogicalities and
inconsistencies prior to pooling.
Data management
Data management was an ongoing process. Data entered by sites on to the electronic case report form
were monitored and checked throughout the recruitment period to ensure that data were as complete
and accurate as possible.
Two levels of data validation were incorporated into the electronic case report. The first was to prevent
obviously erroneous data from being entered, for example entering a date of birth that occurred after the
date of randomisation. The second level involved checks for data completeness and any unusual data
entered, for example a physiological variable, such as blood pressure, which was outside of the predefined
range. Site staff could generate data validation reports, listing all outstanding data queries, at any time via
the electronic case report form. The site PI was responsible for ensuring that all of the data queries were
resolved. Ongoing data entry and validation at sites was closely monitored by the data manager (JT) and
any concerns were raised with the site PI.
The contact details for patients and their GPs (name and postal address) were checked weekly for
completeness to avoid unnecessary delays in sending out questionnaire packs at 90 days and at 1 year.
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Adherence to the trial protocol was closely monitored, including adherence to all elements of early
nutritional support delivered via the parenteral and the enteral route. Any queries relating to adherence
were generated in a separate monthly report, which was sent to the site PI. For each query, the PI was
asked to explain the reason for any non-adherence to the protocol. If deemed necessary, a teleconference
was arranged with the site to ensure that effective plans were put in place to improve future adherence.
Data received from completed Health and Health Services questionnaires were entered centrally into
a secure database at the ICNARC CTU following a standard operating procedure. All identifiable
information, such as names (e.g. of patients, family members or hospital staff members) were removed.
All queries relating to data entry were reviewed by two members of the TMG (SH/BM) and any
disagreement was reviewed and discussed with a third (KR).
To ensure that data were entered accurately, all questionnaire data entered into the database were
cross-checked by a second member of the CTU team. Any errors that were found were logged and
corrected on the database.
Sample size
Applying the trial entry criteria to over 500,000 admissions to adult, general critical care units in the
Case Mix Programme Database, the 30-day mortality for unplanned, ventilated adult admissions staying
≥ 3 days was 32%. As the enteral route is the predominant choice for nutritional support, this mortality
was used as the basis to estimate control group mortality.
A meta-analysis of existing randomised controlled trials of PN compared with EN indicated a potential
relative risk reduction associated with PN of around 20% (see Figure 1). To have 90% power, with a type I
error rate of 5% (two sided), to detect a 20% relative risk reduction (6.4% absolute risk reduction) from
32% in the enteral route group to 25.6% in the parenteral route group, requires a sample size of 1082
per treatment group (Stata/SE version 10.1, StataCorp LP, College Station, TX, USA). To allow 2% for
crossover/protocol violation (in each direction) and 2% for loss to follow-up/withdrawal prior to
30 days (based on observed rates from the PAC-Man Study40), a sample size of 1200 per treatment group
(2400 total) was required. No adjustment to the sample size calculation was made to account for
subgroup analyses.
Interim analysis
Unblinded, comparative data on recruitment, withdrawal, adherence (to the allocated treatment) and
serious adverse events were regularly reviewed by an independent DMEC.
Without specific analysis of the primary outcome, the DMEC reviewed data from the first 37 trial
participants and continued to review data at least 6-monthly to assess potential safety issues and to review
adherence. A single, planned, formal, interim analysis was performed at the point that 30-day outcome
data for the first 1200 patients enrolled were available. A Haybittle–Peto stopping rule (p< 0.001) was
used to guide recommendations for early termination as a result of harm. Following the planned interim
analysis, the DMEC recommended that the trial continue with no changes.
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Analysis principles
All analyses were based on the intention-to-treat principle. Patients were analysed according to the
treatment group to which they were randomised, irrespective of whether or not the allocated treatment
was received (i.e. regardless of whether they did or did not adhere to the allocated route). All tests were
two-sided, with significance levels set at p< 0.05 and with no adjustment for multiplicity. All a priori
subgroup analyses were carried out irrespective of whether or not there was strong evidence of a
treatment effect associated with the primary outcome. As missing data for the clinical effectiveness primary
outcome were anticipated to be minimal, a sensitivity approach was taken when the primary outcome was
missing (see Secondary analyses of the primary outcome). Missing data for the cost-effectiveness analysis,
as well as missing baseline data for adjusted analysis of clinical outcomes, were handled by
multiple imputation.
Multiple imputation
Missing data in baseline covariates, resource use and health-related quality-of-life variables at 90 days and
1 year were handled with multivariate imputation by chained equations.41 Under this approach, each
variable was imputed conditional on fully observed baseline variables, such as age, sex, ICNARC Physiology
Score, presence of cancer, length of stay in critical care and general medical wards, and all other imputed
variables. When addressing the missing data, multiple imputation assumes that the data are missing at
random, conditional on the observed data.
Patients who did not return or fully complete the EQ-5D-5L questionnaire administered at 90 days had
their EQ-5D-5L utility scores imputed from those survivors who did fully complete the questionnaire.
Similarly, for those eligible patients who did not return the Health Services Questionnaire, information on
the use of outpatient services up to 90 days following randomisation was imputed from those patients
who did complete this questionnaire. Health Services Questionnaire costs and quality-of-life end points
were conditional on survival status; as such, the imputation was conducted in two stages. In the first stage,
imputation models were specified for mortality at 90 days according to baseline covariates and auxiliary
variables, including hospital length of stay of up to 90 days. In the second stage, for each of the imputed
data sets from stage 1, imputation models were specified for Health Services Questionnaire costs and
quality of life at 90 days for those patients who were missing these but were known to be alive at 90 days,
or were predicted to be alive by the first stage imputation model.
Patients who did not return or fully complete the EQ-5D-5L questionnaire or the Health Services Questionnaire
administered at 1 year also had their information imputed from those survivors who did fully complete the
questionnaire, using a similar two-stage approach.
The resultant estimates were combined with Rubin’s rules, which recognise uncertainty both within and
between imputations.42 All multiple imputation models were implemented in the statistical package
Stata/SE version 13.0 (StataCorp LP, College Station, TX, USA).
Statistical analysis: clinical effectiveness
Statistical analyses were conducted according to a pre-specified, published statistical analysis plan written
prior to the interim analysis.43 The final analyses were conducted using Stata/SE version 13.0.
Baseline characteristics
Baseline demographic and clinical data were summarised by treatment group. Statistical tests for
differences between the groups were not reported, as these may be misleading. Discrete variables were
summarised as numbers and percentages, which were calculated according to the number of patients for
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whom data were available; when values were missing, the denominator was reported. Continuous
variables were summarised by standard measures of central tendency and dispersion, either mean and
standard deviation (SD) and/or median and interquartile range (IQR) as specified below:
l age, mean (SD) and median (IQR)
l sex, n (%)
l severe comorbidities (as defined by APACHE II34), n (%):
¢ severe liver condition
¢ severe renal condition
¢ severe respiratory condition
¢ severe cardiovascular condition
¢ immunocompromised
l acute severity of illness:
¢ SOFA score,33 mean (SD)
¢ APACHE II Score,34 mean (SD)
¢ APACHE II Acute Physiology score,34 mean (SD)
¢ APACHE II predicted risk of death34 (2013 UK recalibration), median (IQR)
¢ ICNARC Physiology Score,35 mean (SD)
¢ ICNARC model predicted risk of death35 (2013 recalibration), median (IQR)
l surgical status – surgery within 24 hours prior to critical care unit admission, n (%)
l ventilation status – mechanical ventilation at admission to the critical care unit, n (%)
l malnourished – yes/no (based on clinical judgement), n (%)
l actual/estimated BMI, mean (SD) and median (IQR)
l ulna length (cm), mean (SD) and median (IQR)
l mid-upper arm circumference (cm), mean (SD) and median (IQR)
l degree of malnutrition (high, BMI of < 18.5 kg/m2 or weight loss of > 10%; moderate, BMI of < 20 kg/m2
or weight loss of > 5%; no malnutrition) (based on NICE definitions1), n (%).
Adherence
Non-adherence with the allocated treatment was reported as the number and percentage of patients who:
l did not receive any nutritional support
l received first nutritional support via the opposite route to assigned
l received initiation of nutritional support more than 36 hours after admission to critical care
l received early nutritional support via assigned route and subsequently changed to opposite route
during first 120 hours, or
l received no nutritional support for at least a full 1-day period during the first 120 hours.
Delivery of care
Delivery of care was summarised by treatment group but not subjected to statistical testing. As with
baseline characteristics, discrete variables were summarised as numbers and percentages. Percentages
were calculated according to the number of patients for whom data were available; where values were
missing, the denominator was reported. Continuous variables were summarised by mean (SD) and/or
median (IQR), as specified below:
l time from critical care unit admission to commencement of nutritional support (hours), median (IQR)
l total calories and average calories per 24 hours received during intervention period (total calories and a
breakdown of the total calories received via the enteral route, the parenteral route, intravenous (i.v.)
glucose, propofol and oral feed), mean (SD)
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l total protein and average protein per 24 hours received during intervention period (total protein and a
breakdown of the total protein received via the enteral and the parenteral route), mean (SD)
l total gastric residual volume aspirated (ml) and average per 24 hours during intervention period, if fed
via the enteral route, mean (SD)
l total gastric residual volume replaced and average per 24 hours during intervention period, if fed via
the enteral route, mean (SD)
l patients receiving additives during intervention period (glutamine, selenium and fish oils), if fed via the
parenteral route, n (%)
l patients receiving prokinetics during intervention period, if fed via the enteral route, n (%)
l patients receiving insulin, n (%), and total insulin received (IU), mean (SD), during intervention period
l patients receiving vasoactive agents during intervention period, n (%)
l incidence of diarrhoea and constipation, n (%)
l time from randomisation to commencement of exclusive oral feeding (days), median (IQR)
l daily SOFA score during the intervention period, median (IQR).
Primary outcome: clinical effectiveness
The number and percentage of deaths at 30 days following randomisation, due to any cause, were
reported for each treatment group. The primary effect estimate was the relative risk of all-cause mortality
at 30 days, reported with a 95% CI. The absolute risk reduction and 95% CI were also reported. Deaths at
30 days after randomisation were compared between the treatment groups, unadjusted, using Fisher’s
exact test. A secondary analysis of the primary outcome, adjusted for baseline variables, was conducted
using multilevel logistic regression. Baseline variables adjusted for in the multilevel logistic regression model
were age, ICNARC Physiology Score, surgical status, degree of malnutrition and a site-level random effect.
Baseline variables were selected for inclusion in the adjusted analysis a priori according to anticipated
relationship with outcome. The results of the multilevel logistic regression model were reported as an
adjusted odds ratio with 95% CI. The unadjusted odds ratio was presented for comparison.
Secondary outcomes: clinical effectiveness
The mean (SD) of the number of days alive and free from advanced respiratory support, advanced
cardiovascular support, renal support, neurological support and gastrointestinal support, as defined by the
CCMDS36 (see Appendix 4), up to 30 days, within each treatment group, were reported. Patients who died
within the first 30 days were assigned zero days alive and free of each organ support. Days of organ
support were recorded only while the patient was in a critical care unit; any days outside of a critical care
unit were assumed to be free of organ support. Differences between the treatment groups were tested
using the t-test, using the non-parametric bootstrap to account for anticipated non-normality in the
distributions.44 A total of 1000 bootstrap replications were taken, stratified by treatment group, with
bias-corrected and accelerated CIs reported.
The mean (SD) number of treated infectious complications per patient and the number and percentage of
patients with each infectious complication (chest infection, central venous catheter infection, other vascular
catheter-related infection, bloodstream infection, infective colitis, urinary tract infection, surgical site
infection, other infectious complication) and each non-infectious complication (episodes of hypoglycaemia,
elevated levels of liver enzymes, nausea requiring treatment, abdominal distension, vomiting, new
or substantially worsened pressure ulcers) within each treatment group were reported. Infectious
complications and pressure ulcers were assessed while the patient was in the critical care unit; all other
non-infectious complications were collected through adverse event reporting up to 30 days following
randomisation. Differences between the treatment groups were tested using the t-test for means and
Fisher’s exact test for percentages.
The median (IQR) of the length of stay in critical care and in acute hospital were reported for each treatment
group. Differences in length of stay between the treatment groups were tested using the Wilcoxon
rank-sum test, stratified by survival at critical care discharge and acute hospital discharge, respectively.
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Kaplan–Meier curves by treatment group were plotted up to 90 days and 1 year after randomisation and
compared using the log-rank test. An adjusted comparison was performed using a Cox proportional
hazards model, which was adjusted for the same baseline variables as the primary outcome, including
shared frailty within sites (gamma-distributed latent random effects). The appropriateness of the
proportional hazards assumption was assessed graphically by plotting –log[−log(survival)] against log(time)
within treatment groups. The number and percentage of deaths at critical care and acute hospital
discharge, and by 90 days and 1 year post-randomisation, were reported for the treatment groups.
Differences in all-cause mortality at each time point were compared, unadjusted, using Fisher’s exact
test and, adjusted, using multilevel logistic regression, adjusted for the same baseline variables as the
primary outcome.
Safety monitoring
The number and percentage of patients experiencing each serious adverse event (occurring between
randomisation and 30 days) were reported for each treatment group. The total number of patients
experiencing one or more serious adverse events was compared between treatment groups using Fisher’s
exact test and summarised as a relative risk with 95% CI.
Subgroup analyses of the primary outcome
Subgroup analyses were conducted to test for a difference in treatment effect according to pre-specified
subgroups. Differences in the primary outcome (30-day mortality) were analysed by age (in quartiles),
degree of malnutrition (high/moderate or none), acute severity of illness (APACHE II34 and ICNARC model35
predicted risk of mortality – in quartiles), mechanical ventilation at admission to the critical care unit,
presence of cancer and time from critical care unit admission to commencement of nutritional support
(< 24 hours vs. ≥ 24 hours).
These analyses tested for an interaction between the subgroup categories and the treatment group in
multilevel logistic regression models, adjusted for the same baseline variables as used in the primary analysis.
Secondary analyses of the primary outcome
Sensitivity analyses for missing data in the primary outcome
As the number of missing data was anticipated to be minimal, a sensitivity approach was taken when the
primary outcome variable was missing. The primary analysis was repeated once, assuming that all patients
in the enteral route group with missing outcomes survived and all patients in the parenteral route
group with missing outcomes did not survive. The analysis was then repeated again with the opposite
assumptions. This approach gives the absolute range of how much the results could change if all of the
data were complete.
Adherence-adjusted analysis
Although the intention-to-treat analysis provides the best estimate of the clinical effectiveness of early
nutritional support via the parenteral route compared with the enteral route, it was also of interest to
estimate what the efficacy of early nutritional support delivered via the parenteral route would be
compared with the enteral route, if delivered as intended. In a randomised controlled trial, the allocated
treatment can be used as an ‘instrumental variable’, that is, a variable associated with receipt of the
intervention and associated with the outcome only through its association with the intervention.45 This
relationship enables us to estimate what the treatment effect would be for patients who are adherent to
the protocol. The primary analysis was repeated adjusting for adherence using a structural mean model
with an instrumental variable of allocated treatment, assuming a linear relationship between the degree of
adherence (duration of allocated treatment received) and treatment effect.46
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Cost-effectiveness analysis
A full cost-effectiveness analysis was undertaken to assess which route of delivery for early nutritional
support in critically ill adults, parenteral compared with enteral, was most cost-effective. This analysis
assessed whether or not the additional intervention costs of early nutritional support via the parenteral
route compared with the enteral route were justified by any subsequent reductions in morbidity costs and/
or improvements in patient outcomes. The cost-effectiveness analysis was reported for three time periods:
randomisation to 90 days; randomisation to 1 year; and lifetime. For each time period the cost-effectiveness
analysis took a health and personal health services perspective,47 using information on health-related quality
of life collected at 90 days and 1-year follow-up, combined with information on vital status, to report
QALY. Each QALY was valued using the NICE-recommended threshold of willingness to pay for a QALY
gain (£20,000),47 in conjunction with the costs of each strategy to report the incremental net monetary
benefits (INBs) of early nutritional support via the parenteral route compared with early nutritional support
via the enteral route, overall and for the same pre-specified subgroups as for the evaluation of clinical
effectiveness (see Subgroup analyses of the primary outcome, below).
The primary objective of the cost-effectiveness analysis was to compare incremental cost-effectiveness at
1 year of early nutritional support via the parenteral route compared with the enteral route. The secondary
objectives were to:
l compare health-related quality of life at 90 days and 1 year between the treatment groups
l compare resource use and costs at 90 days and 1 year between the treatment groups
l estimate the lifetime incremental cost-effectiveness between the treatment groups.
The main assumptions of the cost-effectiveness analysis were subjected to extensive sensitivity analyses.
Resource use
The resource-use categories considered were chosen a priori, for which differences between the treatment
groups were judged as being possible and likely to drive incremental costs, and were reported for each
treatment group. Data for interventions, staff time and acute hospital stay for the index hospital admission
were collected as part of the CALORIES trial data set. Readmissions to acute hospital including a critical
care stay were identified from the Case Mix Programme Database. Readmission to acute hospital not
involving critical care, as well as hospital outpatient and community services use, were collected as part of
the Health Services Questionnaires completed at 90 days and 1 year.
Interventions
Use of nutritional feeding as a part of the CALORIES trial interventions in critical care unit has been
considered in economic evaluation. For each patient, total volume of nutritional support delivered within
the first six calendar days of nutritional support (encompassing the 120-hour intervention period) was
calculated according to route of feeding and type of nutritional products. The use of alternative nutritional
feeding due to crossover was included in the costing, which followed the intention-to-treat principle, as
per the analysis of clinical effectiveness.
The use of i.v. glucose, propofol and insulin within the first six calendar days of nutritional support was
recorded daily on the trial case report form for each patient. The trial case report form recorded daily
volume and concentration of i.v. glucose and propofol, and total units (IU) of insulin. Use of propofol was
recorded because of its relatively high calorie content.
Nutritional support from day 7 following initiation of nutritional support to discharge from the critical care
unit was reported using trial case report form data. From calendar day 7 up to discharge from the critical
care unit, trial case report forms recorded the date of each change of route of nutritional support, and
these were aggregated to calculate the number of days each patient received nutritional support via each
route. Costs of nutritional support from calendar day 7 up to discharge from critical care unit were
calculated according to number of days of nutritional support via each route.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Staff time
The cost-effectiveness analysis recognised that the delivery of nutritional support in critically ill adult
patients via the parenteral route rather than the enteral route requires additional staff input. A
multidisciplinary team with dietetic, nursing, pharmacy and medical expertise is required to provide PN in
routine clinical practice. It was considered that critical care units have existing medical expertise but do not
have a dedicated nutritional team to deliver nutritional support. The delivery of nutritional support required
staff time for initial dietary assessment (dietitians’ time); prescribing and preparing PN (pharmacists’ time);
daily monitoring and support of patients (dietitians’ and pharmacists’ time); and for changing gowns and
bed sheets in the event of episodes of vomiting or diarrhoea (nurses’ time). The level of additional staff
time for the delivery of nutritional support via the parenteral route was estimated according to expert
opinion reflecting the most plausible assumption for routine practice in majority of the centres (Table 1),
with alternative levels considered in the sensitivity analyses (see Table 3). The base-case analysis assumed
that, compared with delivery of nutritional support via the enteral route, the delivery of nutritional support
via the parenteral route required additional pharmacist’s time for initial assessment and set-up (30 minutes)
and daily monitoring and support (30 minutes). It was recognised that the delivery of protocol would
require additional staff time within the intervention period. To reflect routine critical care practice, it was
considered that additional support from the nutritional team (dietitian and pharmacist) is available on
weekdays and any additional nutritional bags over the weekends were prearranged during weekdays.
Acute hospital length of stay
Length of stay in critical care and general medical wards within the index hospital admission (i.e. the
hospital in which a patient was randomised to the trial) were reported. Each critical care stay was assigned
a Healthcare Resource Group (HRG), applying the standard HRG grouper algorithm, according to the
maximum number of organs supported during the stay.48
An acute hospital readmission was defined as a further hospital admission, for any reason, following
discharge home from the index admission. Length of stay in critical care and general medical wards within
acute hospital readmissions were taken from the Case Mix Programme Database49 and the Health
Services Questionnaires.
TABLE 1 Additional staff time for nutritional support
Support requirement
Delivery of nutritional support via the:
Parenteral route Enteral route
Initial dietary assessment and set-up of
nutritional supporta
30 minutes of dietitian’s time 30 minutes of dietitian’s time
30 minutes of pharmacist’s time No additional pharmacist’s time
Monitoring and support (daily)b 20 minutes of dietitian’s time 20 minutes of dietitian’s time
30 minutes of pharmacist’s time No additional pharmacist’s time
Adverse events
Vomiting (episode) Three nurses for 10 minutes Three nurses for 10 minutes
Diarrhoea (episode)c Three nurses for 10 minutes Three nurses for 10 minutes
a It is assumed that support from the dietitian and the pharmacist is available only on weekdays, and that for patients
randomised at weekends the initial dietary assessment and set-up was done by the on-call pharmacists (10 minutes).
b Daily dietitian monitoring and support is required for both PN and EN. Pharmacist’s monitoring and support is required
only for PN.
c It was assumed that patients experiencing diarrhoea had three episodes of diarrhoea per day.
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Hospital outpatient visits and community service use
The number of hospital outpatient visits and community service use following discharge from the index
admission, for any reason, were reported. Items of community service use included visits to the GP (family
doctor), nurse, health visitor, occupational therapist, dietitian, physiotherapist and psychologist. The levels
of resource use were taken from responses to the Health Services Questionnaire.
Unit costs
The unit costs required for valuing the resource-use data listed in Table 2 were taken from four sources:
the British National Formulary (BNF); manufacturers’ list prices; national unit cost databases; and local NHS
prices. The unit costs of nutritional products were taken from the BNF50 and manufacturer’s list price.
During the intervention period, the use of the top five high-volume nutritional products were costed
individually; the rest were costed based on the weighted average of the costs for the top five high-volume
products. Enteral nutritional products were costed using the weighted average of the costs of the top five
high-volume products. The use of feeding after the intervention period up to discharge from the critical
care unit was costed according to the number of days that a patient was receiving either PN or EN.
The daily use of nutritional support after the intervention period was calculated from the weighted average
of the number of bags of nutritional products which the patient had used during the intervention period.
The unit costs of other interventions (glucose, propofol and insulin) were obtained from personal
communication with local NHS finance department or from the BNF. The use of glutamine, selenium and
fish oil in the parenteral group were not considered as separate items: their costs were included within the
unit cost of a critical care bed-day according to the HRG definition.
The unit costs associated with the additional staff time required to deliver nutritional support and address
adverse events were taken from national sources. The costs per critical care bed-day, by HRG, and general
medical bed-day were taken from the ‘Payment by Results’ database.51 Unit costs for hospital outpatient
visits and community service use were obtained from a recommended published source for Health and
Social Care costs.52 All unit costs were reported in 2013–14 prices.
TABLE 2 Unit costs in GB pounds (£)
Items Unit costs (£) Source
Nutritional products
Parenteral
Kabiven® 7gN (1920ml) 50.00 BNF50
NuTRIflex® Lipid Peri (2500ml) 64.22 BNF50
Kabiven 9gN (2400ml) 64.00 BNF50
Kabiven 11gN (2053ml) 67.00 BNF50
Kabiven 5gN (1440ml) 35.00 BNF50
Weighted average unit cost of PN 57.37 BNF50 and CALORIESa
Enteral
Nutrison (1000ml) 8.25 BNF50
Nutrison Multi Fibre (1000ml) 9.54 BNF50
Fresubin® Original (1000ml) 7.96 BNF50
Nutrison Protein Plus (1000ml) 9.80 BNF50
Nutrison Low Sodium 16.85 Manufacturer’s list priceb
Weighted average unit cost of EN 9.87 BNF50 and CALORIESa
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TABLE 2 Unit costs in GB pounds (£) (continued )
Items Unit costs (£) Source
Other interventions
Glucose (4%): 500ml 0.93 Local NHS finance department
Glucose (5%): 500ml 0.85 Local NHS finance department
Glucose (10%): 500ml 0.70 Local NHS finance department
Glucose (20%): 500ml 1.50 Local NHS finance department
Glucose (50%): 500ml 2.00 Local NHS finance department
Propofol (1%): 50ml 10.10 Local NHS finance department
Propofol (2%): 50ml 21.30 Local NHS finance department
Insulin: 1000 units 7.48 BNF50
Staff time
Hospital dietitian
Band 6 (per hour) 43 PSSRU52
Band 7 (per hour) 53 PSSRU52
Hospital costs (bed-day)
Critical care bed-day
0 organs supported 696 NHS reference costs51
1 organ supported 932 NHS reference costs51
2 organs supported 1304 NHS reference costs51
3 organs supported 1479 NHS reference costs51
4 organs supported 1622 NHS reference costs51
5 organs supported 1692 NHS reference costs51
≥ 6 organs supported 1947 NHS reference costs51
General ward bed-day 275 NHS reference costs51
Outpatient and community health services
Hospital outpatient (per visit) 109 PSSRU52
GP practice visit (per visit) 45 PSSRU52
GP home visit (per visit) 114 PSSRU52
GP practice nursec 13 PSSRU52
Hospital staff nursec 13 PSSRU52
Health visitorc 13 PSSRU52
Occupational therapistc 9 PSSRU52
Psychologistc 15 PSSRU52
Speech and language therapistc 9 PSSRU52
Physiotherapistc 9 PSSRU52
Dietitianc 9 PSSRU52
PSSRU, Personal Social Services Research Unit.
a BNF prices weighted by frequency of use in the CALORIES trial.
b Low sodium is not approved by Advisory Committee on Borderline Substances and, therefore, BNF price is not available.
c Fifteen minutes of consultation time.
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Nutritional and health-related quality of life
The responses to the EQ-5D-5L questionnaire were used to report each patient’s described health, which
was then valued according to health state preferences from the general population to calculate EQ-5D-5L
utility scores, anchored on a scale from 0 (death) to 1 (perfect health).53 The number and percentage
of patients in each level of each dimension were reported by treatment group. The responses to the
Satisfaction with Food-related Life questionnaire were used to evaluate the patient’s nutritional quality of
life and were reported on a scale from 1 (worst possible satisfaction) to 7 (best possible satisfaction).
Cost-effectiveness at 90 days following randomisation
Mean EQ-5D-5L utility scores, QALYs, total costs and incremental net monetary benefits up to 90 days
were reported for each treatment group. Unadjusted mean differences between the treatment groups,
in quality of life, QALYs and incremental costs at 90 days were reported with 95% CIs. These were
reported both overall and by each of the pre-specified subgroups (see Subgroup analyses of the primary
outcome, below).
Total costs up to 90 days were calculated by combining the resource use with unit costs. For survivors at
90 days, QALYs were calculated by valuing each patient’s survival time by his/her health-related quality of
life according to the ‘area under the curve’ approach,54 assuming an EQ-5D-5L utility score of zero at
randomisation, and a linear interpolation of between randomisation and 90 days. Zero QALYs were
assumed for decedents at between randomisation and 90 days. The differences in average costs and
QALYs between the treatment groups were used to calculate the incremental net monetary benefit of
delivery of early nutritional support via the parenteral route compared with the enteral route. The
incremental QALY was valued according to the NICE-recommended threshold of willingness to pay for a
QALY gain (£20,000) and the incremental cost was subtracted from this.
The uncertainty around the differences in average costs and QALYs between the treatment groups was
illustrated on the cost-effectiveness plane. The incremental costs and QALYs were estimated with a
seemingly unrelated regression model.55 To express the uncertainty in the estimation of the incremental
costs and QALYs, the estimates of the means, variances and the covariance from the regression model
were used to generate 500 estimates of incremental costs and QALYs from the joint distribution of these
end points, assuming asymptotic normality. A cost-effectiveness acceptability curve was also plotted, by
calculating the probability that, compared with early nutritional support via the enteral route, early
nutritional support via the parenteral route is cost-effective – given the data – at alternative levels of
willingness to pay for a QALY gain.
The mean incremental net monetary benefit at 90 days with corresponding 95% CI was reported both
overall and by each of the pre-specified subgroups (see Subgroup analyses of the primary outcome,
below). As for the analysis of clinical effectiveness, the base-case analysis was repeated adjusting for
adherence using a structural mean model with an instrumental variable of allocated treatment.46
The cost-effectiveness analysis was repeated applying alternative assumptions in sensitivity analyses.
The main assumptions made in the base-case scenario, and how each was relaxed in sensitivity analyses
are detailed below and summarised in Table 3.
Costs of nutritional products
In the base case, unit costs for the nutritional products from the BNF were applied. In the sensitivity
analysis, manufacturer’s list prices were applied.
Dietitian’s time during delivery of nutritional intervention
The intervention requires intensive monitoring and support of patients during the delivery of the nutritional
support protocol (5 days/120 hours). In the base case, it was assumed that this monitoring and support
would involve an additional 20 minutes of dietitian’s time per day for either type of nutritional support.
In the sensitivity analysis, it was considered that daily monitoring and support of patients receiving EN by a
dietitian would not be required.
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Pharmacist’s time during delivery of nutritional intervention
In the base case, it was assumed that hospitals used custom-made PN bags and, therefore, pharmacist’s
time for each day of nutritional support is required. In the sensitivity analysis, it was considered that daily
monitoring and support of patients receiving PN by a pharmacist would not be required.
Additional time of dietitian, pharmacist and nurse
In the base case, it was assumed that any additional time of dietitian, pharmacist and nurse would be
required to implement early nutritional support in critical care. In the sensitivity analysis, it was considered
that the critical care unit has a dedicated nutritional team and, therefore, no additional support from an
on-call nutritional team would be required.
Readmissions from Health Services Questionnaire
The base-case analysis included hospital readmissions, including a critical care stay recorded in the Case
Mix Programme Database, but also hospital readmissions recorded from responses to the Health Services
Questionnaire. To consider the possible impact of double-counting the same readmissions across both
sources, in the sensitivity analysis only the readmissions from the Case Mix Programme Database
were included.
Baseline covariates
The base-case analysis reported incremental costs and QALYs without any covariate adjustment, assuming
that randomisation had ensured no imbalances in key prognostic factors such as age, ICNARC Physiology
Score, ICNARC model predicted risk of death, surgical status and degree of malnutrition. In the sensitivity
analysis, any chance imbalances in these factors were adjusted for using seemingly unrelated regression.
Distributional assumptions for costs and quality-adjusted life-years
The base-case analysis assumed that costs and QALYs were normally distributed when reporting the 95%
CIs around incremental costs and QALYs. In sensitivity analyses the robustness of the cost-effectiveness
results to alternative distributional assumptions about both outcomes were assessed. Following
methodological guidance, the sensitivity analysis considered a gamma distribution for costs, as they had a
right-skewed distribution. For QALYs, the sensitivity analysis also considered a gamma distribution because
a large proportion of decedents had zero QALYs and the remainder of the distribution was again right
skewed. In this sensitivity analysis, costs and QALYs were modelled as univariate regression models,
assuming gamma distribution for each end point (i.e. ignoring possible correlation between the end points).
TABLE 3 Alternative assumptions for sensitivity analysis
Assumption Base case Sensitivity analysis
Costs of nutritional products BNF price Manufacturer’s list price
Dietitian’s time for daily
monitoring and support
20 minutes daily for both EN
and PN
No additional dietitian’s time for daily monitoring and
support of EN
Pharmacist’s time for daily
monitoring and support
30 minutes daily for PN No additional pharmacist’s time for daily monitoring
and support of PN
Additional staff time Additional staff time included No additional staff time to implement the interventions
Readmissions from Health
Services Questionnaires
Included in the analysis Excluded from the analysis
Baseline covariates Unadjusted analysis Adjusted for age, ICNARC model physiology score,
surgical status and degree of malnutrition
Distributional assumptions Costs and QALYs
normally distributed
Costs and QALYs gamma distributed
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Cost-effectiveness at 1 year following randomisation (primary outcome)
Mean EQ-5D-5L utility scores, QALYs, total costs and incremental net monetary benefits up to 1 year were
reported for each treatment group. Unadjusted mean differences between the treatment groups in quality
of life, QALYs and incremental costs at 1 year were reported with 95% CIs. These were reported both
overall and by each of the pre-specified subgroups.
Total costs up to 1 year were calculated by combining the resource use with unit costs. For survivors at
1 year, QALYs were calculated assuming an EQ-5D-5L utility score of zero at randomisation, and using the
EQ-5D-5L utility scores at 90 days and 1 year, applying linear interpolation between each pair of time
points. Zero QALYs were assumed for decedents at between randomisation and 90 days. For decedents
at between 90 days and 1 year, a linear interpolation was applied between the EQ-5D-5L utility score at
90 days and the date of death, when an EQ-5D-5L utility score of zero was applied.
The incremental costs and QALYs at 1 year were plotted on the cost-effectiveness plane, and the
cost-effectiveness acceptability curve was plotted. As for the cost-effectiveness analysis at 90 days,
the mean INB at 1 year with corresponding 95% CI was reported overall, by each of the pre-specified
subgroups, and adjusted for adherence.
For the 1-year cost-effectiveness analysis, sensitivity analyses considered the same scenarios as the 90-day
cost-effectiveness analysis (see Table 3).
Lifetime incremental cost-effectiveness
The cost and outcome data reported at 1 year were used to estimate the effect of early nutritional support
for critically ill adult patients via the parenteral route compared with the enteral route on longer-term
costs and outcomes. A time horizon of 20 years was chosen to fully assess the relative impact alternative
routes of early nutritional support. The maximum available survival data from the trial was used to plot
Kaplan–Meier survival curves out to the date of censoring (17 March 2015). The patients who were
observed to be alive at 1 year were extrapolated for years 2–20 by applying parametric extrapolations.
The approach recommended by Latimer was used,56 considering alternative parametric survival curves
and examining their relative fit to the observed data, but also the clinical plausibility of the ensuing
extrapolations. In fitting these curves, survival data for the first 30 days were excluded, as the event
rate during this early period was atypical and would not provide an appropriate basis for subsequent
extrapolation. The relative fit of the alternative survival curves to the observed data was reported. In the
base-case analysis, the survival curve that gave the most plausible extrapolation was applied according to
previous literature and in comparison with age–gender-matched all-cause mortality.56–58 Survival was then
extrapolated according to the chosen parametric function for the duration of years that the parametric
curve predicted excess mortality compared with the age–gender-matched general population, after which
it was assumed that all-cause mortality rates were those of the age–gender-matched general population.
The parametric extrapolation was combined with all-cause mortality rates to report life expectancy for each
CALORIES trial patient who was observed to survive to 1 year.
To project lifetime costs attributable to the initial episode of critical illness, it was assumed that the average
inpatient (general wards not critical care), outpatient and community service costs reported up to 1 year
post-randomisation applied annually for the number of years (within the time horizon) over which the
parametric survival curve predicted excess mortality compared with the age–gender-matched general
population. After the period of excess mortality, it was assumed that there were no further costs
attributable to the initial episode. Similarly, it was assumed that the quality-of-life decrement observed at
1 year compared with the age–gender-matched general population59 was maintained for the years of
excess mortality, after which quality-of-life values for the age–gender-matched general population were
applied. Lifetime QALYs were reported by combining life-years and health-related quality of life.
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The lifetime INB was reported by valuing each QALY according to the NICE-recommended threshold of
willingness to pay for a QALY gain (£20,000) and subtracting the incremental cost. All future costs and
life-years were discounted at the recommended rate of 3.5%.47 The mean lifetime INB with corresponding
95% CI was reported overall, by each of the pre-specified subgroups, and adjusted for adherence.
For the lifetime cost-effectiveness analysis, sensitivity analyses considered the scenarios from the 90-day
and 1-year cost-effectiveness analyses (see Table 3) and also additional scenarios pertinent to the lifetime
analysis. The main assumptions made in the base-case scenario, and how each was relaxed in the
additional sensitivity analyses are detailed below and summarised in Table 4.
Parametric survival model
In the base case, the parametric survival curve that gave the most plausible extrapolation was selected.
In the sensitivity analysis, an alternative parametric survival model was applied.
Death rate for years 2–20
In the base case, the observed mortality data from the CALORIES trial were used for year 1 and the
parametric extrapolation was applied for years 2–20 over the period of excess mortality. In a first sensitivity
analysis, the age–gender-matched general population all-cause death rates were applied for years 2–20.
In a second sensitivity analysis, the observed mortality data from the CALORIES trial were used for years 1
and 2, switching to age–gender-matched general population all-cause death rates for years 3–20.
Quality-of-life decrement
In the base case, a 16% decrement in quality of life was applied over the years of excess mortality. In the
sensitivity analysis, this was reduced to a 5% or 10% decrement.
TABLE 4 Alternative assumptions for sensitivity analysis of lifetime cost-effectiveness
Assumption Base case Sensitivity analysis
Parametric survival model Selected model Alternative model
Death rate years 2–20 Parametric extrapolation applied
over period of excess mortality
Age–gender-matched general population all-cause death
rate applied for years 2–20
Observed mortality data from the CALORIES trial applied
to year 2, and age–gender-matched general population
all-cause death rate applied for years 3–20
Quality-of-life decrement 16% decrement applied over
years of excess mortality
5% or 10% decrement
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Chapter 3 Results: sites and patients
Participants: sites
Expressions of interests were received from 58 NHS adult, general critical care units in the UK. A total of
34 hospitals in England obtained local NHS permissions and opened to recruitment between 17 June 2011
and 14 October 2013. Twenty-one sites were opened within the first 3 months of the trial opening on
17 June 2011 (Figure 4).
The median (IQR) time from local NHS permission to the trial opening at sites (i.e. start of screening) was
63 (23–88) days (Figure 5). Reasons for delays in opening were issues related to confirmation of NHS
support costs from the CLRN and delays in local set-up of the trial, for example training staff.
Overall, sites participated in the CALORIES trial for a median (IQR) of 31 (13–33) months. Of the 34 sites
that opened, five were closed early because of poor recruitment (one unit did not recruit any patients) and
one closed due to loss of eligibility to participate in the trial (no longer actively participating in the Case Mix
Programme). There were 28 sites that remained open until the end of recruitment in March 2014 (Figure 6).
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FIGURE 4 Sites open to recruitment during the trial recruitment period.
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Characteristics of participating sites
The characteristics of the 33 adult general critical care units that participated in the CALORIES trial and
recruited at least one patient compared with all adult general critical care units in the Case Mix Programme
(n= 181) are presented in Table 5. Overall, a mix of university and non-university hospitals, geographically
spread across England, took part in the trial. However, the proportions of units located in a university
hospital and a hospital with a separate high-dependency unit were slightly higher in the CALORIES trial
compared with the Case Mix Programme. There were also a higher proportion of large units (≥ 16 beds)
and units with 1000 or more admissions per year that participated in the CALORIES trial compared with
the Case Mix Programme. There was a higher proportion of units in the CALORIES trial, with > 60% of
bed-days delivered at level 3 (intensive care), than in the Case Mix Programme (see Table 5).
TABLE 5 Representativeness of participating adult, general critical care units
Critical care unit characteristic Units in CALORIES (N= 33) Units in Englanda (N= 181)
Region in England, n (%)
North 5 (15.2) 62 (34.3)
Midlands/East 12 (36.4) 47 (26.0)
London/South East 9 (27.3) 40 (22.1)
South West/South Central 7 (21.2) 32 (17.7)
Teaching status, n (%)
University teaching hospital 12 (36.4) 53 (29.3)
Non-university hospital 21 (63.6) 128 (70.7)
Size of critical care unit, n (%)
< 8 beds 3 (9.1) 39 (21.5)
8–11 beds 8 (24.2) 62 (34.3)
12–15 beds 6 (18.2) 33 (18.2)
≥ 16 beds 16 (48.5) 47 (26.0)
Separate HDU in the same hospital, n (%)
No 21 (63.6) 133 (73.5)
Yes 12 (36.4) 48 (26.5)
Annual critical care unit admissions, n (%)
< 500 admissions 5 (15.2) 55 (30.4)
500–749 admissions 7 (21.2) 60 (33.1)
750–999 admissions 8 (24.2) 31 (17.1)
≥ 1000 admissions 13 (39.4) 35 (19.3)
Percentage of bed-days delivered at level 3 (intensive care), n (%)
< 40% 7 (21.2) 35 (19.3)
40–59.9% 13 (39.4) 100 (55.2)
≥ 60% 13 (39.4) 46 (25.4)
HDU, high-dependency unit.
a Critical care units participating in the Case Mix Programme during 2013.
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Participants: patients
In total, 11,108 patients were screened between 17 June 2011 and 2 March 2014. Of these, 6195
(55.8%) met one or more exclusion criteria. There were 2513 (22.6%) patients who, although eligible for
inclusion in the trial, were not recruited. The most frequently reported reason for not recruiting eligible
patients was that the treating clinician had refused to recruit the patient. Other reported reasons included:
the patient (or their personal/professional consultee) declined to take part; the patient was unable to
provide informed consent and a personal or professional consultee was unavailable or unable to provide
agreement; or logistical issues, which were mainly due to no research staff being available, for example the
patient was not screened for eligibility prior to commencement of early nutritional support (see Figure 7).
The required sample of 2400 (21.6%) patients was recruited between 22 June 2011 and 2 March 2014,
with 1200 randomised to receive early nutritional support via the parenteral route and 1200 to receive
early nutritional support via the enteral route (Figures 7 and 8). There was variation across the 33 sites in
the rate of recruitment (Figure 9); the overall median (IQR) recruitment rate was 0.6 (0.4–0.8) patients per
site per week, with the highest recruitment rate of 1.2 patients per week. Manual randomisation was
required for two patients as a result of the telephone randomisation service being briefly unavailable.
Patients were generally recruited into the CALORIES trial during week days (Monday to Friday) and during
usual office hours (Figures 10 and 11); most of the recruiting sites reported having insufficient resources to
enable screening and recruitment at weekends and outside usual office hours.
For the majority of patients, agreement to participate in the trial was obtained from a personal consultee
prior to randomisation (n= 2212, 92.2%). For the remaining patients, agreement was obtained from a
professional consultee (6.1%) or informed consent was obtained from the patient prior to randomisation
(1.7%) (Table 6). Twelve patients withdrew from the trial, requesting removal of all of their data from the
analysis, resulting in data on 2388 patients for initial analysis (n= 1191 parenteral group; n= 1197 enteral
group). Five patients were subsequently lost to follow-up before 30 days, resulting in data from 2383
patients for analysis of the primary clinical effectiveness outcome (n= 1188, 99.7% parenteral group;
n= 1195, 99.8% enteral group) (see Figure 7). Four patients withdrew from follow-up (n= 3 parenteral
group; n= 1 enteral group) and one was lost to follow-up (enteral group) before 90 days. A further
two patients withdrew from follow-up (both parenteral group) and three were lost to follow-up (n= 2
parenteral group; n= 1 enteral group) before 1 year, resulting in final follow-up of 2372 patients for
1-year mortality (n= 1181, 99.2% parenteral group; n= 1192, 99.5% enteral group). Follow-up was
completed on 23 March 2015.
Characteristics of patients at baseline
The groups were well matched at baseline (Table 7). The mean age of patients was similar in both groups
(63.3 years parenteral group, 62.9 years enteral group) and more than half were male (57.9% parenteral
group, 60.6% enteral group). The severity of illness of patients was similar in the two groups, with a
median (IQR) ICNARC model predicted risk of death of 0.42 (0.22–0.65) in the parenteral group and 0.43
(0.23–0.650 in the enteral group, and mean (SD) SOFA scores of 9.5 (3.4) and 9.6 (3.3), respectively. The
median (IQR) actual or estimated BMI was similar [26.2 kg/m2 (23.0–30.7 kg/m2) parenteral group and
26.8 kg/m2 (23.4–31.3 kg/m2) enteral group].
Multiple imputation
Table 8 reports all the variables considered for multiple imputation, and for each variable, the number of
missing values, and the imputation model chosen.
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Patients met inclusion criteria
(n = 11,108)
Underwent randomisation
(n = 2400)
Met exclusion criteria
(n = 6195)
• Had contraindication to PN or EN, n = 2025
• Received nutritional support within last 
   7 days, n = 1648
• In critical care unit > 36 hours, n = 1368
• Palliative care, n = 504
• Admitted with PEG, PEJ or needle/surgical 
   jejunostomy in situ, n = 428
• Were expected stay in UK < 6 months, n = 99
• Were previously enrolled in CALORIES, n = 84
• Were known to be pregnant, n = 34
• Had injury from burns, n = 5
Were eligible but not randomised
(n = 2513)
• Were excluded by clinician, n = 716
• Declined to give consent/agreement, n = 628
• Were unable to obtain consent/agreement, n = 453
• No research staff available/out of hours, n = 252
• Were participating in another interventional 
   study, n = 209
• PN or EN not available, n = 75
• Site error, n = 25
• Had other reasons, n = 91
• Had no reason given, n = 64
Were assigned to early nutritional
support via the enteral route
(n = 1200)
Received assigned nutritional support
(n = 1167)
Were eligible for analysis
(n = 1197)
Requested removal of all data 
(n = 3)
Were included in cost-effectiveness
primary outcome analysis
(n = 1197)
Were included in clinical primary
outcome analysis
(n = 1195)
Were lost to follow-up 
(n = 2)
Were alive at 90 days
(n = 727)
(79%) returned EQ-5D-5L, n = 574
Were complete, n = 544
Were alive at 1 year
(n = 658)
(76%) returned EQ-5D-5L, n = 498
Were complete, n = 473
Were assigned to early nutritional
support via the parenteral route
(n = 1200)
Received assigned nutritional support
(n = 1155)
Were eligible for analysis
(n = 1191)
Requested removal of all data 
(n = 9)
Were included in cost-effectiveness
primary outcome analysis
(n = 1191)
Were included in clinical primary
outcome analysis
(n = 1188)
Were lost to follow-up
 (n = 3)
Were alive at 90 days
(n = 743)
(80%) returned EQ-5D-5L, n = 591
Were complete, n = 558
Were alive at 1 year
(n = 676)
(74%) returned EQ-5D-5L, n = 497
Were complete, n = 467
FIGURE 7 Screening, randomisation and follow-up. PEG, percutaneous endoscopic gastrostomy; PEJ, percutaneous
endoscopic jejunostomy.
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FIGURE 8 Patient recruitment.
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FIGURE 9 Patient recruitment rate (patients per week).
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FIGURE 10 Randomisation by day of week.
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FIGURE 11 Randomisation by time of day.
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TABLE 6 Informed consent and withdrawals
Type of consent/
agreementa
All patients Parenteral group Enteral group
Patients, n (%) Withdrawalsb Patients, n (%) Withdrawalsb Patients, n (%) Withdrawalsb
Informed consent
from patient prior
to randomisation
41 (1.7) 0 20 (1.7) 0 21 (1.8) 0
Agreement from a
personal consultee
2212 (92.2) 10 1105 (92.1) 8 1107 (92.3) 2
Agreement from a
professional
consultee
147 (6.1) 2 75 (6.3) 1 72 (6.0) 1
Total 2400 (100) 12 1200 (100) 9 1200 (100) 3
a All consent processes were in accordance with the Mental Capacity Act.27
b Patient/consultee requested withdrawal of all data from the analysis.
TABLE 7 Baseline characteristics of patients by treatment group
Characteristic Parenteral group (N= 1191) Enteral group (N= 1197)
Age (years), mean (SD) 63.3 (15.1) [1191] 62.9 (15.4) [1197]
Age (years), median (IQR) 66 (54–75) [1191] 66 (54–74) [1197]
Age < 65 years,a n/N (%) 530/1191 (44.5) 540/1197 (45.1)
Male sex, n/N (%) 689/1191 (57.9) 725/1197 (60.6)
Severe co-existing illness, n/N (%):
Liver 29/1181 (2.5) 34/1193 (2.8)
Renal 20/1181 (1.7) 15/1193 (1.3)
Respiratory 34/1181 (2.9) 23/1193 (1.9)
Cardiovascular 11/1181 (0.9) 14/1193 (1.2)
Immunodeficiency 78/1181 (6.6) 95/1193 (8.0)
Surgery < 24 hours before ICU admission,a n/N (%) 162/1191 (13.6) 167/1197 (14.0)
APACHE II Acute Physiology score,b mean (SD) 15.1 (6.2) [1191] 15.2 (6.2) [1197]
APACHE II Score,c mean (SD) 19.6 (6.9) [1191] 19.6 (7.0) [1197]
APACHE II predicted risk of death,d median (IQR) 0.34 (0.18–0.52) [1162] 0.34 (0.18–0.52) [1173]
ICNARC Physiology Score,e mean (SD) 25.6 (8.0) [1191] 25.8 (7.8) [1197]
ICNARC model predicted risk of death,f median (IQR) 0.42 (0.22–0.65) [1190] 0.43 (0.23–0.65) [1197]
Mechanical ventilation, n/N (%) 979/1178 (83.1) 993/1185 (83.8)
SOFA score,
g
mean (SD) 9.5 (3.4) [1191] 9.6 (3.3) [1191]
Malnutrition status (based on clinical judgement),a n/N (%) 151/1191 (12.7) 152/1197 (12.7)
Actual or estimated BMIh (kg/m2), mean (SD) 27.7 (7.4) [1177] 28.2 (7.5) [1187]
Actual or estimated BMIh (kg/m2), median (IQR) 26.2 (23.0–30.7) [1177] 26.8 (23.4–31.3) [1187]
Ulna length (cm), mean (SD) 26.4 (3.4) [1130] 26.6 (3.7) [1121]
Ulna length (cm), median (IQR) 26.0 (25.0–28.0) [1130] 26.1 (25.0–28.0) [1121]
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TABLE 7 Baseline characteristics of patients by treatment group (continued )
Characteristic Parenteral group (N= 1191) Enteral group (N= 1197)
Mid-upper arm circumference (cm), mean (SD) 30.5 (5.3) [1127] 30.9 (5.4) [1123]
Mid-upper arm circumference (cm), median (IQR) 30.0 (27.0–34.0) [1127] 31.0 (27.0–34.0) [1123]
Degree of malnutrition, n/N (%):
High 74/1152 (6.4) 81/1161 (7.0)
Moderate 8/1152 (0.7) 10/1161 (0.9)
None 1070/1152 (92.9) 1070/1161 (92.2)
a Characteristic included in the minimisation algorithm.
b APACHE II Acute Physiology scores range from 0 to 60, with higher scores indicating greater severity of illness.
The APACHE II Acute Physiology score was based on physiology data from the first 24 hours following admission to the
critical care unit.
c APACHE II scores range from 0 to 71, with higher scores indicating greater severity of illness. The APACHE II score was
based on physiology data from the first 24 hours following admission to the critical care unit.
d APACHE II predicted risk of death before discharge from acute hospital, based on 2013 UK recalibration.
e ICNARC Physiology Scores range from 0 to 100, with higher scores indicating greater severity of illness. The ICNARC
Physiology Score was based on physiology data from the first 24 hours following admission to the critical care unit.
f The ICNARC model predicted risk of death before discharge from acute hospital, based on 2013 UK recalibration.
g SOFA scores range from 0 to 24, with higher scores indicating a greater degree of organ failure. The SOFA score was
calculated using data from the 24 hours prior to randomisation.
h The BMI is the weight, in kilograms, divided by the square of the height, in metres. BMI was based on estimated weight
and/or height for 1552 patients (780 parenteral, 772 enteral).
TABLE 8 Variables considered for multiple imputation and form of imputation model
Variable Missing values,a n (%) Imputation model
Baseline variables
Treatment group 0 (0) None required
Age 0 (0) None required
Sex 0 (0) None required
Surgery within 24 hours prior to admission to ICU 0 (0) None required
Presence of cancer 0 (0) None required
ICNARC Physiology Score 0 (0) None required
Height 23 (1.0) Predictive mean matching
Weight 4 (0.2) Predictive mean matching
Length of forearm (ulna) 137 (5.7) Predictive mean matching
BMI 24 (1.0) Predictive mean matching
APACHE II predicted risk of death 53 (2.2) Predictive mean matching
ICNARC model predicted risk of death 52 (2.2) Predictive mean matching
Mechanical ventilation 25 (1.0) Logistic regression
Degree of malnutrition 75 (3.1) Logistic regression
Extent of fluid retention 44 (1.8) Ordered logistic regression
continued
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TABLE 8 Variables considered for multiple imputation and form of imputation model (continued )
Variable Missing values,a n (%) Imputation model
Resource-use variables
Feeding days 15 (0.6) Predictive mean matching
Days in critical care: index admission 0 (0) None required
Days in critical care: readmission 9 (0.4) Predictive mean matching
Days in general ward: index admission 0 (0) None required
Days in general ward: readmission 9 (0.4) Predictive mean matching
Outpatient, primary and social care visits up to 90 days 616 (41.9) Predictive mean matching
Outpatient, primary and social care visits, 90 days to 1 year 414 (31.0) Predictive mean matching
Mortality and quality-of-life variables
Mortality at 90 days 10 (0.4) Logistic regression
EQ-5D-5L at 90 days 368 (25.0) Predictive mean matching
Mortality at 1 year 15 (0.6) Logistic regression
EQ-5D-5L at 1 year 394 (29.5) Predictive mean matching
a For baseline, resource use in critical care and general medical and mortality variables, the overall sample size was all
randomised patients (n= 2388). For other resource use and quality-of-life variables, the relevant sample sizes were those
patients who were eligible for 90-day follow-up (n= 1470) or 1-year follow-up (n= 1334).
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Chapter 4 Results: clinical effectiveness
Adherence to the protocol
Overall, adherence to delivery of nutritional support during the intervention period was high (Table 9).
A similar number of patients in each treatment group received nutritional support throughout the
intervention period. Any non-adherence to the protocol was reported for 150 (12.6%) patients in the
parenteral group and 127 (10.6%) patients in the enteral group (Table 10).
TABLE 9 Daily adherence according to treatment group
Days from
initiation of
nutritional
supporta
Number
receiving
interventionb
Nutritional support received, n (%) End of intervention, n (%)
Allocated
route
Opposite
route Both Neither Death Discharge
Oral
feeding 120 hours
Parenteral group
Day 1 1167 1155 (99.0) 11 (0.9) 1 (0.1) 0 (0.0) 8 (0.7) 1 (0.1) 1 (0.1) 0 (0.0)
Day 2 1157 1134 (98.0) 11 (1.0) 6 (0.5) 6 (0.5) 39 (3.4) 21 (1.8) 23 (2.0) 0 (0.0)
Day 3 1074 1033 (96.2) 15 (1.4) 12 (1.1) 14 (1.3) 28 (2.6) 35 (3.3) 52 (4.8) 0 (0.0)
Day 4 959 898 (93.6) 22 (2.3) 16 (1.7) 23 (2.4) 36 (3.8) 34 (3.5) 43 (4.5) 0 (0.0)
Day 5 846 793 (93.7) 22 (2.6) 19 (2.2) 12 (1.4) 22 (2.6) 30 (3.5) 33 (3.9) 0 (0.0)
Day 6 761 619 (81.3) 39 (5.1) 77 (10.1) 26 (3.4) 11 (1.4) 11 (1.4) 39 (5.1) 700 (92.0)
Enteral group
Day 1 1171 1167 (99.7) 4 (0.3) 0 (0.0) 0 (0.0) 16 (1.4) 4 (0.3) 5 (0.4) 0 (0.0)
Day 2 1146 1120 (97.7) 3 (0.3) 2 (0.2) 21 (1.8) 44 (3.8) 13 (1.1) 42 (3.7) 0 (0.0)
Day 3 1047 987 (94.3) 7 (0.7) 3 (0.3) 50 (4.8) 46 (4.4) 29 (2.8) 69 (6.6) 0 (0.0)
Day 4 903 840 (93.0) 7 (0.8) 7 (0.8) 49 (5.4) 24 (2.7) 24 (2.7) 60 (6.6) 0 (0.0)
Day 5 795 736 (92.6) 9 (1.1) 7 (0.9) 43 (5.4) 38 (4.8) 31 (3.9) 35 (4.4) 0 (0.0)
Day 6 691 627 (90.7) 12 (1.7) 6 (0.9) 46 (6.7) 10 (1.4) 6 (0.9) 26 (3.8) 649 (93.9)
a Day 1 is from initiation of nutritional support until 23.59 on the same day.
b The number receiving intervention at the start of the day. Note: 50 patients (24 parenteral, 26 enteral) were excluded as
they did not receive nutritional support.
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Ninety-seven per cent of patients received nutritional support via the assigned route, with 24 patients
assigned to the parenteral route and 26 patients assigned to the enteral route receiving no nutritional support
(Table 11). The primary reasons in both groups were due to withdrawal of treatment or death [11 (45.8%)
in the parenteral group compared with 11 (42.3%) in the enteral group] and unexpected early extubation
[six (25.0%) in the parenteral group vs. seven (26.9%) in the enteral group]. Twelve patients assigned to the
parenteral route and four patients assigned to the enteral route received their first nutritional support via
the opposite route to that assigned (Table 12). Initiation of nutritional support was delayed beyond 36 hours
from original critical care unit admission for 37 patients assigned to the parenteral route and 41 patients
assigned to the enteral route (Table 13). In the parenteral group, this was primarily due to delays in
prescribing or obtaining PN (n= 12, 32.4%) and problems (i.e. insertion difficulties or delays) with the central
line (n= 8, 21.6%). In the enteral group, over half of the delays were due to problems (i.e. insertion difficulties
or delays) with the nasogastric tube (n= 24, 58.5%).
TABLE 11 Reasons for non-adherence by treatment group: did not receive nutritional support
Reason for non-adherence, n (%) Parenteral group (N= 24) Enteral group (N= 26)
Clinical decision 1 (4.2) 0
New contraindication 1 (4.2) 1 (3.8)
Difficulty siting nasogastric tube 0 3 (11.5)
Treatment withdrawn/death 11 (45.8) 11 (42.3)
Unexpected early extubation 6 (25.0) 7 (26.9)
Unanticipated inter-hospital transfer 3 (12.5) 2 (7.7)
Patient declined intervention 1 (4.2) 0
No reason given 1 (4.2) 2 (7.7)
TABLE 10 Non-adherence according to treatment group
Variable Parenteral group (N= 1191) Enteral group (N= 1197)
Any non-adherence to delivery of nutritional support
during intervention period,a n/N (%)
150/1191 (12.6) 127/1197 (10.6)
Non-adherence, n/N (%)
Did not receive nutritional support 24/1191 (2.0) 26/1197 (2.2)
Received first nutritional support via the opposite route
to assigned
12/1191 (1.0) 4/1197 (0.3)
Initiation of nutritional support > 36 hours after admission
to critical care
37/1191 (3.1) 41/1197 (3.4)
Received early nutritional support via assigned route and
subsequently changed to opposite route during first
120 hours
81/1191 (6.8) 18/1197 (1.5)
Received no nutritional support for at least a full one day
period during the first 120 hours
4/1191 (0.3) 45/1197 (3.8)
Numbers do not add as some patients experienced more than one non-adherence.
a Intervention period is from start of nutritional support to 120 hours, transition to exclusive oral feeding or discharge
from the unit.
RESULTS: CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
Of patients who initially received nutrition via the assigned route, 81 assigned to the parenteral route and
18 assigned to the enteral route subsequently received nutritional support via the alternative route (i.e.
‘crossed over’) during the 120-hour intervention period (Table 14). However, the greatest proportion of
these were towards the end of the 120-hour period, with 27 of the crossovers among those assigned to
the parenteral route occurring in the final 6 hours of the 120-hour intervention period and 41 in the final
24 hours (Figure 12; see also Table 14). Reasons for these late crossovers were primarily due to an error by
the clinical team regarding the precise timing of the end of the 120-hour period (n= 24 in final 24 hours).
TABLE 12 Reasons for non-adherence by treatment group: received first nutritional support via the opposite route
to assigned
Reason for non-adherence, n (%) Parenteral group (N= 12) Enteral group (N= 4)
Clinical decision 2 (16.7) 1 (25.0)
New contraindication 1 (8.3) 0
Did not want to insert new central line 4 (33.3) 0
Difficulty siting nasogastric tube 0 2 (50.0)
Delay prescribing/obtaining PN 2 (16.7) 0
Staff not available 1 (8.3) 0
Error by clinical team 2 (16.7) 1 (25.0)
TABLE 13 Reasons for non-adherence by treatment group: initiation of nutritional support > 36 hours after
admission to critical care
Reason for non-adherence, n (%) Parenteral group (N= 37) Enteral group (N= 41)
Clinical decision 1 (2.7) 5 (12.2)
Vomiting/aspirates 0 2 (4.9)
Agitation 0 1 (2.4)
Difficulty inserting central line 4 (10.8) 0
Delay inserting/confirming position of central line 3 (8.1) 0
Problem with central line 1 (2.7) 0
Did not want to insert new central line 1 (2.7) 0
Difficulty siting nasogastric tube 0 11 (26.8)
Delay inserting/confirming position of
nasogastric tube
0 8 (19.5)
Problem with nasogastric tube 0 5 (12.2)
Delay prescribing/obtaining PN 12 (32.4) 0
Problem with PN bag 1 (2.7) 0
Equipment not available 1 (2.7) 0
Delayed for surgery, scan or other intervention 7 (18.9) 7 (17.1)
Error by clinical team 5 (13.5) 1 (2.4)
No reason given 1 (2.7) 1 (2.4)
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Patients assigned to the enteral route were more likely to have full days with no nutritional support; this
was more likely to occur in the last 48 hours of the intervention period (see Figure 12; Table 15). Among
those receiving nutritional support, the mean number of full days with no nutritional support was 0.004
for the parenteral group and 0.044 for the enteral group. Reasons for no nutritional support for a full day
in the enteral group were primarily due to the patient vomiting or high volumes of aspirates via the
nasogastric tube (n= 12). Nutritional support was stopped temporarily in eight patients for surgery, and a
scan or another intervention and was stopped permanently in eight patients because treatment was
withdrawn and/or the patient was receiving palliative care.
TABLE 14 Reasons for non-adherence by treatment group: crossovers
Reason for non-adherence, n (%)
Parenteral group
Enteral group
(N= 18)
0–95 hours
(N= 40)
96–113 hours
(N= 14)
114–119 hours
(N= 27)
Clinical decision 8 (20.0) 3 (21.4) 0 6 (33.3)
New contraindication 1 (2.5) 0 0 4 (22.2)
Vomiting/aspirates 0 0 0 3 (16.7)
Other complication 4 (10.0) 0 1 (3.4) 1 (5.6)
Problem with central line 10 (25.0) 2 (14.3) 1 (3.4) 0
Problem with nasogastric tube 0 0 0 2 (11.1)
To facilitate discharge 6 (15.0) 1 (7.1) 0 0
EN started while weaning from PN 0 0 2 (6.9) 0
Did not want to start new bag 0 1 (7.1) 6 (22.2) 0
Error by clinical team 11 (27.5) 7 (50.0) 17a (63.0) 2 (11.1)
a For nine patients, crossover occurred at ≥ 119 hours.
TABLE 15 Reasons for non-adherence by treatment group: days with no nutritional support
Reason for non-adherence, n (%) Parenteral group (N= 4) Enteral group (N= 45)
Clinical decision 0 1 (2.2)
New contraindication 0 1 (2.2)
Vomiting/aspirates 1a (25.0) 12 (26.7)
Other complication 0 3 (6.7)
Problem with nasogastric tube 0 6 (13.3)
Treatment withdrawn/palliative care 2 (50.0) 8 (17.8)
Stopped for surgery, scan or other intervention 0 8 (17.8)
No reason given 1 (25.0) 6 (13.3)
a Patient crossed over to nutritional support via the enteral route, which was subsequently stopped because of
high aspirates.
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FIGURE 12 Timing of non-adherence according to treatment group. (a) The timing of crossovers in hours from
initiation of nutritional support; and (b) days (from initiation of nutritional support) on which patients received no
nutritional support for the full day. Seven patients received no nutritional support on more than 1 day.
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Delivery of care by treatment group
In both treatment groups, the median time to initiation of nutritional support was within 24 hours of
critical care unit admission [median (IQR) 23.5 (16.8–30.0) hours in the parenteral group and 21.8
(15.5–27.8) hours in the enteral group] (Table 16).
The mean total calories received during the 120-hour intervention period was higher in the parenteral
group than the enteral group [mean (SD) 88.7 (44.0) kcal/kg in the parenteral group vs. 74.2 (44.2) kcal/kg
in the enteral group] (see Table 16). On average, daily caloric intake was higher in patients assigned to
the parenteral route [mean (SD) 21.3 (7.7) kcal/kg/day] than in those assigned to the enteral route
[mean (SD) 18.5 (7.7) kcal/kg/day] (Table 17; Figure 13). However, in the majority of patients, the targeted
delivery of 25 kcal/kg/day was not achieved irrespective of route of delivery (Figure 14).
The mean total protein received during the 120-hour intervention period was similar in the two groups
[mean (SD) 2.9 (1.6) g/kg in the parenteral group vs. 2.7 (1.8) g/kg in the enteral group] (see Table 16). The
average daily protein received per day was also similar for the two groups [mean (SD) 0.7 (0.3) g/kg/day in
the parenteral group vs. 0.6 (0.3) g/kg/day in the enteral group] (see Table 17; Figure 15).
TABLE 16 Delivery of care according to treatment group
Variable
Parenteral group
(N= 1191)
Enteral group
(N= 1197)
Time from ICU admission to initiation of early nutritional support
(hours), median (IQR)
23.5 (16.8–30.0) [1167] 21.8 (15.5–27.8) [1171]
Calories received during intervention period (kcal/kg),a mean (SD)
Total 88.7 (44.0) [1155] 74.2 (44.2) [1175]
From parenteral feed 76.2 (40.9) [1186] 0.7 (7.1) [1196]
From enteral feed 2.0 (12.1) [1188] 63.5 (41.1) [1196]
From i.v. glucose 1.6 (3.6) [1180] 2.1 (4.8) [1189]
From propofol 7.6 (8.0) [1180] 7.1 (8.1) [1189]
From oral feed 0.7 (3.7) [1165] 0.5 (2.4) [1182]
Protein received during intervention period (g/kg), mean (SD)
Total 2.9 (1.6) [1186] 2.7 (1.8) [1196]
From parenteral feed 2.8 (1.6) [1186] 0.0 (0.3) [1196]
From enteral feed 0.1 (0.5) [1188] 2.6 (1.8) [1196]
Gastric residual volume (ml),b mean (SD)
Total aspirated during intervention period 35.1 (264.7) [1191] 958.3 (1312.1) [1197]
Total replaced during intervention period 24.2 (170.1) [1191] 617.8 (863.0) [1197]
Patients receiving prokinetic drugs during intervention period,b
n/N (%)
26/1191 (2.2) 426/1197 (35.6)
Patients receiving vasoactive agents during intervention period,
n/N (%)
958/1184 (80.9) 1007/1191 (84.6)
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TABLE 16 Delivery of care according to treatment group (continued )
Variable
Parenteral group
(N= 1191)
Enteral group
(N= 1197)
Patients receiving additives during intervention period,c n/N (%)
Glutamine 50/1191 (4.2) 0/1197 (0.0)
Selenium 268/1191 (22.5) 3/1197 (0.3)
Fish oils 38/1191 (3.2) 1/1197 (0.1)
Patients receiving insulin during intervention period, n/N (%) 694/1184 (58.6) 668/1191 (56.1)
Total insulin received during intervention period (IU), mean (SD) 154 (223) [1184] 122 (204) [1191]
Blood glucose during intervention period (mmol/l), mean (SD)
Daily lowest 7.0 (1.4) [1181] 6.5 (1.5) [1186]
Daily highest 10.2 (2.4) [1176] 10.0 (2.5) [1181]
Incidence of diarrhoea during intervention period,d n/N (%) 192/1184 (16.2) 250/1191 (21.0)
Incidence of constipation during intervention period,e n/N (%) 726/1184 (61.3) 643/1191 (54.0)
Time from randomisation to initiation of exclusive oral feeding (days),
median (IQR)
14 (5–36) [1189] 13 (5–32) [1197]
a Intervention period is from start of nutritional support to 120 hours, transition to exclusive oral feeding or discharge from
the unit.
b Recorded only for patients receiving nutritional support via the enteral route.
c Recorded only for patients receiving nutritional support via the parenteral route.
d Diarrhoea defined as loose and unformed or liquid stools on three consecutive days.
e Constipation defined as bowels not opened on three consecutive days.
TABLE 17 Nutritional support per 24 hours
Variable
Parenteral group
(N= 1191)
Enteral group
(N= 1197)
Calories received per 24 hours during intervention period (kcal/kg), mean (SD)
Total 21.3 (7.7) [1155] 18.5 (7.7) [1175]
From parenteral feed 18.2 (7.3) [1186] 0.1 (1.4) [1196]
From enteral feed 0.4 (2.5) [1188] 15.5 (7.3) [1196]
From i.v. glucose 0.5 (1.1) [1180] 0.7 (1.5) [1189]
From propofol 1.9 (2.1) [1180] 1.9 (2.1) [1189]
From oral feed 0.2 (0.9) [1165] 0.2 (0.9) [1182]
Protein received per 24 hours during intervention period (g/kg), mean (SD)
Total 0.7 (0.3) [1186] 0.6 (0.3) [1196]
From parenteral feed 0.7 (0.3) [1186] 0.0 (0.1) [1196]
From enteral feed 0.0 (0.1) [1188] 0.6 (0.3) [1196]
Aspirates per 24 hours during intervention perioda (ml), mean (SD) 7.6 (56.1) [1191] 253.1 (321.4) [1197]
Aspirates put back per 24 hours during intervention perioda (ml),
mean (SD)
5.3 (37.0) [1191] 158.3 (200.8) [1197]
a Recorded only for patients receiving nutritional support via the enteral route.
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FIGURE 13 Daily calories according to treatment group, showing the total calories received per kilogram of actual
(or estimated) body weight for each day from days 1–6. Day 1 data are the values from the time of initiation of
nutritional support to the end of the day of initiation of nutritional support. The horizontal lines within the boxes
indicate medians, the lower and upper ends of the boxes indicate the 25th and 75th percentiles, respectively, and
the lower and upper whiskers indicate the 1st and 99th percentiles, respectively.
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FIGURE 14 Percentage of patients meeting daily energy target according to treatment group, showing the
percentage of patients who met the daily energy target of 25 kcal/kg/day for each day from days 1–6. Day 1 data
are the values from the time of initiation of nutritional support to the end of the day of initiation of nutritional
support. The faded bars show the percentage of patients who met the target having adjusted for part-days of
feeding (e.g. following the death of a patient).
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For patients assigned to the enteral route, the mean total volume of gastric aspirates during the
intervention period was 958ml (253ml/day) and one-third received prokinetics (see Tables 16 and 17).
These were recorded only for patients receiving EN.
For patients assigned to the parenteral route, the most frequent additive to PN during the intervention
period was selenium (22.5%, compared with 4.2% for glutamine and 3.2% for fish oils). These were
recorded only for patients receiving PN.
In both groups, a high proportion of patients received vasoactive agents, although this was slightly higher
in the enteral group (84.6%) than in the parenteral group (80.9%). In both groups, more than half of the
patients received insulin during the intervention period (58.6% in the parenteral group and 56.1% in
the enteral group) (see Table 16). However, patients in the parenteral group received a higher total amount
of insulin [mean (SD) 153.5 (223.0) IU] than patients in the enteral group [mean (SD) 122.3 (204.1) IU].
Median daily SOFA scores were similar in both groups, and decreased during the intervention period (Figure 16).
Patients in the enteral group had a higher incidence of diarrhoea (21% vs. 16% in the parenteral group),
whereas patients in the parenteral group had a higher incidence of constipation (61% vs. 54% in the
enteral group) (see Table 16).
Median time from randomisation to exclusive oral feeding was about 2 weeks in both treatment groups
[median (IQR) 14 (5–36) days in the parenteral group and 13 (5–32) days in the enteral group] (see Table 16).
Table 18 details the nutritional support delivered to patients, by treatment group, in the critical care unit
after the 120-hour intervention period, that is, from 120 hours following initiation of nutritional support to
critical care unit discharge or death. In both groups the most frequently used route for delivery of nutritional
support was the enteral route either exclusively (30% for the parenteral group and 43% for the enteral
group) or with oral feeding (22% and 35%, respectively) (see Table 18). However, those assigned to the
parenteral route were more likely to continue to receive PN, either exclusively or with other routes, beyond
120 hours (37% compared with 7% for the enteral group).
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FIGURE 15 Daily protein according to treatment group. Shows the total protein received for each day from days
1–6. Day 1 data are the values from the time of initiation of nutritional support to the end of the day of initiation
of nutritional support. The horizontal lines within the boxes indicate medians, the lower and upper ends of the
boxes indicate the 25th and 75th percentiles, respectively, and the lower and upper whiskers indicate the 1st and
99th percentiles, respectively.
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FIGURE 16 Daily SOFA score according to treatment group. Shows the SOFA scores for the 24 hours prior to
randomisation (baseline) and from days 1–6. Day 1 data are the values from the time of initiation of nutritional
support to the end of the day of initiation of nutritional support. The horizontal lines within the boxes indicate
medians, the lower and upper ends of the boxes indicate the 25th and 75th percentiles, respectively, and the lower
and upper whiskers indicate the 1st and 99th percentiles, respectively. SOFA scores range from 0 to 24, with higher
scores indicating a greater degree of organ failure.
TABLE 18 Nutritional support in the critical care unit post-intervention
Nutritional support received between 120 hours
and death or discharge,a n (%)
Parenteral group
(N= 700)
Enteral group
(N= 649)
No feed recorded 38b (5.4) 49c (7.6)
Enteral (exclusive) 210 (30.0) 276 (42.5)
Parenteral (exclusive) 13 (1.9) 2 (0.3)
Oral feeding (exclusive) 40 (5.7) 48 (7.4)
Enteral and parenteral feeding 137 (19.6) 25 (3.9)
Enteral and oral feeding 154 (22.0) 230 (35.4)
Parenteral and oral feeding 26 (3.7) 7 (1.1)
Enteral, parenteral and oral feeding 82 (11.7) 12 (1.9)
a For those patients who were alive and in the critical care unit at 120 hours, nutritional support data were collected on
each day until death or discharge from the critical care unit.
b Twenty-seven patients either died or were discharged from the critical care unit within 24 hours following the end of
the intervention.
c Thirty-three patients either died or were discharged from the critical care unit within 24 hours following the end of
the intervention.
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Primary outcome: clinical effectiveness
At 30 days following randomisation, 393 (33.1%) patients assigned to receive nutritional support via the
parenteral route had died compared with 409 (34.2%) patients assigned to receive nutritional support via
the enteral route, corresponding to an absolute risk reduction of 1.15 percentage points (95% CI −2.65 to
4.94; p= 0.57) and a relative risk of 0.97 (95% CI 0.86 to 1.08). This difference remained non-significant
after adjustment for baseline characteristics (odds ratio 0.95, 95% CI 0.79 to 1.13; p= 0.55) (Table 19).
Secondary outcomes: clinical effectiveness
The proportions of patients in the parenteral group who experienced episodes of hypoglycaemia
(p= 0.006) and of vomiting (p< 0.001) were significantly lower than for patients in the enteral group.
There were no significant differences between the groups in any of the other secondary outcomes,
including duration of survival (log-rank test p= 0.056; adjusted Cox proportional hazards regression hazard
ratio 0.90, 95% CI 0.80 to 1.00; p= 0.057) (Table 20; Figures 17 and 18).
Safety monitoring
Fifty-eight patients in both the parenteral group (4.9%) and in the enteral group (4.8%) experienced one
or more serious adverse events (Table 21). The most frequently reported serious adverse events were
ischaemic bowel [n= 8 (0.7%) in the parenteral group and n= 11 (0.9%) in the enteral group], cardiac
arrest [n= 9 (0.8%) in the parenteral group and n= 6 (0.5%) in the enteral group], electrolyte disturbance
[n= 8 (0.7%) in the parenteral group and n= 5 (0.4%) in the enteral group], raised liver enzymes [n= 3
(0.3%) in the parenteral group and n= 7 (0.6%) in the enteral group] and gastrointestinal haemorrhage
[n= 3 (0.3%) in the parenteral group and n= 8 (0.7%) in the enteral group]. There were eight episodes of
hypoglycaemia [n= 5 (0.4%) in the parenteral group and n= 3 (0.3%) in the enteral group] that were
reported as a serious adverse event (see Table 21).
There were five serious, unexpected adverse events that were deemed by the site investigator to be
potentially related to the study treatment in four patients (one with ischaemic bowel and hypoglycaemia,
and one each with upper gastrointestinal haemorrhage and anterolateral myocardial infarction in the
parenteral group, and one with lower gastrointestinal haemorrhage in the enteral group).
TABLE 19 Primary outcome: clinical effectiveness
Outcome
Parenteral group
(N= 1191)
Enteral group
(N= 1197)
Effect estimate
(95% CI) p-value
All-cause mortality at 30 days, n/N (%) 393/1188 (33.1) 409/1195 (34.2) 0.97 (0.86 to 1.08)a 0.57e
1.15 (−2.65 to 4.94)b
0.95 (0.80 to 1.13)c
0.95 (0.79 to 1.13)d 0.55
a Relative risk.
b Absolute risk reduction.
c Unadjusted odds ratio.
d Adjusted odds ratio.
e Fisher’s exact test.
DOI: 10.3310/hta20280 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 28
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harvey et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
TABLE 20 Secondary outcomes: clinical effectiveness
Outcome
Parenteral group
(N= 1191)
Enteral group
(N= 1197)
Effect estimate
(95% CI) p-value
Days alive and free from advanced respiratory
support up to 30 days, mean (SD)
14.3 (12.1) [1186] 14.3
(12.2) [1195]
0.04
(−0.94 to 1.01)a
0.94
Days alive and free from advanced cardiovascular
support up to 30 days, mean (SD)
18.9 (13.5) [1185] 18.5
(13.6) [1195]
0.41
(−0.63 to 1.53)a
0.44
Days alive and free from renal support up to
30 days, mean (SD)
19.1 (13.9) [1186] 18.8
(14.0) [1195]
0.26
(−0.85 to 1.47)a
0.66
Days alive and free from neurological support up
to 30 days, mean (SD)
19.2 (13.8) [1186] 18.9
(14.0) [1195]
0.34
(−0.81 to 1.36)a
0.57
Days alive and free from gastrointestinal support
up to 30 days, mean (SD)
13.0 (11.7) [1186] 13.2
(11.8) [1195]
−0.12
(−1.05 to 0.80)a
0.81
Number of treated infectious complications per
patient, mean (SD)
0.22 (0.60) [1191] 0.21
(0.56) [1197]
0.01
(−0.04 to 0.06)a
0.72
Treated infectious complications, n/N (%)
Chest infection (pneumonia/lower respiratory
tract infection)
135/1191 (11.3) 143/1197 (11.9) 0.61
(−1.96 to 3.18)b
0.66c
Central venous catheter infection 11/1191 (0.9) 9/1197 (0.8) −0.17
(−0.90 to 0.56)b
0.66c
Other vascular catheter infection 4/1191 (0.3) 3/1197 (0.3) −0.09
(−0.52 to 0.35)b
0.73c
Bloodstream infection 27/1191 (2.3) 21/1197 (1.8) −0.51
(−1.64 to 0.61)b
0.39c
Infective colitis 8/1191 (0.7) 4/1197 (0.3) −0.34
(−0.91 to 0.23)b
0.26c
Urinary tract infection 16/1191 (1.3) 15/1197 (1.3) −0.09
(−1.00 to 0.82)b
0.86c
Surgical site infection 10/1191 (0.8) 12/1197 (1.0) 0.16
(−0.60 to 0.93)b
0.83c
Other infectious complications 18/1191 (1.5) 24/1197 (2.0) 0.49
(−0.56 to 1.55)b
0.44c
Non-infectious complications, n/N (%)
Episodes of hypoglycaemiad 44/1191 (3.7)d 74/1197 (6.2)e 2.49
(0.75 to 4.22)b
0.006c
Elevated liver enzymes 212/1191 (17.8) 179/1197 (15.0) −2.85
(−5.81 to 0.12)b
0.07c
Nausea requiring treatment 44/1191 (3.7) 53/1197 (4.4) 0.73
(−0.85 to 2.32)b
0.41c
Abdominal distension 78/1191 (6.5) 99/1197 (8.3) 1.72
(−0.38 to 3.82)b
0.12c
Vomiting 100/1191 (8.4) 194/1197 (16.2) 7.81
(5.20 to 10.43)b
< 0.001c
New or substantially worsened pressure ulcers 181/1190 (15.2) 179/1195 (15.0) −0.23
(−3.10 to 2.64)b
0.91c
Length of stay in the ICU (days), median (IQR)
All 8.1
(4.0–15.8) [1190]
7.3
(3.9–14.3) [1197]
– 0.15
Survivors 8.8
(4.8–17.2) [872]
8.2
(4.9–16.0) [845]
– 0.62
Non-survivors 5.2
(2.3–11.3) [317]
4.3
(1.9–10.2) [352]
– 0.19
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TABLE 20 Secondary outcomes: clinical effectiveness (continued )
Outcome
Parenteral group
(N= 1191)
Enteral group
(N= 1197)
Effect estimate
(95% CI) p-value
Length of stay in acute hospital (days), median (IQR)
All 17 (8–34) [1185] 16 (8–33) [1186] – 0.32
Survivors 24 (14–43) [753] 24 (14–43) [736] – 0.87
Non-survivors 7 (3–16) [431] 6 (2–14) [450] – 0.48
All-cause mortality at ICU discharge, n/N (%) 317/1190 (26.6) 352/1197 (29.4) 0.91
(0.80 to 1.03)f
0.13c
0.86
(0.71 to 1.04)
g
0.12
All-cause mortality at acute hospital discharge,
n/N (%)
431/1185 (36.4) 450/1186 (37.9) 0.96
(0.86 to 1.06)f
0.44c
0.93
(0.78 to 1.11)g
0.43
All-cause mortality at 90 days, n/N (%) 442/1185 (37.3) 466/1193 (39.1) 0.95
(0.86 to 1.06)f
0.40c
0.92
(0.77 to 1.10)g
0.35
All-cause mortality at 1 year, n/N (%) 505/1181 (42.8) 534/1192 (44.8) 0.95
(0.87 to 1.05)f
0.32c
0.91
(0.76 to 1.08)
g
0.28
a Difference in means.
b Absolute risk reduction.
c Fisher’s exact test.
d Twenty-five of these occurred during the first 6 days and the lowest blood glucose was recorded as mean (SD) 3.2
(0.8)mmol/l, median (IQR) 2.9 (2.5–3.7)mmol/l.
e Forty-eight of these occurred during the first 6 days and the lowest blood glucose was recorded as mean (SD) 3.0
(0.8)mmol/l, median (IQR) 3.2 (2.3–3.6)mmol/l.
f Relative risk.
g Adjusted odds ratio.
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FIGURE 17 Kaplan–Meier curves for survival to 90 days following randomisation.
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FIGURE 18 Kaplan–Meier curves for survival to 1 year following randomisation.
TABLE 21 Serious adverse events within 30 days following randomisation
Serious adverse events,a n/N (%)
Parenteral group
(N= 1191)
Enteral group
(N= 1197)
Any 58/1191 (4.9) 58/1197 (4.8)
Specified
Abdominal distension 1/1191 (0.1) 2/1197 (0.2)
Abdominal pain 0/1191 (0.0) 0/1197 (0.0)
Electrolyte disturbance 8/1191 (0.7) 5/1197 (0.4)
Haemopneumothorax 0/1191 (0.0) 0/1197 (0.0)
Hepatomegaly 0/1191 (0.0) 0/1197 (0.0)
Hyperosmolar syndrome 0/1191 (0.0) 0/1197 (0.0)
Hypersensitivity reaction (anaphylactic reaction) 0/1191 (0.0) 0/1197 (0.0)
Hypoglycaemia 5/1191 (0.4) 3/1197 (0.3)
Ischaemic bowel 8/1191 (0.7) 11/1197 (0.9)
Jaundice 1/1191 (0.1) 1/1197 (0.1)
Nausea requiring treatment 0/1191 (0.0) 0/1197 (0.0)
Pneumothorax 1/1191 (0.1) 1/1197 (0.1)
Raised liver enzymes 3/1191 (0.3) 7/1197 (0.6)
Regurgitation or aspiration 2/1191 (0.2) 4/1197 (0.3)
Vascular catheter-related infection 0/1191 (0.0) 0/1197 (0.0)
Vomiting 1/1191 (0.1) 1/1197 (0.1)
Unspecified
Acidosis – metabolic 1/1191 (0.1) 0/1197 (0.0)
Air embolus 1/1191 (0.1) 0/1197 (0.0)
Anterolateral myocardial infarction 1/1191 (0.1) 0/1197 (0.0)
Bilateral pleural effusions 1/1191 (0.1) 0/1197 (0.0)
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Subgroup analyses of the primary outcome
There was no statistically significant interaction between the effect of treatment group on 30-day mortality
and any of the pre-specified subgroups: age, degree of malnutrition, APACHE II predicted risk of death,34
ICNARC predicted risk of death,35 use of mechanical ventilation, presence of cancer and time from
randomisation to start of feeding. The p-values ranged from 0.15 to 0.83 (Figure 19).
TABLE 21 Serious adverse events within 30 days following randomisation (continued )
Serious adverse events,a n/N (%)
Parenteral group
(N= 1191)
Enteral group
(N= 1197)
Bowel obstruction 1/1191 (0.1) 0/1197 (0.0)
Caecal perforation 0/1191 (0.0) 1/1197 (0.1)
Cardiac arrest 9/1191 (0.8) 6/1197 (0.5)
Cerebral infarction 0/1191 (0.0) 2/1197 (0.2)
Complete heart block 1/1191 (0.1) 0/1197 (0.0)
Deteriorating neurological condition 0/1191 (0.0) 1/1197 (0.1)
Extravasation of PN 1/1191 (0.1) 0/1197 (0.0)
Gastrointestinal haemorrhage or bleed 3/1191 (0.3) 8/1197 (0.7)
Hospital-acquired pneumonia leading to acute respiratory
distress syndrome and acute lung injury
1/1191 (0.1) 0/1197 (0.0)
Hypotension 0/1191 (0.0) 1/1197 (0.1)
Hypoxia 3/1191 (0.3) 1/1197 (0.1)
Intracranial haemorrhage 1/1191 (0.1) 0/1197 (0.0)
Liver failure 1/1191 (0.1) 0/1197 (0.0)
Loss of vision 1/1191 (0.1) 0/1197 (0.0)
Lower limb ischaemia 0/1191 (0.0) 1/1197 (0.1)
Multiple organ failure 0/1191 (0.0) 2/1197 (0.2)
Other haemorrhage or bleed 2/1191 (0.2) 1/1197 (0.1)
Perforated duodenal ulcer 1/1191 (0.1) 1/1197 (0.1)
Popliteal artery thrombus 0/1191 (0.0) 1/1197 (0.1)
Pulmonary oedema 2/1191 (0.2) 0/1197 (0.0)
Renal failure 4/1191 (0.3) 1/1197 (0.1)
Respiratory distress 1/1191 (0.1) 0/1197 (0.0)
Sepsis or septic shock 2/1191 (0.2) 2/1197 (0.2)
Shock state 0/1191 (0.0) 1/1197 (0.1)
Sigmoid perforation 0/1191 (0.0) 1/1197 (0.1)
Stroke 1/1191 (0.1) 0/1197 (0.0)
Suspected bacterial peritonitis 1/1191 (0.1) 0/1197 (0.0)
Suspected intra-abdominal ischaemia 0/1191 (0.0) 1/1197 (0.1)
a Adverse events assessed to be serious (i.e. prolonging hospitalisation or resulting in persistent or significant
disability/incapacity), life-threatening or fatal.
Numbers do not add as some patients experienced more than one serious adverse event.
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Secondary analyses of the primary outcome
Only five patients were lost to follow-up prior to 30 days and, therefore, making extreme assumptions for
the outcomes of these patients made minimal difference to the result (relative risk of 30-day mortality
between 0.96 and 0.97).
Adjusting for non-adherence also made minimal difference to the result (relative risk of 30-day mortality
0.96, 95% CI 0.85 to 1.09; p= 0.55).
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Chapter 5 Results: cost-effectiveness
Cost-effectiveness at 90 days following randomisation
Resource use up to 90 days
Most patients followed their randomised route of early nutritional support, with only 81 (6.8%) and 18
(1.5%) patients crossing over in the parenteral route and enteral route groups, respectively (see Chapter 4,
Adherence to protocol). The total volume of feeding per patient (including both parenteral and enteral
products) was higher in the parenteral group (6776ml) than in the enteral group (4446ml) (Table 22).
Patients in the enteral group received more additional energy sources than the parenteral group (except for
insulin and propofol). The intervention required higher staff time for assessment and daily monitoring and
support for the parenteral group, but the enteral group required slightly more staff time to address adverse
events, such as diarrhoea and vomiting. After calendar day 6, the parenteral group had more days on
feeding via both the parenteral and enteral routes than the enteral group. For the index hospital episode,
the mean length of stay in critical care and on general medical wards was higher in the parenteral than
the enteral group. The proportions of patients readmitted, and the average lengths of stay following
readmission were similar between the treatment groups (see Table 22). The average total length of stay in
acute hospital up to 90 days post-randomisation was 26.4 days in the parenteral group compared with
25.9 days in the enteral group.
TABLE 22 Resource use up to 90 days post-randomisation
Resource-use category Parenteral group (N= 1191) Enteral group (N= 1197)
Interventions (from initiation of nutritional support to calendar day 6)
Nutritional products
PN (ml):
Kabiven® 7gN 758 (2197) 0 (0)
NuTRIflex® Lipid Peri 918 (2455) 22 (257)
Kabiven 9gN 909 (2547) 2 (35)
Kabiven 11gN 873 (2441) 7 (203)
Kabiven 5gN 228 (791) 3 (87)
Other parenteral nutrition productsa 2935 (3302) 25 (291)
EN (ml)b 155 (626) 4387 (2722)
Other interventions:
i.v. glucose (4%) (ml) 78 (388) 152 (634)
i.v. glucose (5%) (ml) 592 (955) 618 (918)
i.v. glucose (10%) (ml) 9 (98) 68 (433)
i.v. glucose (20%) (ml) 5 (89) 23 (185)
i.v. glucose (50%) (ml) 7 (79) 18 (222)
Propofol (1%) (ml) 388 (609) 396 (610)
Propofol (2%) (ml) 192 (384) 191 (392)
Insulin (IU) 154 (224) 123 (204)
continued
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Table 23 summarises the resource use reported from responses to the Health Services Questionnaire for
all patients randomised. The mean number of inpatient days reported from hospital admissions, other
than those involving critical care, were 5.1 days for the parenteral group and 4.7 for the enteral group.
The enteral group had a higher average number of contacts with nurses and health visitors than the
parenteral group. All other community care contacts up to 90 days were similar between the treatment
groups. Patients in both groups reported low use of community health services over the 90 days
following randomisation.
Total costs up to 90 days
Intervention costs were higher for the parenteral group, driven by both higher volume of feeding and
higher unit costs of PN products relative to EN products. The net effect of the higher intervention, critical
care and general medical ward costs was that the parenteral group had higher mean total costs per
patient than the enteral group (£24,458 vs. £23,164) (Table 24).
TABLE 22 Resource use up to 90 days post-randomisation (continued )
Resource-use category Parenteral group (N= 1191) Enteral group (N= 1197)
Staff time:
Assessment and set-up (hours) 0.8 (0.3) 0.4 (0.2)
Monitoring and support (hours) 2.3 (1.0) 0.9 (0.5)
Addressing adverse events (hours) 1.8 (2.3) 2.1 (2.4)
Nutritional support in critical care unit between calendar day 7 and 90 days post-randomisation
PN (days) 0.4 (2.8) 0.2 (1.3)
EN (days) 5.7 (11.1) 5.4 (10.9)
Enteral and PN (days) 0.7 (3.6) 0.2 (2.3)
Hospital length of stay
Index admission:
Days in critical care 11.9 (11.3) 11.3 (10.9)
General medical bed-days 13.4 (18.0) 13.3 (18.7)
Readmissions:
Readmissions, n (%) 124 (10) 136 (11)
Days in critical care 0.9 (4.5) 0.9 (4.6)
General medical bed-days 0.3 (3.2) 0.3 (3.2)
Total length of stay up to 90 days 26.4 (23.8) 25.9 (23.8)
a Total volume of all other PN products (excluding top five high-volume products listed in the table). This category includes
35 PN products.
b Total volume of EN products is reported rather than volume for each product.
All values are mean (SD), unless stated otherwise.
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TABLE 23 Resource use from the Health Services Questionnaire between discharge from hospital and 90 days following
randomisation for patients who were alive and who completed the questionnaire at 90 days post-randomisation
Resource-use category Parenteral group (n= 432)a Enteral group (n= 422)a
Inpatient days (general medical) 5.1 (12.8) 4.7 (10.7)
Outpatient visits 2.1 (3.6) 2.4 (4.0)
GP contacts 2.1 (2.5) 2.2 (2.8)
Nurse contacts 2.5 (6.9) 3.0 (7.6)
Occupational therapist contacts 0.8 (2.2) 0.8 (2.2)
Health visitor contacts 0.8 (4.7) 1.6 (8.5)
Clinical psychologist contacts 0.1 (1.0) 0.2 (1.2)
Speech therapist contacts 0.1 (0.7) 0.1 (1.1)
Physiotherapist contacts 1.3 (5.0) 1.4 (4.3)
Dietitian contacts 0.1 (0.6) 0.1 (0.7)
a A total of 311 (42%) and 305 (42%) patients had incomplete 90-day questionnaires in the parenteral and enteral
groups, respectively. Results are presented for the samples with complete information; the number of complete
responses/eligible patients at 90 days were as follows: parenteral group 432/743 (58%), enteral group 422/727 (58%).
All values are mean (SD).
TABLE 24 Costs (£) up to 90 days post-randomisation
Resource-use category Parenteral group (n= 1191) Enteral group (n= 1197)
Interventions (from initiation of nutritional support to calendar day 6)
Nutritional product costs 228 (107) 51 (32)
Other nutritional intervention costs 207 (189) 206 (194)
Staff time costs
Assessment and set-up 41 (16) 17 (8)
Monitoring and support 113 (51) 38 (23)
Addressing adverse events 75 (94) 87 (100)
Nutritional support in critical care unit between calendar day 7 and 90 days post-randomisation
122 (330) 79 (222)
Hospital costs
Index admission
Critical care 17,384 (17,590) 16,545 (16,698)
General medical ward 3672 (4961) 3670 (5131)
Readmission costsa
Critical care 1181 (6327) 1137 (6045)
General medical 77 (886) 91 (892)
Outpatient and community costsb,c 1359 (3376) 1244 (2728)
Total costs up to 90 daysa,b,c 24,458 (21,400) 23,164 (20,449)
a Source: CALORIES data set and Case Mix Programme Database.
b Source: Health Services Questionnaire.
c Following multiple imputation to handle missing resource-use data.
All values are mean (SD), unless stated otherwise.
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Nutritional and health-related quality of life at 90 days
The health status profiles reported from responses to the EQ-5D-5L questionnaires administered at 90 days
post-randomisation are summarised by treatment group in Table 25. The distribution of health status
profiles was similar between the treatment groups. At 90 days, the proportion of patients who reported
‘no problems’ for each dimension of the EQ-5D-5L in the parenteral group was no greater than for the
enteral group. The resultant mean EQ-5D-5L utility scores and QALYs were also similar between the
treatment groups (Table 26). The Satisfaction with Food-related Life questionnaire was very poorly
completed. At 90 days, complete responses were available for only 405/743 (54.5%) eligible patients in
the parenteral group and 378/727 (52.0%) in the enteral group. There was no significant difference in the
mean response with a mean (SD) of 5.2 (1.6) in the parenteral group and 5.1 (1.7) in the enteral group
(mean difference 0.10, 95% CI −0.14 to 0.33; p= 0.43).
Cost-effectiveness at 90 days
The incremental QALY gain for early nutritional support via the parenteral versus the enteral route was
small and with a 95% CI that included zero (Table 27). The average costs were higher for the parenteral
group, but this difference was not statistically significant. The INB for the parenteral route compared with
the enteral route was negative at −£1263 (95% CI −£2952 to £426) (see Table 27).
When the uncertainty in the incremental costs and QALYs is represented on the cost-effectiveness plane,
the majority of the points are in the quadrant that shows that early nutritional support via the parenteral
route has, on average, higher costs and improves QALYs, although the magnitude of these average QALY
gains was small (Figure 20). The probability that early nutritional support via the parenteral route is more
cost-effective at 90 days than via the enteral route – given the data – is never > 10%, irrespective of how
much society is willing to pay for a QALY gain (Figure 21).
TABLE 25 The EQ-5D-5L health state profiles for patients who were alive and fully completed the questionnaire at
90 days post-randomisation
EQ-5D-5L component Parenteral group (n= 558)a Enteral group (n= 544)a
Mobility
No problems 170 (30) 168 (31)
Slight problems 118 (21) 108 (20)
Moderate problems 135 (24) 142 (26)
Severe problems 75 (13) 76 (14)
Extreme problems 60 (11) 50 (9)
Self-care
No problems 299 (54) 293 (54)
Slight problems 106 (19) 113 (21)
Moderate problems 85 (15) 72 (13)
Severe problems 31 (6) 29 (5)
Extreme problems 37 (7) 37 (7)
Usual activities
No problems 131 (24) 119 (22)
Slight problems 123 (22) 131 (24)
Moderate problems 140 (25) 130 (24)
Severe problems 74 (13) 67 (12)
Extreme problems 90 (16) 97 (18)
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TABLE 25 The EQ-5D-5L health state profiles for patients who were alive and fully completed the questionnaire at
90 days post-randomisation (continued )
EQ-5D-5L component Parenteral group (n= 558)a Enteral group (n= 544)a
Pain/discomfort
No problems 173 (31) 178 (33)
Slight problems 150 (27) 163 (30)
Moderate problems 162 (29) 133 (24)
Severe problems 56 (10) 54 (10)
Extreme problems 17 (3) 16 (3)
Anxiety/depression
No problems 242 (43) 239 (44)
Slight problems 158 (29) 142 (26)
Moderate problems 111 (20) 114 (21)
Severe problems 28 (5) 35 (6)
Extreme problems 19 (3) 14 (3)
a In total, 185 (25%) and 183 (25%) patients had incomplete 90-day questionnaires in the parenteral and enteral groups,
respectively. Results are presented for the samples with complete information; the number of complete responses/eligible
patients at 90 days were as follows: parenteral group 558/743 (75%), enteral group 544/727 (75%).
All values are number (%).
TABLE 26 The EQ-5D-5L utility scores and QALYs up to 90 days post-randomisation
End point Parenteral group (n= 1191) Enteral group (n= 1197)
EQ-5D-5L utility score
(survivors)a
0.655 (0.282) 0.654 (0.283)
QALYsa 0.051 (0.048) 0.050 (0.049)
a The EQ-5D-5L and QALY results are reported after applying multiple imputation to handle missing data.
All numbers are mean (SD).
TABLE 27 Cost-effectiveness at 90 days: QALYs, total costs (£) and INB (INB, £)
End point
Parenteral group
(n= 1191)
Enteral group
(n= 1197)
Incremental effect (unadjusted),
mean (95% CI) p-value
QALYsa 0.051 (0.048) 0.050 (0.049) 0.002 (−0.002 to 0.006) 0.46
Costs (£)a 24,458 (21,400) 23,164 (20,449) 1293 (−401 to 2988) 0.14
INB (£)a,b −1263 (−2952 to 426) 0.14
a The QALYs, costs and INB results are all reported after applying multiple imputation to handle missing data.
b The INB is calculated according to NICE methods guidance, by multiplying the mean QALY gain (or loss) by £20,000 and
subtracting from this the incremental cost.
All values are mean (SD), unless stated otherwise.
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FIGURE 20 Uncertainty in the mean costs (£) and QALY differences and their distribution for early nutritional
support via the parenteral vs. the enteral route (within 90 days post-randomisation).
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FIGURE 21 Cost-effectiveness acceptability curve, reporting the probability that early nutritional support via the
parenteral route is cost-effective (within 90 days post-randomisation) at alternative willingness to pay for a
QALY gain.
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The estimated INBs were similar across all the scenarios considered in the sensitivity analyses (Figure 22).
For example, the INB remains around −£1300 whether additional staff time is required to deliver
nutritional support in the critical care or list prices of feeding products are considered. Similarly, excluding
readmissions that were reported from responses to the Health Services Questionnaire – to avoid any risk of
double-counting – had only a small impact on the mean INB (−£1147 vs. −£1263).
The results of the subgroup analyses are presented in Table 28, and show that the incremental QALYs
were similar across all subgroups. Although there were some subgroups of patients for whom the
incremental costs of early nutritional support via the parenteral route were negative, and hence the INBs
were positive, the statistical uncertainty surrounding these findings was high. For patients with higher
APACHE II predicted risk of death (0.52–0.98), early nutritional support via the parenteral route was more
costly and the QALY gain was small, leading to significant negative INB. For all other subgroups, as for the
overall results, the CIs around the INB included zero.
Distributional assumptions
Baseline covariates
Excluding readmissions
No additional staff time for 
nutritional support
No additional dietitian 
monitoring time
No additional pharmacist 
monitoring time
Costs of nutritional products
Base case
INBs at £20,000 per QALY gain (PN vs. EN)
–3500 –3000 –2500 –2000 –1500 –1000 –500 0 500 1000
FIGURE 22 Sensitivity analyses that report the mean (95% CI) INB (at £20,000 per QALY) within 90 days
post-randomisation according to alternative assumptions compared with the base case. The vertical dashed line
indicates INBs in the base-case analysis. The solid vertical line indicates no difference in net monetary benefits
between comparator groups.
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TABLE 28 Incremental cost, incremental QALY and INB (at £20,000 per QALY) within 90 days post-randomisation,
by pre-specified subgroups
Subgroup
Incremental cost (£)
(95% CI)
Incremental QALY
(95% CI) INB (£) (95% CI)
Age (years) 18–53 764
(−2611 to 4140)
0.002
(−0.006 to 0.01)
−729
(−4096 to 2638)
54–65 2027
(−1453 to 5508)
0.007
(−0.001 to 0.015)
−1893
(−5363 to 1577)
66–73 1625
(−1814 to 5065)
−0.002
(−0.01 to 0.006)
−1659
(−5090 to 1772)
74–100 1039
(−2149 to 4227)
0.000
(−0.007 to 0.008)
−1030
(−4209 to 2149)
Degree of malnutrition None 1171
(−590 to 2933)
0.001
(−0.003 to 0.005)
−1148
(−2904 to 608)
Moderate/severe 2683
(−3573 to 8939)
0.004
(−0.011 to 0.02)
−2593
(−8830 to 3644)
APACHE II predicted risk 0.01–0.18 −838
(−4253 to 2578)
0.005
(−0.003 to 0.013)
934
(−2469 to 4337)
0.18–0.34 1669
(−1709 to 5047)
−0.002
(−0.01 to 0.006)
−1706
(−5075 to 1663)
0.34–0.52 −429
(−3906 to 3047)
0.002
(−0.006 to 0.01)
460
(−3006 to 3926)
0.52–0.98 4494
(1182 to 7807)
0.001
(−0.006 to 0.009)
−4469
(−7773 to −1165)
ICNARC model predicted risk 0.00–0.22 −1520
(−4899 to 1859)
0.005
(−0.003 to 0.013)
1618
(−1751 to 4987)
0.22–0.43 2735
(−651 to 6122)
−0.003
(−0.011 to 0.005)
−2798
(−6177 to 581)
0.43–0.65 1353
(−2024 to 4730)
0.002
(−0.006 to 0.01)
−1311
(−4679 to 2057)
0.65–0.99 2606
(−757 to 5969)
0.002
(−0.006 to 0.009)
−2572
(−5926 to 782)
Mechanically ventilated No 2514
(−1666 to 6695)
0.007
(−0.003 to 0.017)
−2372
(−6541 to 1797)
Yes 1053
(−801 to 2907)
0.000
(−0.004 to 0.005)
−1044
(−2892 to 804)
Presence of cancer No 1378
(−370 to 3125)
0.001
(−0.003 to 0.005)
−1356
(−3098 to 386)
Yes −581
(−7453 to 6292)
0.007
(−0.009 to 0.023)
718
(−6132 to 7568)
Time to start of feeding (hours) < 24 1482
(−796 to 3759)
0.001
(−0.004 to 0.006)
−1460
(−3731 to 811)
≥ 24 741
(−1876 to 3358)
0.002
(−0.005 to 0.008)
−704
(−3314 to 1906)
Adherence adjusted 1400
(−435 to 3235)
0.002
(−0.003 to 0.006)
−1367
(−3196 to 462)
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Cost-effectiveness at 1 year following randomisation
(primary outcome)
Resource use up to 1 year
The resource use up to 1 year post-randomisation is presented in Table 29. The use of nutritional support
between 90 days and 1 year post-randomisation was very low and similar between the treatment groups.
The number of continuing index admissions and readmissions to hospital between 90 days and 1 year
post-randomisation were also similar. Between 90 days and 1 year post-randomisation, the mean number
of days in critical care was higher for the parenteral than the enteral group, but the mean number
of days on general medical wards was lower. The average total hospital length of stay up to 1 year
post-randomisation was 30.1 days in the parenteral group compared with 29.9 days in the enteral group.
Table 30 reports results from responses to the Health Services Questionnaire administered at 1 year
post-randomisation concerning resource use between 90 days and 1 year. The average number of inpatient
days reported from admissions, which were not to critical care, were lower in the parenteral group
(7.8 days) than in the enteral group (8.9 days). The enteral group had a slightly higher average number of
outpatient visits and contact with health visitors. The parenteral group had slightly higher average number
of outpatient visits and contacts with nurses, and a lower number of contacts with health visitors than the
enteral group. All other community care contacts between 90 days and 1 year post-randomisation were
similar between the treatment groups. Patients in both groups reported low use of community health
services over 1 year following randomisation.
Total costs up to 1 year
Table 31 reports the total costs at 1 year, across all the resource use items recorded. At 1 year, the mean
total costs per patient were £28,354 for the parenteral group and £26,775 for the enteral group.
TABLE 29 Resource use up to 1 year post-randomisation
Resource use category Parenteral group (N= 1191) Enteral group (N= 1197)
Total hospital length of stay up to 90 days 26.4 (23.8) 25.9 (23.8)
Nutritional support between 90 days and 1 year:
PN (days) 0.03 (1.1) 0 (0)
EN (days) 0.1 (2.4) 0.1 (1.8)
Enteral and PN (days) 0 (0) 0 (0)
Hospital length of stay between 90 days and 1 year
Continuing index admission, n (%) 56 (4.7) 54 (4.5)
Days in critical carea 0.4 (8.4) 0.01 (0.2)
General medical bed-daysa 2.3 (15.5) 2.4 (15.1)
Readmissions, n (%) 61 (5.1) 57 (4.7)
Days in critical carea,b 0.4 (2.2) 0.4 (3.2)
General medical bed-daysa,b 0.7 (6.6) 1.2 (8.8)
Total hospital length of stay up to 1 year 30.1 (36.7) 29.9 (36.0)
a Source: CALORIES trial data set and Case Mix Programme Database.
b Following multiple imputation to handle missing data.
All numbers are mean (SD), unless stated otherwise.
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TABLE 30 Resource use from Health Services Questionnaire between 90 days and 1 year following randomisation
for patients who were alive and who completed the questionnaire at 1 year post-randomisation
Resource-use category Parenteral group (n= 457)a Enteral group (n= 463)a
Inpatient days (general medical) 7.8 (24.9) 8.9 (22.5)
Outpatient visits 6.1 (9.8) 5.6 (7.2)
GP contacts 5.4 (7.5) 5.5 (6.6)
Nurse contacts 7.9 (26.7) 7.3 (17.8)
Occupational therapist contacts 1.4 (5.8) 1.4 (6.5)
Health visitor contacts 0.6 (4.4) 3.9 (53.2)
Clinical psychologist contacts 0.4 (1.8) 0.5 (3.6)
Speech therapist contacts 0.6 (3.2) 0.4 (2.8)
Physiotherapist contacts 1.7 (5.1) 2.0 (5.9)
Dietitian contacts 0.4 (1.4) 0.3 (1.2)
a In total, 219 (32%) and 195 (30%) patients had incomplete 1-year questionnaires in the parenteral and enteral groups,
respectively. Results are presented for the samples with complete information; the number of complete responses/eligible
patients at 1 year were as follows: parenteral group 457/676 (68%), enteral group 463/658 (70%).
All values are mean (SD).
TABLE 31 Costs (£) up to 1 year post-randomisation
Resource-use category Parenteral group (n= 1191) Enteral group (n= 1197)
Total costs up to 90 daysa,b,c 24,458 (21,400) 23,164 (20,449)
Hospital costs between 90 days and 1 year:
Nutritional support 3 (67.5) 1 (17.7)
Ongoing index admissions:
Critical care costsa 554 (13,434) 7 (256)
General medical costsa 622 (4274) 650 (4163)
Readmissions:
Critical care costsa,c 453 (3000) 576 (4446)
General medical costsa,c 197 (1827) 337 (2412)
Outpatient and community costsb,c 2069 (6574) 2040 (5193)
Total costs up to 1 yeara,b,c 28,354 (32,144) 26,775 (26,273)
a Source: CALORIES trial data set and Case Mix Programme Database.
b Source: Health Services Questionnaire.
c Following multiple imputation to handle missing resource-use data.
All numbers are mean (SD), unless stated otherwise.
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Nutritional and health-related quality of life at 1 year
The health status profiles reported from responses to the EQ-5D-5L questionnaires administered at 1 year
post-randomisation are summarised by treatment group in Table 32. At 1 year, the proportion of patients
who reported ‘no problems’ for each dimension of the EQ-5D-5L in the parenteral group was no greater
than for the enteral group. A lower proportion of patients in the parenteral group than in the enteral
group reported ‘extreme problems’ for the mobility and usual activities dimensions of health. On the pain/
discomfort and anxiety/depression dimensions, a higher proportion of patients in the parenteral group as
compared with the enteral group reported ‘extreme problems’. The resultant mean EQ-5D-5L utility scores
were similar between the treatment groups (parenteral group 0.684 vs. enteral group 0.683) (Table 33). At
1 year post-randomisation, a slightly higher proportion of patients in the parenteral group were alive than
in the enteral group but the difference was not statistically significant (see Chapter 4, Secondary outcomes:
clinical effectiveness) and the 1-year QALYs were similar between the treatment groups (see Table 33). At
1 year, complete responses to the Satisfaction with Food-related Life Questionnaire were available for 338
of 676 (50.0%) eligible patients in the parenteral group and 322 of 658 (48.9%) in the enteral group.
There was no significant difference in the mean response, with a mean (SD) of 5.3 (1.6) in the parenteral
group and 5.4 (1.6) in the enteral group (mean difference −0.10, 95% CI −0.35 to 0.14; p= 0.41).
TABLE 32 The EQ-5D-5L health state profiles for patients who were alive and who fully completed the
questionnaire at 1 year post-randomisation
EQ-5D-5L component Parenteral group (N= 467)a Enteral group (N= 473)a
Mobility
No problems 166 (36) 172 (37)
Slight problems 93 (20) 90 (19)
Moderate problems 114 (24) 99 (21)
Severe problems 65 (20) 80 (17)
Extreme problems 29 (6) 32 (7)
Self-care
No problems 280 (61) 287 (61)
Slight problems 87 (19) 71 (15)
Moderate problems 60 (13) 71 (15)
Severe problems 20 (4) 24 (5)
Extreme problems 20 (4) 20 (4)
Usual activities
No problems 151 (32) 163 (34)
Slight problems 110 (24) 104 (22)
Moderate problems 103 (22) 99 (21)
Severe problems 65 (14) 62 (13)
Extreme problems 38 (8) 45 (10)
Pain/discomfort
No problems 145 (31) 159 (34)
Slight problems 139 (30) 136 (29)
Moderate problems 111 (23) 125 (26)
Severe problems 54 (12) 42 (9)
Extreme problems 18 (4) 11 (2)
continued
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Cost-effectiveness at 1 year
The incremental QALY gain for the parenteral group compared with the enteral group was positive, but
with a 95% CI that included zero (Table 34). The mean total costs were higher in the parenteral group, with
an incremental cost of £1580 (95% CI −£792 to £3951). Hence the INB for the parenteral group compared
with the enteral group was negative at −£1320 (95% CI −£3709 to £1069).
When the uncertainty in the incremental costs and QALYs is represented on the cost-effectiveness plane,
the majority of the points are in the quadrant that shows early nutritional support via the parenteral route
has, on average, higher costs and improves QALYs, but again the magnitude of the average QALY gains
was small (Figure 23). The cost-effectiveness acceptability curve (Figure 24) shows that at 1 year the
probability that early nutritional support via the parenteral route is more cost-effective than via the enteral
route – given the data – is < 20% at the £20,000 willingness-to-pay threshold stipulated by NICE and does
not exceed 50% even at £100,000 per QALY.
The estimated INBs were similar across all of the scenarios considered in the sensitivity analyses (Figure 25).
This shows that the base-case results are robust to alternative assumptions.
TABLE 32 The EQ-5D-5L health state profiles for patients who were alive and who fully completed the
questionnaire at 1 year post-randomisation (continued )
EQ-5D-5L component Parenteral group (N= 467)a Enteral group (N= 473)a
Anxiety/depression
No problems 218 (47) 235 (50)
Slight problems 109 (23) 91 (19)
Moderate problems 95 (20) 95 (20)
Severe problems 30 (6) 41 (9)
Extreme problems 15 (3) 11 (2)
a Totals of 209 (31%) and 185 (28%) patients had incomplete 12-month questionnaires in the PN and EN group,
respectively. Results are presented for the samples with complete information; the number of complete responses/eligible
patients at 12 months are as follows: PN: 467/676 (69%), EN: 473/658 (72%).
All values are number (%).
TABLE 33 EQ-5D-5L utility scores and QALYs up to 1 year post-randomisation
End point Parenteral group (N= 1191) Enteral group (N= 1197)
EQ-5D-5L utility score (survivors)a 0.684 (0.285) 0.683 (0.292)
QALYsa 0.348 (0.333) 0.335 (0.332)
a The EQ-5D-5L and QALY results are all reported after applying multiple imputation to handle missing data.
All numbers are mean (SD).
TABLE 34 Cost-effectiveness at 1 year: QALYs, total costs (£) and INB (INB, £)
End point
Parenteral group
(N= 1191)
Enteral group
(N= 1197)
Incremental effect (unadjusted),
mean (95% CI) p-value
QALYsa 0.348 (0.333) 0.335 (0.332) 0.013 (−0.014 to 0.040) 0.35
Costs (£)a 28,354 (32,144) 26,775 (26,273) 1580 (−792 to 3951) 0.19
INB (£)a,b −1320 (−3709 to 1069) 0.28
a The QALYs, costs and INB results are all reported after applying multiple imputation to handle missing data.
b The INB is calculated according to NICE methods guidance, by multiplying the mean QALY gain (or loss) by £20,000, and
subtracting from this the incremental cost.
All numbers are mean (SD), unless stated otherwise.
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FIGURE 23 Uncertainty in the mean costs (£) and QALY differences and their distribution for early nutritional
support via the parenteral route vs. the enteral route (within 1 year post-randomisation).
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FIGURE 24 Cost-effectiveness acceptability curve, reporting the probability that early nutritional support via the
parenteral route is cost-effective (within 1 year post-randomisation) at alternative willingness to pay for a QALY gain.
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The estimated INBs were similar across all pre-specified subgroups (Table 35). As for the results at 90 days,
although there were some subgroups of patients for whom early nutritional support via the parenteral route
was cost-saving and hence their INBs were positive, there was high statistical uncertainty around these
findings. For patients with higher APACHE II predicted risk of death (0.52–0.98), early nutritional support via
the parenteral route was more costly and the INB was negative, and both of these end points were
statistically significant for this subgroup. For all other subgroups, as for the overall results, the CIs around
the INBs included zero.
Lifetime incremental cost-effectiveness
Long-term survival
The Kaplan–Meier survival curves show that when the time horizon was extended beyond 1 year, for those
with survival data available, the probability of survival was higher for the parenteral group than the enteral
group (Figure 26). The survival difference between the treatment groups was maintained over time, even
though a large proportion of cases were censored beyond year 2 following randomisation.
Distributional assumptions
Baseline covariates
Excluding readmissions
No additional staff time for 
nutritional support
No additional dietitian 
monitoring time
No additional pharmacist 
monitoring time
Costs of nutritional products
Base case
INBs at £20,000 per QALY gain (PN vs. EN)
–5000 –4000 –3000 –2000 –1000 0 1000 2000
FIGURE 25 Sensitivity analyses that report the mean (95% CI) INB (at £20,000 per QALY) within 1 year
post-randomisation according to alternative assumptions compared with the base case. The vertical dashed line
indicates INBs in the base-case analysis. The solid vertical line indicates no difference in net monetary benefits
between comparator groups.
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TABLE 35 Incremental cost, incremental QALY and INB (at £20,000 per QALY) within 1 year post-randomisation,
by pre-specified subgroups
Subgroup
Incremental cost (£)
(95% CI)
Incremental QALY
(95% CI) INB (£) (95% CI)
Age (years) 18–53 2017
(−2743 to 6777)
0.016
(−0.037 to 0.07)
−1691
(−6509 to 3127)
54–65 2396
(−2491 to 7283)
0.033
(−0.022 to 0.088)
−1731
(−6671 to 3209)
66–73 983
(−3843 to 5808)
0.005
(−0.049 to 0.06)
−880
(−5754 to 3994)
74–100 1283
(−3189 to 5756)
0.005
(−0.045 to 0.056)
−1177
(−5700 to 3346)
Degree of malnutrition None 1308
(−1157 to 3774)
0.011
(−0.017 to 0.039)
−1086
(−3570 to 1398)
Moderate/severe 4735
(−4052 to 13521)
0.025
(−0.078 to 0.128)
−4235
(−13103 to 4633)
APACHE II predicted risk 0.01–0.18 −1793
(−6581 to 2995)
0.041
(−0.013 to 0.094)
2611
(−2210 to 7432)
0.18–0.34 1776
(−2959 to 6512)
−0.01
(−0.064 to 0.043)
−1985
(−6770 to 2800)
0.34–0.52 −442
(−5308 to 4423)
0.006
(−0.048 to 0.06)
564
(−4333 to 5461)
0.52–0.98 6380
(1745 to 11014)
0.013
(−0.04 to 0.065)
−6129
(−10810 to −1448)
ICNARC model predicted risk 0.00–0.22 −2692
(−7441 to 2058)
0.034
(−0.018 to 0.086)
3370
(−1430 to 8170)
0.22–0.43 4059
(−701 to 8818)
−0.01
(−0.063 to 0.043)
−4260
(−9078 to 558)
0.43–0.65 612
(−4155 to 5379)
0.009
(−0.043 to 0.061)
−428
(−5238 to 4382)
0.65–0.99 4272
(−443 to 8988)
0.015
(−0.037 to 0.066)
−3977
(−8736 to 782)
Mechanically ventilated No 3114
(−2746 to 8973)
0.056
(−0.012 to 0.123)
−1998
(−7910 to 3914)
Yes 1280
(−1320 to 3880)
0.005
(−0.025 to 0.034)
−1187
(−3806 to 1432)
Presence of cancer No 1743
(−702 to 4189)
0.009
(−0.02 to 0.037)
−1573
(−4037 to 891)
Yes −1850
(−11479 to 7779)
0.065
(−0.045 to 0.174)
3142
(−6565 to 12,849)
Time to start of feeding < 24 hours 2766
(−443 to 5974)
0.015
(−0.022 to 0.051)
−2473
(−5704 to 758)
≥ 24 hours −90
(−3778 to 3598)
0.01
(−0.033 to 0.052)
282
(−3441 to 4005)
Adherence adjusted 1710
(−858 to 4277)
0.014
(−0.015 to 0.044)
−1428
(−4014 to 1158)
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To calculate QALYs over 20 years, the long-term survival for each patient was estimated by combining the
observed survival for each patient up to 1 year with their predicted survival for years 2–20. Alternative
parametric extrapolation approaches were compared with predict the longer-term survival of patients
recruited to the CALORIES trial. Figure 27 considers alternative parametric extrapolations for CALORIES trial
patients, using the observed survival data after day 30. The survival data were pooled across the treatment
groups, given that there was no statistically significant evidence of treatment effect on survival at 1 year
and beyond. The parametric models predict excess mortality in patients recruited to the CALORIES trial
compared with the age–gender-matched general population. Of the alternative survival functions, the
log-normal distribution appears to fit the observed data best, in that it reports the lowest Akaike
information criterion (AIC) and Bayesian information criterion (BIC) (Table 36). It also offers the most
plausible projections of future survival (see Figure 27 and Table 36), for which the excess mortality of the
CALORIES trial patients is maintained over the time horizon of the study. In the base case, death rates
were applied according to the most plausible parametric model (i.e. log-normal) for years 2–20. The
logistic model also provides a reasonable fit to the observed data, but the excess mortality is higher than
that of the base-case parametric model. Therefore, a sensitivity analysis extrapolating survival according to
the logistic function was run.
Long-term health-related quality of life
The lifetime cost-effectiveness analysis required quality of life to be estimated over time. Quality of life from
the general population at the age of 64 years (median age of the CALORIES trial 1-year survivors) was used
to predict the long-term health-related quality of life of patients recruited to the CALORIES trial. In the
base case, general population quality of life for years 2–20 with a decrement of 16% to allow for the lower
average quality of life of the CALORIES trial patients (who had survived a critical care episode) was applied.
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FIGURE 26 Kaplan–Meier survival curves.
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Long-term costs
To project lifetime costs attributable to the initial critical care episode, mean inpatient, outpatient and
community costs up to 1 year estimated from the Health Services Questionnaires were considered.
The mean costs for each treatment group were calculated for those patients who survived at least up to
1 year. These mean costs were used to impute mean costs for years 2–20. For each group, these mean
costs were similar (£5629 for the parenteral group and £5625 for the enteral group).
Lifetime incremental cost-effectiveness
Table 37 presents the resultant lifetime QALYs, costs and INB according to the base case assumptions.
Overall, at the NICE-stipulated threshold of £20,000 per QALY, the INB was positive (£440) but with a
wide 95% CI that included zero.
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FIGURE 27 Comparison of alternative parametric survival functions applied to CALORIES data after day 30.
TABLE 36 Fit of alternative parametric survival functions applied to CALORIES data after day 30
Distribution AIC BIC
Gompertz 2930.062 2962.260
Log-normal 2862.885 2895.083
Logistic 2867.942 2900.140
Weibull 2870.448 2902.647
Exponential 3003.800 3030.632
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Figure 28 presents the uncertainties in costs and QALYs extrapolated to the lifetime. There are
considerable uncertainties around both costs and QALYs, with the majority of the points in the quadrant
which shows that early nutritional support via the parenteral route has, on average, higher costs and
improves QALYs. The cost-effectiveness acceptability curve shows that that the probability of early
nutritional support via the parenteral route being most cost-effective is around 60% at the NICE-stipulated
threshold of £20,000 per QALY, increasing to around 80% at higher willingness to pay (Figure 29).
The sensitivity analyses on the lifetime results suggest that these findings are robust to alternative
assumptions, including those applied to extrapolation of long-term survival and to quality of life for
survivors (Figure 30). For example, alternative assumptions for survival extrapolation had small effect on the
mean INB. Similarly, a large decrement compared with a smaller decrement in quality of life had only
marginal impact on the mean INB.
The results of the subgroup analyses presented in Table 38 show that there were some differences in the
direction of mean incremental effects, but high statistical uncertainty surrounds these findings. For each
subgroup, as for the overall results, there was high statistical uncertainty surrounding INBs and all 95% CIs
included zero.
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FIGURE 28 Uncertainty in the mean costs (£) and QALY differences and their distribution for early nutritional
support via the parenteral vs. the enteral route (at lifetime).
TABLE 37 Lifetime cost-effectiveness: QALYs, total costs (£) and INB (INB, £)
End point
Parenteral group
(n= 1191)
Enteral group
(n= 1197)
Incremental effect (unadjusted),
mean (95% CI) p-value
QALYsa 3.996 (3.432) 3.849 (3.448) 0.147 (−0.129 to 0.423) 0.30
Costs (£)a 53,100 (42,282) 50,595 (37,968) 2505 (−733 to 5744) 0.13
INB (£)a,b 440 (−3586 to 4466) 0.83
a The QALYs, costs and INB results are all reported after applying multiple imputation to handle missing data.
b The INB is calculated according to NICE methods guidance, by multiplying the mean QALY gain (or loss) by £20,000, and
subtracting from this the incremental cost.
All numbers are mean (SD), unless stated otherwise.
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FIGURE 29 Cost-effectiveness acceptability curve, reporting the probability that early nutritional support via the
parenteral route is cost-effective (at lifetime) at alternative willingness to pay for a QALY gain.
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FIGURE 30 Sensitivity analyses that report the mean (95% CI) INB (at £20,000 per QALY) at lifetime according to
alternative assumptions compared with the base case. The vertical dashed line indicates INBs in the base-case
analysis. The solid vertical line indicates no difference in net monetary benefits between comparator groups.
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TABLE 38 Lifetime incremental cost, lifetime incremental QALY and lifetime INB (at £20,000 per QALY),
by pre-specified subgroups
Subgroup
Incremental cost (£)
(95% CI)
Incremental QALY
(95% CI) INB (£) (95% CI)
Age (years) 18–53 4246
(−2125 to 10,617)
0.342
(−0.191 to 0.875)
2596
(−5317 to 10,509)
54–65 4558
(−1990 to 11,106)
0.35
(−0.2 to 0.899)
2434
(−5720 to 10,588)
66–73 1192
(−5285 to 7668)
0.034
(−0.51 to 0.578)
−514
(−8568 to 7540)
74–100 1057
(−4942 to 7056)
−0.03
(−0.533 to 0.474)
−1649
(−9104 to 5806)
Degree of malnutrition None 2094
(−1269 to 5458)
0.125
(−0.162 to 0.411)
400
(−3781 to 4581)
Moderate/severe 6654
(−5318 to 18,626)
0.306
(−0.723 to 1.335)
−529
(−15,589 to 14,531)
APACHE II predicted risk 0.01–0.18 304
(−6116 to 6724)
0.347
(−0.187 to 0.881)
6636
(−1259 to 14,531)
0.18–0.34 1958
(−4391 to 8307)
0.014
(−0.516 to 0.544)
−1679
(−9521 to 6163)
0.34–0.52 −1810
(−8362 to 4742)
−0.198
(−0.743 to 0.348)
−2142
(−10,160 to 5876)
0.52–0.98 8776
(2562 to 14,991)
0.364
(−0.155 to 0.884)
−1488
(−9170 to 6194)
ICNARC model predicted risk 0.00–0.22 −1038
(−7359 to 5282)
0.275
(−0.251 to 0.8)
6529
(−1310 to 14,368)
0.22–0.43 5481
(−867 to 11,829)
0.197
(−0.329 to 0.723)
−1539
(−9359 to 6281)
0.43–0.65 −246
(−6592 to 6101)
−0.119
(−0.643 to 0.404)
−2141
(−9927 to 5645)
0.65–0.99 5438
(−853 to 11,730)
0.185
(−0.334 to 0.705)
−1730
(−9447 to 5987)
Mechanically ventilated No 6324
(−1658 to 14,305)
0.527
(−0.153 to 1.207)
4217
(−5726 to 14,160)
Yes 1762
(−1783 to 5308)
0.074
(−0.229 to 0.376)
−292
(−4705 to 4121)
Presence of cancer No 2421
(−908 to 5750)
0.106
(−0.177 to 0.39)
−298
(−4439 to 3843)
Yes 1016
(−12,078 to 14,109)
0.486
(−0.628 to 1.6)
8700
(−7597 to 24,997)
Time to start of feeding < 24 hours 4014
(−345 to 8373)
0.196
(−0.175 to 0.568)
−85
(−5524 to 5354)
≥ 24 hours 394
(−4614 to 5401)
0.079
(−0.348 to 0.505)
1181
(−5070 to 7432)
Adherence adjusted 2711
(−794 to 6217)
0.159
(−0.14 to 0.458)
476
(−3881 to 4833)
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Chapter 6 Discussion and conclusions
Principal findings
Among adults with an unplanned critical care unit admission for whom early nutritional support could be
provided through either the parenteral or the enteral route, there was no significant difference in mortality
at 30 days according to the route of delivery. In addition, there was no significant interaction on the basis
of age, degree of malnutrition, severity of illness or timing of the initiation of nutritional support. The
enteral route was associated with significantly more episodes of hypoglycaemia and vomiting, but there
were no significant differences between treatment groups in the duration of organ support, infectious
complications, critical care unit or hospital length of stay, or duration of survival up to 1 year. The energy
target of 25 kcal/kg/day was not reached in a majority of patients in each treatment group.
Providing nutritional support to critically ill adult patients via the parenteral route compared with the
enteral route is unlikely to be cost-effective. At the primary end point for the cost-effectiveness analysis
at 1 year post-randomisation, on average, early nutritional support via the parenteral route had
higher intervention and morbidity costs, similar QALYs and a negative INB than the enteral route.
Cost-effectiveness results for the pre-specified subgroups were similar to the overall results and the
sensitivity analyses indicated that the conclusions were robust to alternative assumptions to those made
in the base-case analysis. The lifetime analysis indicated that early nutritional support via the parenteral
route had higher mean lifetime QALY at higher additional mean costs, leading to a positive INB but
with a wide 95% CI that included zero.
Interpretation
The CALORIES trial was conducted in a sample of adult general critical care units in the NHS in England
that had pre-existing, established protocols for nutritional support, prevention of infection and for
glycaemic control – reflecting good mainstream practice. The characteristics of participating units were
broadly representative (with a slight preponderance of larger units located in university hospitals unlikely
to jeopardise the generalisability of our findings) and, as a pragmatic effectiveness study, probably
represents the reality of current, NHS nutritional practice in critical care.
There is debate not only about the route, but also about the timing, dose, duration, delivery (continuous
vs. intermittent) and type of nutritional support for critically ill patients. The aim of the CALORIES trial
was to address solely the question about the optimal route. Our pragmatic trial had two major findings.
First, there was no significant difference in outcomes between the two groups, other than the perhaps
unsurprising increase in the incidence of vomiting and hypoglycaemia in patients receiving early nutritional
support via the enteral route. Specifically, we observed neither the trend towards decreased mortality nor
the increase in infectious complications previously reported for patients fed via the parenteral route.2–4
It is possible that the lack of an infectious burden from feeding via the parenteral route is because of
improvements in central venous catheter management (CALORIES data indicate a low incidence
of catheter-related and bloodstream infections);60 delivery and composition of feed; and avoidance of
overfeeding and hyperglycaemia.
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Second, there was only a very small difference in the energy delivered. In both groups, a majority of
patients did not reach caloric targets. Although enteral feeding is commonly associated with a failure to
reach nutritional targets,7,8 there is a widespread assumption that the parenteral route should be more
reliable in guaranteeing delivery.61,62 Although we do not know exactly why target was not achieved in
those fed via the parenteral route, we do know that participation in the CALORIES trial required units to
deliver nutritional support via the parenteral route to more patients than would be their usual practice.
Other possible factors include the lack of availability of feed out-of-hours (nights/weekends); the use of
commercially available products with fixed energy content rather than individualised feeds (with selection
of fixed energy products to under- rather than overprovide energy); interruptions in delivery to allow other
critical care-related procedures to occur; and transfer out of the critical care unit for other procedures.
Another contributory factor, derived from adherence data from the CALORIES trial, indicates that there
was a reluctance to continue delivery via the parenteral route towards the end of the 5-day (120 hours)
intervention period if this necessitated insertion of a new central venous catheter and/or commencement
of a new bag of feed. Finally, there may have been clinical preference for a lower dose. The similar energy
intake between the groups, however, reinforced the evaluation and interpretation of our findings on the
route of delivery, unconfounded by dose.
Although there was a low probability of early nutritional support via the parenteral route being cost-
effective at the primary end point of 1 year, extrapolation to the lifetime resulted in positive INB. At 1 year,
the parenteral route group had higher mean survival than the enteral route group, but survival difference
between the groups was not statistically significant. The lifetime analysis allowed for the non-significant
gains observed in survival at 1 year but did not assume that any gains in mortality were maintained after
1 year. The projected lifetime results indicated QALY gain and higher net monetary benefits for the
parenteral group compared with the enteral route group. However, considerable uncertainty surrounded
the lifetime cost-effectiveness results. The results of the subgroup analysis suggested that the point
estimate of the INB was positive for some subgroups, negative for others, but that the CIs around each of
these estimates were wide and included zero. In interpreting these findings, it should be recognised that
this study was not powered to detect whether there were subgroup by treatment interactions for either
the clinical effectiveness or cost-effectiveness end points, and hence the subgroup results should be
regarded as exploratory.
Strengths and limitations
The CALORIES trial is the largest trial addressing the question of the optimal route of nutritional support in
critical care. In comparison, of trials included in the Canadian Clinical Practice Guidelines Committee’s
meta-analysis of the use of EN versus PN, no trial published prior to the year 2000 contained more than
100 critically ill patients, and those published since 2000 contribute a total of 207 critically ill patients.63
The CALORIES trial was rigorously conducted, with randomised treatment groups that were well balanced
at baseline and with early initiation of nutritional support, as intended. Protocol compliance was high and
loss to follow-up was extremely low.
Our understanding of the consequences of critical illness is much greater than when we designed this trial
back in 2007. The primary outcome measure of mortality, although objective and accurate, does not
recognise the other health states, in particular the consequences of muscle wasting and fatigue,
experienced by many survivors of critical illness. It may also have not been sufficiently sensitive to detect
meaningful differences between the groups.
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Blinding of nutritional support was deemed to be impractical and, although the primary outcome was
objective, some of the secondary outcomes, although defined and objectively assessed, may have been
more vulnerable to observer bias. Given the very large number of participating critical care units and
investigators, it seems improbable that any resulting bias could have been systematic. A relatively large
number of secondary outcomes was evaluated and no formal statistical approach was taken to control for
the multiple analyses; caution should therefore be taken in interpreting statistically significant results on
the secondary outcomes.
Although the trial was not designed specifically to recruit malnourished patients, the small number of
these patients recruited limits the relevant subgroup analysis, thus we cannot rule out a difference in
outcome according to route for this group of patients. The results of the CALORIES trial should not be
generalised to other types of units, other patient groups (from those studied) or other timing, dose (target)
or duration of nutritional support. In addition, a large proportion of eligible but not randomised patients
(28%) were excluded by the clinician, which may limit the generalisability of the results.
The CALORIES trial included the detailed measurement of resource use within a prospectively designed
cost-effectiveness analysis with the collection of resource use data from index and readmissions beyond
the trial intervention period. Three sources (trial case report forms, linked data from the Case Mix
Programme and responses to Health Service Questionnaires) provided detailed resource use measurement
for those events that were anticipated to be the key drivers of the incremental costs of early nutritional
support via the parenteral and enteral routes. Costs of the interventions were calculated to represent
routine NHS critical care practice and extensive sensitivity analyses were performed. Unlike previous
cost-effectiveness analyses, our study has made a direct comparison of early nutritional support via the
parenteral route compared with the enteral route, based on data from a large trial with projected lifetime
cost-effectiveness results using appropriate methods. The study has assessed quality of life at two time
points allowing comparison of changes over time and comparison with the age–gender-matched general
population. Quality of life was measured with the EQ-5D-5L; this version of the instrument was anticipated
to be sensitive to differences in health status between the treatment groups. Nutritional quality of life was
measured by Satisfaction with Food-related Life Questionnaire; it ended up being poorly completed and
thus limited the reliability of the results. To address missing data, we undertook a recommended approach
for multiple imputation and imputed missing values, conditional on all the information observed.
Inevitably, assumptions – in particular, about mortality, quality of life and costs – were required to be made
beyond the observed data. The cost-effectiveness analysis made maximum use of available data from the
CALORIES trial and followed a recommended approach to inform these assumptions. These, and other
requisite structural assumptions, were made transparent and were subjected to extensive sensitivity
analyses. The cost-effectiveness analysis presented results for the same pre-specified subgroups as for the
clinical effectiveness analysis.
Results in context
How do our findings compare with those of other recent trials on nutritional support in the critically ill?
In the Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients (EPaNIC) trial,61
which was conducted in two hospitals (involving seven different ICUs) with patients recruited to receive
early or late parenteral supplementation of enteral feeding (if the enteral route alone was not meeting
their nutritional target). The investigators found an association between supplemental PN delivered within
48 hours after admission (compared with supplemental PN delayed until after 8 days) and an increased
number of new infectious episodes and days of mechanical ventilation. These differences were found both
for the large subgroup of cardiac surgical patients and for other critically ill patients. However, the need of
many patients for nutritional support, the high target energy intake and the practice of using tight
glycaemic control have all been questioned, and make the generalisability of these findings to NHS critical
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care potentially challenging. Post hoc analysis suggested a dose–response relationship between an
increased amount of parenteral supplementation and an increased rate of infectious episodes.64 Despite
important differences between the CALORIES and the EPaNIC trials (research question evaluated, patients
studied, nutrition and other care practices), our results potentially support the hypothesis that among
patients receiving early PN/supplementation, the dose administered may be more associated with harm
than the route of delivery.
In a trial conducted at two ICUs, Heidegger et al.62 found no difference in the rate of infection between
day 8 and day 28 among patients receiving individually optimised PN to supplement inadequate enteral
intake on day 4 and patients receiving EN only. In a trial conducted at 31 ICUs, Doig et al.65 studied
patients with relative contraindications to early enteral feeding and found no differences in 60-day
mortality or the incidence of infection but fewer days of mechanical ventilation in patients receiving early
PN than those with standard care. However, in the standard care group, 27% received early PN and 41%
received no nutritional support.
There are two major and contradictory perspectives when it comes to how much to feed critically ill
patients in the early phase. One perspective maintains that overfeeding is potentially harmful,61,66 a second
that underfeeding is potentially harmful67–69 and a third that there is no difference between underfeeding
and standard feeding.70–72 Still others argue that any effect of nutritional support is likely to be seen only
in selected patients who are at greater nutritional risk as a result either of pre-existing malnutrition, obesity
or of the nature of their presenting illness. In the CALORIES trial, in both groups, the amount of nutrition
delivered was below target but similar to that seen in previous studies in which nutritional targets were
also commonly not met.67,73,74 This suggests that there are substantial practical and organisational obstacles
for both routes of feeding. Other research, more recently, has suggested that it is adequacy of protein
intake, rather than simply energy intake, which requires to be supported in critical illness.70
Previous economic analyses report cost savings with the use of the enteral route, rather than the
parenteral route, in critically ill patients.3,75,76 However, these results need to be interpreted with caution,
as no incremental cost-effectiveness results were provided. A few economic analyses performed only
cost-minimisation analysis because there were no differences in outcome between the parenteral and
enteral routes. These studies have suggested that the parenteral route may significantly reduce total costs
of hospital care.65,77 A few other studies have performed economic analysis of nutritional support in
critically ill patients but the treatment comparators were different from those in the CALORIES trial. For
example, use of early PN compared with late PN in critically ill patients was associated with higher costs
and no additional clinical benefit.78 Early nutrition compared with standard enteral nutrition was found
cost-effective for patients admitted to ICUs.79
Compared with previous economic analyses, our analysis undertook an integrated, full economic
evaluation to provide a direct comparison of early nutritional support via the parenteral route compared
with the enteral route and extrapolated to lifetime cost-effectiveness results. A key advantage of the
integrated economic evaluation, undertaken as part of the CALORIES trial, is that individual-level data
on quality of life and resource use were collected prospectively. The quality-of-life data were collected at
90 days and at 1 year post-randomisation with the EQ-5D-5L version.38 Hence the cost-effectiveness
analysis was able to incorporate any quality-of-life differences between the treatment groups into the final
measures of cost-effectiveness. The quality-of-life results also showed that, for both treatment groups and
time points, patients’ average quality of life (which was between 0.65 and 0.68) was substantially lower
than that for the age–gender-matched general population (approximately 0.81)59 and similar to previous
estimates for general ICU survivors.80 In the CALORIES trial, at 1 year post-randomisation, about 30–40%
of responders reported ‘severe’ or ‘extreme’ problems with mobility and/or undertaking usual activities
indicating substantial ongoing morbidity for this patient group.
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The findings of our study support previous analyses that nutritional support via the parenteral route is
more costly. The results of Doig et al.,65 that early PN is cost saving, are in contrast with both our
integrated economic analysis and another recent costing analysis, by Vanderheyden et al.,78 reporting
increased treatment costs attributable to PN. However, clinical indication and population groups are
different across these studies. The CALORIES trial compared costs and QALYs in critically ill adults for
whom either route was indicated. Doig et al.65 addressed the financial consequences of administering
PN to patients who were unable to receive early enteral nutrition because of short-term relative
contraindications and Vanderheyden et al.78 assessed costs of early PN compared with late PN to critically
ill patients who were able to receive enteral nutrition.
In drawing any comparisons between nutrition studies, it must always be noted that the CALORIES trial
asked a different research question in a different population of critically ill patients to other studies. the
CALORIES trial does, however, suggest that modern, early nutritional support via the parenteral route, as
typically utilised in critical care units in the NHS, is neither more harmful nor more beneficial than via the
enteral route and is unlikely to be cost-effective.
Implications for health care
Providing nutritional support to critically ill patients (who are typically unable to eat and therefore require
artificial feeding) is an accepted fundamental element of providing critical care.
Guidelines
As outlined in Chapter 1, evidence is conflicting regarding the optimum route (parenteral or enteral) of
delivery.2–4 Interpretation of the existing, published meta-analyses of trials comparing nutritional support via
the enteral and parenteral routes in critically ill patients was complicated by small sample sizes; poor
methodological quality; selected groups of critically ill patients studied; lack of standardised definitions for
outcome measures; and interventions combining more than one element of nutritional support, for
example timing and route. CALORIES, as the largest trial addressing the question of optimal route for early
nutritional support in critical care, has substantially added to, and improved, the evidence base. The results
from the CALORIES trial have already been incorporated into the Canadian Clinical Practice Guidelines
Committee’s meta-analysis of the use of EN versus PN63 and it is envisaged that wider incorporation into
ongoing/updated meta-analyses and into national and international guidelines will continue.
Practice
The results of the CALORIES trial support the continuation of current, widespread practice in
NHS critical care units of delivering early nutritional support via the enteral route as both clinically effective
and cost-effective. However, they also challenge concerns about possible harm from delivering early
nutritional support via the parenteral route when such delivery is clinically indicated.
Recommendations for research
Recommendation 1
Evaluation of the longer-term outcomes for patients recruited to the CALORIES trial should be extended
beyond 1 year.
The CALORIES trial indicated considerable uncertainty for both the long-term survival analysis and the
lifetime cost-effectiveness results. Both of these analyses made use of the maximum available observed
data, with the cost-effectiveness analysis making certain plausible assumptions to project longer-term
mortality, quality of life and costs. The cohort of patients recruited to the CALORIES trial provides the
opportunity to obtain ethics approval for a follow-on study to obtain longer-term clinical and economic
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outcomes beyond 1 year – the final end point for the CALORIES trial. These data would reduce the
uncertainty in the survival and cost-effectiveness evidence.
Recommendation 2
Following evaluation of the route for delivery of early nutritional support (CALORIES), a study employing
rigorous consensus methods is required to establish future priorities for research on optimal nutritional
support for all/groups of critically ill patients.
Nutritional support is standard for critically ill patients. The CALORIES trial delivered nutritional support,
early, for 5 days, to a broadly defined patient group, and largely excluded an effect of route of feeding on
clinical outcomes. Nutritional support, however, is a complex combination of other elements – timing,
dose, duration, delivery and type – all of which may affect outcomes and costs. Recent findings from other
contemporaneous, large-scale randomised controlled trials have led to considerable changes in the
understanding of the metabolic response to critical illness and various aspects of nutritional management
and support. Conflicting evidence and controversies remain regarding the optimum provision of nutritional
support to critically ill patients, including timing, duration, optimal calorie and protein intake, the incidence
and management of re-feeding syndrome, the role of gastric residual volume monitoring, the place of
supplemental PN when enteral feeding is deemed insufficient, the role of indirect calorimetry, and
potential indications for several pharmaconutrients.81 There is a need to engage rigorous consensus
methods, involving all stakeholders, to establish the future priorities for basic and clinical research in
this area.
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Appendix 1 Patient information sheet
 
To be printed on local hospital headed paper 
 
 
 
 
 
 
 
 
 
 
Patient Information Sheet 
 
 
CALORIES: Clinical and cost-effectiveness of early nutritional support in critically ill 
patients via the parenteral versus the enteral route  
 
 
Introduction 
We would like to invite you to take part in a research study which aims to find out the best way of 
providing early nutrition to patients in critical care.  The study is being conducted in National Health 
Service (NHS) critical care units around the UK, and is being managed by the Intensive Care 
National Audit & Research Centre (ICNARC) in London. 
 
Before you decide, it is important that you understand why the research is being done and what it 
involves. One of our team will go through this information sheet with you and answer any 
questions you may have.  Feel free to talk to your friends and family about the study if you wish 
and please ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
During illness, after surgery or following an injury, good nutrition is essential to help repair 
damaged tissues and aid recovery. However, providing nutrition to patients, especially those in the 
critical care unit, is difficult because they are often unable to eat food normally.  Patients who are
unable to eat adequate amounts of food are fed special liquid diets which contain all the essential
nutrients they need (e.g. energy, vitamins and minerals).  Liquid diets may be given either via a 
small tube that is passed into the stomach via the nose or mouth (enteral or tube feeding) or via a
catheter into a vein, directly into the bloodstream (parenteral or intravenous feeding).  
 
Both tube feeding and intravenous feeding are routinely used to feed patients in critical care units
but it is not known which is the best method for providing nutrition, particularly during the first few  
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 days following admission, when patients are often at their sickest. The Department of Health is
supporting this clinical study in order to answer this important question. 
 
Why have I been asked to take part in the study? 
You have been asked to take part in the study because the doctors think that you are likely to
remain in the critical care unit for at least three days, and will be unable to eat and drink normally
during that time. To meet your nutritional needs, you will need either tube feeding or intravenous
feeding.  
 
Do I have to take part? 
Joining the study is entirely voluntary. Once you have read this information sheet and you agree to
take part, we will ask you to sign a consent form. You are free to withdraw from the study at any
time, without giving a reason, and this will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
To find out which of the two methods (tube feeding or intravenous feeding) is best, we will put each
patient who agrees to take part into either the tube feeding group or into the intravenous feeding 
group.  At the end of the study we will compare the results to see which method of feeding is best.  
 
To make sure the groups are the same, each patient will be put into one of the two groups
randomly. This will be done by computer based on chance (as if it were tossing a coin). There is an
equal chance that you will receive tube feeding or intravenous feeding. Neither you nor your doctor
will be able to decide which method of feeding you receive.  
 
If you are assigned to the tube feeding group, the amount of liquid feed required will be calculated 
based on your body weight and nutritional needs, and administered according to standard
procedures routinely used in your hospital’s critical care unit. The liquid feed will be given via a
soft, narrow feeding tube inserted into the stomach via the nose or mouth.  These tubes are 
routinely placed into patients admitted to the critical care unit, not only for the purpose of feeding,
but also for giving medication and to help reduce the risk of abdominal bloating and vomiting.  You
will receive tube feeding for five days, unless you are able to eat normally before then.  After this,
the medical team looking after you will decide whether to continue tube feeding or not, based on
your nutritional needs.  You will receive all other care as usual.     
 
If you are assigned to the intravenous feeding group, the amount of liquid feed required will be 
calculated based on your body weight and nutritional needs, and administered according to
standard procedures routinely used in your hospital’s critical care unit. The liquid feed will be given
via a catheter that is placed into a large vein, usually in the neck or chest called a central venous  
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catheter.  Most patients admitted to a critical care unit will have a central venous catheter inserted
for administration of intravenous fluids and medication, as well as for intravenous feeding. You will
receive intravenous feeding for five days, unless you are able to eat normally before then.  After 
this, the medical team looking after you will decide whether to continue intravenous feeding or not,
based on your nutritional needs.  You will receive all other care as usual.     
 
We will collect information about your progress during your stay in the critical care unit and in
hospital.  You will be contacted by a researcher from ICNARC by letter three months and then one
year after you started in the study, and asked to fill in a short questionnaire about your general
health and wellbeing.  We will need your home address for this.  The questionnaires will take about
15-20 minutes to complete. Please see patient progress diagram below. 
 
Patient progress 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other than the way in which you are fed (either tube feeding or intravenous feeding) taking part in 
the study will not affect the care you receive, which will be decided by the medical team looking 
after you.  At any time during the study the medical team responsible for your care may decide to 
change the way you are fed depending on what is appropriate for your needs at the time.  
 
Your GP will be informed about your participation in this study. A researcher from ICNARC will
contact your GP before sending you the questionnaires to complete about your general health and 
well being at three months and again at one year after you entered the study.  
Patient admitted to critical care unit 
Random 
allocation 
Tube feeding 
for 5 days 
Intravenous feeding 
for 5 days 
All other care as decided by 
the medical staff 
3 months after starting in study 
Patient receives health related/nutritional quality of life questionnaire 
1 year after starting in study 
Patient receives health related/nutritional quality of life questionnaire  
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 What are the possible disadvantages and risks of taking part? 
Both tube feeding and intravenous feeding are routinely used in the critical care unit to feed 
patients who are unable to eat a normal diet.  Tube feeding is more common but we do not know if 
it is better than intravenous feeding. There are no additional risks to you if you agree to participate 
in the study, the risks associated with both methods of feeding would be present regardless of 
taking part in this study.     
 
Tube feeding 
The risks are mainly related to placement of the feeding tube and may include irritation to the nose, 
nose bleeds, sinusitis or, rarely, the feeding tube entering the lung.  
 
Intravenous feeding  
The risks are mainly related to placement of the central venous catheter and may include injury to 
the blood vessel causing bleeding or bruising, infection or very rarely puncture of the lung.   
 
Most patients admitted to a critical care unit will have both a feeding tube and a central venous 
catheter inserted as part of routine care. You will be monitored very closely for any complications 
while you are receiving either tube feeding or intravenous feeding and during your entire stay in the 
hospital.  
 
What are the possible benefits of taking part? 
We cannot promise that participation in the study will benefit you during your hospital stay but the 
information we get from this study may help improve the way in which we feed patients in critical 
care units in the future. 
 
What happens when the research study stops? 
Once the research has finished you will receive usual medical care up to and following discharge 
from hospital. However, three months and then one year after you started in the study you will be 
contacted by a researcher from ICNARC by letter to ask you to answer some questions about your 
general health and wellbeing. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed.  If you wish to complain about any aspect of the way you have been 
approached or treated during the course of this study, please contact the Consultant leading the 
study at your hospital (name and contact details are provided below) or the Hospital’s Patient 
Advice & Liaison Service (PALS) – details provided below. 
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In the event that something does go wrong and you are harmed during the research and this is due 
to someone’s negligence then you may have grounds for a legal action for compensation against 
[add relevant NHS Trust here] but you may have to pay your legal costs. The normal NHS 
complaints mechanisms will still be available to you (if appropriate). 
 
Will my taking part in this study be kept confidential? 
Yes at all times, we will follow ethical and legal practice and all information about you will be 
handled in strict confidence. Authorised members of the research team at your hospita l will need to
have access to your medical records in order to collect information needed for this study.   
 
Where possible, any information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised from it.  As some patients may lose touch with
their hospital, we will need to collect important basic information from national records held by the 
NHS Data Linkage Service. To ensure that we identify you correctly on the Data Linkage Service
database, your name, date of birth, postcode and NHS number will be given to ICNARC for this
purpose.  In addition, ICNARC will also be given your address and telephone number so that the 
questionnaires (mentioned previously) can be sent to you. This information will be stored securely
and in strict confidence at ICNARC.  Procedures for handling, processing, storing and destroying 
data at [add relevant NHS Trust here] and at ICNARC are compliant with the Data Protection Act
1998. 
 
What will happen if I don’t want to carry on with the study? 
You may withdraw from the study at any time but we would like to use the data collected up to your
withdrawal. 
 
What will happen to the results of the research study? 
The results of the study will be published in a scientific journal and on the ICNARC website 
(www.icnarc.org). It will not be possible to identify any individual who has taken part in the study in 
the report.  If you would like a copy of the published results, please contact the Consultant leading 
the CALORIES Study at your hospital (contact details below). 
 
Who is funding and organising the study? 
This study is being funded by the National Institute for Health Research (NIHR), Health Technology
Assessment (HTA) Programme.  The study is being sponsored and managed by the Intensive 
Care National Audit & Research Centre (ICNARC). 
DOI: 10.3310/hta20280 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 28
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harvey et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
101
 Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given a favourable opinion 
by the North West London Research Ethics Committee 1.  
 
 
Thank you for taking the time to read this information 
 
For more information about CALORIES: 
Consultant leading the CALORIES Study in your hospital:  
[Insert name local Principal Investigator] 
[Contact telephone number local Principal Investigator] 
 
Research Nurse:  
[Insert name of nurse working on CALORIES locally]  
[Contact telephone number of nurse] 
 
If you are unhappy with any aspect of the study: 
If you do not wish to speak to the research staff listed above, please contact: 
Patient Advisory and Liaison Service (PALS):  
[insert local PALS contact details here] 
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Appendix 2 Case report form
 
Unplanned admission
(including planned now unplanned):
Needs artificial nutrition for two or more days: 
(use clinical judgement)
Yes Y
Yes Y
Process used:
Trial number:Treatment allocation:
Time: (24-hour clock)D D M M 2 0 Y Y H H : M M
Early nutritional support via parenteral route
Patient consent Personal Consultee1 2 Professional Consultee 3
No N
No N
Expected stay in UK less than six months:
Known pregnancy: 
Received PN/EN in last seven days:
Admitted for palliative care:
Pre-existing contraindication to PN/EN:
Percutaneous endoscopic 
gastrostomy/jejunostomy or 
needle/surgical jejunostomy in situ:
Previously randomised into CALORIES:
Burns patient:
No N
Date:
 
Yes YNo planned discharge within three days: 
(use clinical judgement)
Surgery within 24 hours prior 
to critical care:
Yes NoY N Malnourished:
(use clinical judgement)
Age (18 years or over):
Yes NoY N
(24-hour clock)H H : M M
Early nutritional support via enteral route EN
PN
No N
No N
No N
No N
No N
Date: D D M M 2 0 Y Y Time:
Time of original 
admission: (24-hour clock)D D M M 2 0 Y Y H H : M M
Date of original 
admission:
Patient admitted direct from another critical care unit: Yes NoY N
If yes
(24-hour clock)H H : M MDate: D D M M 2 0 Y Y Time:
Signature:
Completed by:
(print name)
N.B. If during screening, a patient is found to be participating in another interventional study/trial, then please contact 
the ICNARC CTU on                          to discuss their participation in CALORIES
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Randomisation – Eligibility 
  
To be completed once consent/agreement is obtained and before calling the Randomisation Service 
 
Admission to your critical care unit  
Record the date and time of admission to your critical care unit.  
 
Original admission to critical care 
If the patient was admitted to your critical care unit from another critical care unit, record the date and time of the 
original admission. 
 
Inclusion – all should be ticked ‘Yes’ to be eligible. 
 
Exclusion – all should be ticked ‘No’ to be eligible. 
 
Surgical/Malnutrition status 
Surgery within 24 hours prior to critical care – i.e within 24 hours prior to original admission to critical care. Surgery 
is defined as undergoing all or part of a surgical procedure or anaesthesia for a surgical procedure in an operating 
theatre or an anaesthetic room.  
 
Malnourished (use clinical judgement) – indicate whether you consider the patient to be malnourished.  
 
Consent/Agreement 
Process used 
Patient consent – the patient provided informed consent.  
Personal Consultee – a relative or friend provided agreement. 
Professional Consultee – an Independent Mental Capacity Advocate provided agreement. 
 
Randomisation 
Treatment allocation – provided by the Randomisation Service.  
 
Trial number – enter 4-digit number, provided by the Randomisation Service. 
 
Information needed by site to randomise a patient 
Randomisation Service – 
Study number – 6551 
Investigator number – XXX 
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 A phase III, open, multicentre randomised controlled trial 
comparing the clinical and cost-effectiveness of 
early nutritional support in critically ill patients 
via the parenteral versus the enteral route 
 
Early nutritional support via parenteral route
Early nutritional support via enteral route
PN
EN
(24-hour clock)H H : M MDate: D D M M 2 0 Y Y Time:
(24-hour clock)H H : M MDate: D D M M 2 0 Y Y Time:
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 First name:
Surname:
NHS number:
Hospital number:
If address not known
Telephone number:
House name/number:
Surname:
Gender:
Address 1:
Address 2:
Postcode:
City:
County:
Country:
House name/number:
Address 1:
Address 2:
Postcode:
City:
County:
Country:
Initials:
Mobile number:
Other number:
Practice name:
Title:
Abroad
Homeless
Military
No fixed abode
A
H
M
N
Residence/status:
Male FemaleM F
Signature: Date completed: D D M M 2 0 Y Y
Case Mix Programme 
Admission number: 
 
Completed by:
(print name)
DOI: 10.3310/hta20280 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 28
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harvey et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
 >5 μg kg-1 min-1
>15 μg kg-1 min-1
≤5 μg kg-1 min-1
Obeys commands
Date completed:Signature:
Pre-sedation value:
Motor response
Spontaneous
To speech 3
To painful stimulation
No response
2
1
Localises to painful stimuli
6
5
Withdrawal to painful stimuli
Abnormal flexion
4
3
Extends to painful stimuli
No response
2
1
Oriented 5
Confused
Inappropriate words
4
3
Incomprehensible sounds
No response
2
1
Vasoactives administered:
If yes
Dobutamine:
Dopamine:Epinephrine:
Norepinephrine:
Yes NoY N
Lowest total GCS:
Eye opening response
4
Yes Y
Yes
Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Not recorded: NR
Verbal response
Y
Yes NoY N
Max. rateMax. rate
Max. rate
D D M M 2 0 Y Y
mlUrine output: NR
M
U
L
x109 l-1Lowest platelets:
Highest creatinine: μmol l-1Lowest MAP:
Lowest SBP/DBP:
mmHg
mmHg
NR
NR
NR
Not recorded (NR) Not recorded (NR)
or
PaO2:
FiO2:
NRkPa mmHgK M.
.
P/F ratio on mechanical ventilation: Yes NoY N
μmol l-1Highest bilirubin: . NR
Lowest P/F ratio:
 
Completed by:
(print name)
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 Hard and formed
N Unable to assessBowels open:
 
2 3 41
Change either to route/site/product 
or a change to exclusive oral feeding: Yes NoY N
If yes, then please complete 
Change to nutritional support form 
and attach to CRF
IV glucose:
Insulin:
ml
IU
Propofol:
D D M M 2 0 Y Y
Adverse event related 
to trial treatment: Yes NoY N If yes, then please complete Safety monitoring form (page 38)
New infectious episode: Yes NoY N If yes, then please complete Infectious episodes form (page 34)
Yes No
Soft and formed Loose and unformed Liquid
Y
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
Yes NoY N
If yes
Yes NoY N
Yes NoY N If yes
ml
U
Oral feed: Yes NoY N Product: Total:
 
Total units:
If yes
Product: Total volume: ml
Route:
PN
EN
J FS OP
S D OJ
Nose Mouth Percutaneous PMN
OtherStomach
Specify other:
Parenteral
Exclusive 
oral feeding O
Enteral
Specify other:
Duodenum Jejunum
Total volume: ml
Total volume of aspirates: Total volume ‘put back’:
Prokinetics: Yes NoY N
ml ml
Product:
Jugular Subclavian Femoral PICC Other
mlIf yes ml1% 2%
ml
Additives: 
Yes NoY NGlutamine: Fish oils: 
Selenium: 
Yes NoY N
Yes NoY N
%%%
(print name)
ml
calories
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Lowest glucose:
Highest glucose:
Highest creatinine:mmol
-1
mmol-1
μmol-1
Lowest Albumin: 
Highest AST:
Highest bilirubin: 
g l-1
units l-1
Highest ALP: units l-1
NR
NR
NR
NR
NR
NR
Systemic antibacterials: Systemic antifungals:
x109 l-1Lowest platelets:
PaO2:
FiO2:
Lowest MAP:
Lowest SBP/DBP:
mmHg
mmHg
NR
NR
NR
Not recorded (NR) Not recorded (NR)
kPa mmHgK M.
.
or
mlUrine output:
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
.
.
.
Lowest P/F ratio:
P/F ratio on mechanical ventilation: Yes NoY N
NR
Vasoactives administered:
If yes
Dobutamine:
Dopamine:Epinephrine:
Norepinephrine:
Yes NoY N
Yes Y
Yes
Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
Max. rateMax. rate
Max. rate
M
U
L≤5 μg kg-1 min-1
>5 μg kg-1 min-1
>15 μg kg-1 min-1
Yes
μmol-1
Highest ALT: units l-1 NR
P TTherapeuticProphylactic
Yes NoY N
If yes
Yes NoY N
P TTherapeutic
If yes
Prophylactic
NR
.
(print name)
Obeys commands
Pre-sedation value:
Motor response
Spontaneous
To speech 3
To painful stimulation
No response
2
1
Localises to painful stimuli
6
5
Withdrawal to painful stimuli
Abnormal flexion
4
3
Extends to painful stimuli
No response
2
1
Oriented 5
Confused
Inappropriate words
4
3
Incomprehensible sounds
No response
2
1
Lowest total GCS:
Eye opening response
4
Not recorded: NR
Verbal response
Yes NoY N
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D D M M 2 0 Y Y
 
Hard and formed
N Unable to assessBowels open:
2 3 41
Change either to route/site/product 
or a change to exclusive oral feeding: Yes NoY N
If yes, then please complete 
Change to nutritional support form 
and attach to CRF
IV glucose:
Insulin:
ml
IU
Propofol:
Adverse event related 
to trial treatment: Yes NoY N If yes, then please complete Safety monitoring form (page 38)
New infectious episode: Yes NoY N If yes, then please complete Infectious episodes form (page 34)
Yes No
Soft and formed Loose and unformed Liquid
Y
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
Yes NoY N
If yes
Yes NoY N
Yes NoY N If yes
ml
U
Oral feed: Yes NoY N Product: Total:
Total units:
If yes
Product: Total volume: ml
Route:
PN
EN
J FS OP
S D OJ
Nose Mouth Percutaneous PMN
OtherStomach
Specify other:
Parenteral
Exclusive 
oral feeding O
Enteral
Specify other:
Duodenum Jejunum
Total volume: ml
Total volume of aspirates: Total volume ‘put back’:
Prokinetics: Yes NoY N
ml ml
Product:
Jugular Subclavian Femoral PICC Other
ml
Additives: 
Yes NoY NGlutamine: Fish oils: 
Selenium: 
Yes NoY N
Yes NoY N
%%%
(print name)
ml
calories
mlIf yes ml1% 2%
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Lowest glucose:
Highest glucose:
Highest creatinine:mmol
-1
mmol-1
μmol-1
Lowest Albumin: 
Highest AST:
Highest bilirubin: 
g l-1
units l-1
Highest ALP: units l-1
NR
NR
NR
NR
NR
NR
Systemic antibacterials: Systemic antifungals:
x109 l-1Lowest platelets:
PaO2:
FiO2:
Lowest MAP:
Lowest SBP/DBP:
mmHg
mmHg
NR
NR
NR
Not recorded (NR) Not recorded (NR)
kPa mmHgK M.
.
or
mlUrine output:
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
.
.
.
Lowest P/F ratio:
P/F ratio on mechanical ventilation: Yes NoY N
NR
Vasoactives administered:
If yes
Dobutamine:
Dopamine:Epinephrine:
Norepinephrine:
Yes NoY N
Yes Y
Yes
Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
Max. rateMax. rate
Max. rate
M
U
L≤5 μg kg-1 min-1
>5 μg kg-1 min-1
>15 μg kg-1 min-1
Yes
μmol-1
Highest ALT: units l-1 NR
P TTherapeuticProphylactic
Yes NoY N
If yes
Yes NoY N
P TTherapeutic
If yes
Prophylactic
NR
.
(print name)
Obeys commands
Pre-sedation value:
Motor response
Spontaneous
To speech 3
To painful stimulation
No response
2
1
Localises to painful stimuli
6
5
Withdrawal to painful stimuli
Abnormal flexion
4
3
Extends to painful stimuli
No response
2
1
Oriented 5
Confused
Inappropriate words
4
3
Incomprehensible sounds
No response
2
1
Lowest total GCS:
Eye opening response
4
Not recorded: NR
Verbal response
Yes NoY N
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D D M M 2 0 Y Y
 
Hard and formed
N Unable to assessBowels open:
2 3 41
Change either to route/site/product 
or a change to exclusive oral feeding: Yes NoY N
If yes, then please complete 
Change to nutritional support form 
and attach to CRF
IV glucose:
Insulin:
ml
IU
Propofol:
Adverse event related 
to trial treatment: Yes NoY N If yes, then please complete Safety monitoring form (page 38)
New infectious episode: Yes NoY N If yes, then please complete Infectious episodes form (page 34)
Yes No
Soft and formed Loose and unformed Liquid
Y
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
Yes NoY N
If yes
Yes NoY N
Yes NoY N If yes
ml
U
Oral feed: Yes NoY N Product: Total:
Total units:
If yes
Product: Total volume: ml
Route:
PN
EN
J FS OP
S D OJ
Nose Mouth Percutaneous PMN
OtherStomach
Specify other:
Parenteral
Exclusive 
oral feeding O
Enteral
Specify other:
Duodenum Jejunum
Total volume: ml
Total volume of aspirates: Total volume ‘put back’:
Prokinetics: Yes NoY N
ml ml
Product:
Jugular Subclavian Femoral PICC Other
ml
Additives: 
Yes NoY NGlutamine: Fish oils: 
Selenium: 
Yes NoY N
Yes NoY N
%%%
(print name)
ml
calories
mlIf yes ml1% 2%
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Lowest glucose:
Highest glucose:
Highest creatinine:mmol
-1
mmol-1
μmol-1
Lowest Albumin: 
Highest AST:
Highest bilirubin: 
g l-1
units l-1
Highest ALP: units l-1
NR
NR
NR
NR
NR
NR
Systemic antibacterials: Systemic antifungals:
x109 l-1Lowest platelets:
PaO2:
FiO2:
Lowest MAP:
Lowest SBP/DBP:
mmHg
mmHg
NR
NR
NR
Not recorded (NR) Not recorded (NR)
kPa mmHgK M.
.
or
mlUrine output:
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
.
.
.
Lowest P/F ratio:
P/F ratio on mechanical ventilation: Yes NoY N
NR
Vasoactives administered:
If yes
Dobutamine:
Dopamine:Epinephrine:
Norepinephrine:
Yes NoY N
Yes Y
Yes
Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
Max. rateMax. rate
Max. rate
M
U
L≤5 μg kg-1 min-1
>5 μg kg-1 min-1
>15 μg kg-1 min-1
Yes
μmol-1
Highest ALT: units l-1 NR
P TTherapeuticProphylactic
Yes NoY N
If yes
Yes NoY N
P TTherapeutic
If yes
Prophylactic
NR
.
(print name)
Obeys commands
Pre-sedation value:
Motor response
Spontaneous
To speech 3
To painful stimulation
No response
2
1
Localises to painful stimuli
6
5
Withdrawal to painful stimuli
Abnormal flexion
4
3
Extends to painful stimuli
No response
2
1
Oriented 5
Confused
Inappropriate words
4
3
Incomprehensible sounds
No response
2
1
Lowest total GCS:
Eye opening response
4
Not recorded: NR
Verbal response
Yes NoY N
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D D M M 2 0 Y Y
 
Hard and formed
N Unable to assessBowels open:
2 3 41
Change either to route/site/product 
or a change to exclusive oral feeding: Yes NoY N
If yes, then please complete 
Change to nutritional support form 
and attach to CRF
IV glucose:
Insulin:
ml
IU
Propofol:
Adverse event related 
to trial treatment: Yes NoY N If yes, then please complete Safety monitoring form (page 38)
New infectious episode: Yes NoY N If yes, then please complete Infectious episodes form (page 34)
Yes No
Soft and formed Loose and unformed Liquid
Y
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
Yes NoY N
If yes
Yes NoY N
Yes NoY N If yes
ml
U
Oral feed: Yes NoY N Product: Total:
Total units:
If yes
Product: Total volume: ml
Route:
PN
EN
J FS OP
S D OJ
Nose Mouth Percutaneous PMN
OtherStomach
Specify other:
Parenteral
Exclusive 
oral feeding O
Enteral
Specify other:
Duodenum Jejunum
Total volume: ml
Total volume of aspirates: Total volume ‘put back’:
Prokinetics: Yes NoY N
ml ml
Product:
Jugular Subclavian Femoral PICC Other
ml
Additives: 
Yes NoY NGlutamine: Fish oils: 
Selenium: 
Yes NoY N
Yes NoY N
%%%
(print name)
ml
calories
mlIf yes ml1% 2%
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Lowest glucose:
Highest glucose:
Highest creatinine:mmol
-1
mmol-1
μmol-1
Lowest Albumin: 
Highest AST:
Highest bilirubin: 
g l-1
units l-1
Highest ALP: units l-1
NR
NR
NR
NR
NR
NR
Systemic antibacterials: Systemic antifungals:
x109 l-1Lowest platelets:
PaO2:
FiO2:
Lowest MAP:
Lowest SBP/DBP:
mmHg
mmHg
NR
NR
NR
Not recorded (NR) Not recorded (NR)
kPa mmHgK M.
.
or
mlUrine output:
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
.
.
.
Lowest P/F ratio:
P/F ratio on mechanical ventilation: Yes NoY N
NR
Vasoactives administered:
If yes
Dobutamine:
Dopamine:Epinephrine:
Norepinephrine:
Yes NoY N
Yes Y
Yes
Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
Max. rateMax. rate
Max. rate
M
U
L≤5 μg kg-1 min-1
>5 μg kg-1 min-1
>15 μg kg-1 min-1
Yes
μmol-1
Highest ALT: units l-1 NR
P TTherapeuticProphylactic
Yes NoY N
If yes
Yes NoY N
P TTherapeutic
If yes
Prophylactic
NR
.
(print name)
Obeys commands
Pre-sedation value:
Motor response
Spontaneous
To speech 3
To painful stimulation
No response
2
1
Localises to painful stimuli
6
5
Withdrawal to painful stimuli
Abnormal flexion
4
3
Extends to painful stimuli
No response
2
1
Oriented 5
Confused
Inappropriate words
4
3
Incomprehensible sounds
No response
2
1
Lowest total GCS:
Eye opening response
4
Not recorded: NR
Verbal response
Yes NoY N
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D D M M 2 0 Y Y
 
Hard and formed
N Unable to assessBowels open:
2 3 41
Change either to route/site/product 
or a change to exclusive oral feeding: Yes NoY N
If yes, then please complete 
Change to nutritional support form 
and attach to CRF
IV glucose:
Insulin:
ml
IU
Propofol:
Adverse event related 
to trial treatment: Yes NoY N If yes, then please complete Safety monitoring form (page 38)
New infectious episode: Yes NoY N If yes, then please complete Infectious episodes form (page 34)
Yes No
Soft and formed Loose and unformed Liquid
Y
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
Yes NoY N
If yes
Yes NoY N
Yes NoY N If yes
ml
U
Oral feed: Yes NoY N Product: Total:
Total units:
If yes
Product: Total volume: ml
Route:
PN
EN
J FS OP
S D OJ
Nose Mouth Percutaneous PMN
OtherStomach
Specify other:
Parenteral
Exclusive 
oral feeding O
Enteral
Specify other:
Duodenum Jejunum
Total volume: ml
Total volume of aspirates: Total volume ‘put back’:
Prokinetics: Yes NoY N
ml ml
Product:
Jugular Subclavian Femoral PICC Other
ml
Additives: 
Yes NoY NGlutamine: Fish oils: 
Selenium: 
Yes NoY N
Yes NoY N
%%%
(print name)
ml
calories
mlIf yes ml1% 2%
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Lowest glucose:
Highest glucose:
Highest creatinine:mmol
-1
mmol-1
μmol-1
Lowest Albumin: 
Highest AST:
Highest bilirubin: 
g l-1
units l-1
Highest ALP: units l-1
NR
NR
NR
NR
NR
NR
Systemic antibacterials: Systemic antifungals:
x109 l-1Lowest platelets:
PaO2:
FiO2:
Lowest MAP:
Lowest SBP/DBP:
mmHg
mmHg
NR
NR
NR
Not recorded (NR) Not recorded (NR)
kPa mmHgK M.
.
or
mlUrine output:
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
.
.
.
Lowest P/F ratio:
P/F ratio on mechanical ventilation: Yes NoY N
NR
Vasoactives administered:
If yes
Dobutamine:
Dopamine:Epinephrine:
Norepinephrine:
Yes NoY N
Yes Y
Yes
Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
Max. rateMax. rate
Max. rate
M
U
L≤5 μg kg-1 min-1
>5 μg kg-1 min-1
>15 μg kg-1 min-1
Yes
μmol-1
Highest ALT: units l-1 NR
P TTherapeuticProphylactic
Yes NoY N
If yes
Yes NoY N
P TTherapeutic
If yes
Prophylactic
NR
.
(print name)
Obeys commands
Pre-sedation value:
Motor response
Spontaneous
To speech 3
To painful stimulation
No response
2
1
Localises to painful stimuli
6
5
Withdrawal to painful stimuli
Abnormal flexion
4
3
Extends to painful stimuli
No response
2
1
Oriented 5
Confused
Inappropriate words
4
3
Incomprehensible sounds
No response
2
1
Lowest total GCS:
Eye opening response
4
Not recorded: NR
Verbal response
Yes NoY N
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D D M M 2 0 Y Y
 
Hard and formed
N Unable to assessBowels open:
2 3 41
Change either to route/site/product 
or a change to exclusive oral feeding: Yes NoY N
If yes, then please complete 
Change to nutritional support form 
and attach to CRF
IV glucose:
Insulin:
ml
IU
Propofol:
Adverse event related 
to trial treatment: Yes NoY N If yes, then please complete Safety monitoring form (page 38)
New infectious episode: Yes NoY N If yes, then please complete Infectious episodes form (page 34)
Yes No
Soft and formed Loose and unformed Liquid
Y
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
Yes NoY N
If yes
Yes NoY N
Yes NoY N If yes
ml
U
Oral feed: Yes NoY N Product: Total:
Total units:
If yes
Product: Total volume: ml
Route:
PN
EN
J FS OP
S D OJ
Nose Mouth Percutaneous PMN
OtherStomach
Specify other:
Parenteral
Exclusive 
oral feeding O
Enteral
Specify other:
Duodenum Jejunum
Total volume: ml
Total volume of aspirates: Total volume ‘put back’:
Prokinetics: Yes NoY N
ml ml
Product:
Jugular Subclavian Femoral PICC Other
ml
Additives: 
Yes NoY NGlutamine: Fish oils: 
Selenium: 
Yes NoY N
Yes NoY N
%%%
(print name)
ml
calories
mlIf yes ml1% 2%
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Lowest glucose:
Highest glucose:
Highest creatinine:mmol
-1
mmol-1
μmol-1
Lowest Albumin: 
Highest AST:
Highest bilirubin: 
g l-1
units l-1
Highest ALP: units l-1
NR
NR
NR
NR
NR
NR
Systemic antibacterials: Systemic antifungals:
x109 l-1Lowest platelets:
PaO2:
FiO2:
Lowest MAP:
Lowest SBP/DBP:
mmHg
mmHg
NR
NR
NR
Not recorded (NR) Not recorded (NR)
kPa mmHgK M.
.
or
mlUrine output:
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
.
.
.
Lowest P/F ratio:
P/F ratio on mechanical ventilation: Yes NoY N
NR
Vasoactives administered:
If yes
Dobutamine:
Dopamine:Epinephrine:
Norepinephrine:
Yes NoY N
Yes Y
Yes
Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
Max. rateMax. rate
Max. rate
M
U
L≤5 μg kg-1 min-1
>5 μg kg-1 min-1
>15 μg kg-1 min-1
Yes
μmol-1
Highest ALT: units l-1 NR
P TTherapeuticProphylactic
Yes NoY N
If yes
Yes NoY N
P TTherapeutic
If yes
Prophylactic
NR
.
(print name)
Obeys commands
Pre-sedation value:
Motor response
Spontaneous
To speech 3
To painful stimulation
No response
2
1
Localises to painful stimuli
6
5
Withdrawal to painful stimuli
Abnormal flexion
4
3
Extends to painful stimuli
No response
2
1
Oriented 5
Confused
Inappropriate words
4
3
Incomprehensible sounds
No response
2
1
Lowest total GCS:
Eye opening response
4
Not recorded: NR
Verbal response
Yes NoY N
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Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
Date of change: D D M M 2 0 Y Y Estimated time: H H : M M
Product: Total volume: ml
Route:
PN
EN
J FS OP
S D OJ
Nose Mouth Percutaneous PMN
OtherStomach
Specify other:
Parenteral
Exclusive 
oral feeding O
Enteral
Specify other:
Duodenum Jejunum
Total volume: ml
Total volume of aspirates: Total volume ‘put back’:
Prokinetics: Yes NoY N
ml ml
Product:
Jugular Subclavian Femoral PICC Other
Additives: 
Yes NoY NGlutamine: Fish oils: 
Selenium: 
Yes NoY N
Yes NoY N
(print name)
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 A
D Time of death: H H : M MDate of death: D D M M 2 0 Y Y
E=Enteral (exclusive), P=Parenteral (exclusive), O=Oral feeding (exclusive),   EP=Enteral & Parenteral, 
EO=Enteral & Oral feeding, PO=Parenteral & Oral feeding, EPO=Enteral, Parenteral & Oral feeding
Route*: Start date:
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
Basic respiratory:
Advanced respiratory:
Basic cardiovascular:
Advanced cardiovascular:
Renal:
Total calendar days
Neurological:
Liver:
Gastrointestinal:
Dermatological:
Level 2:
Level 3:
Total calendar daysTotal calendar days
Time of discharge: H H : M MDate of discharge: D D M M 2 0 Y YAlive:
Dead:
Signature: Date completed: D D M M 2 0 Y Y
Pressure sores:
D D M M 2 0 Y Y
I II
IVIII
Stage I 
Stage III Stage IV
Staging: Stage II
Please report ALL infectious episodes from day 7 to discharge from your critical care unit (page 34) 
Not recorded (NR)
NR
Yes NoY N
If yes
*Route:
 
Systemic antibacterials: Systemic antifungals:
P TTherapeuticProphylactic
Yes NoY N
If yes
Yes NoY N
P TTherapeutic
If yes
Prophylactic
Completed by:
(print name)
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 Start of treatment date:Confirmed2:
D D M M 2 0 Y Y
Signature: Date completed: D D M M 2 0 Y Y
Clinical 
diagnosis1:
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
1Clinical diagnosis: B=Bloodstream infection, C=CVC infection,  I=Infectious colitis,  
O=Other vascular catheter infection, P=Pneumonia, S=Surgical site infection, U=Urinary tract infection
 
Organism(s):
D D M M 2 0 Y Y
D D M M 2 0 Y Y
Clinical diagnosis: Start of treatment date:Confirmed2 rganism(s):
Yes NoY N
Yes NoY N
Yes NoY N
Yes NoY N
Yes NoY N
Yes NoY N
Yes NoY N
2Confirmed = laboratory/microbiological confirmation 
Treatment:
Treatment:
Completed by:
(print name)
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 Start time: (24-hour clock)
*Location:      A=Acute Admissions Unit (or equivalent), W=Ward, I=ICU or ICU/HDU, 
       H=HDU, E=Emergency Department, T=Theatre
Location*: Start date:
Date of discharge: Date of death:
Acute hospital discharge status (from your hospital):
If alive If dead
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y H H : M M
Alive DeadA D
D D M M 2 0 Y Y
Discharge location:
Home
Nursing Home
H
N
Transfer to other acute hospital T
Other O
Specify
D D M M 2 0 Y Y
H H : M M
H H : M M
H H : M M
H H : M M
H H : M M
From your critical care unit 
Time of death: H H : M M
Exclusive oral feeding commenced since discharge from your critical care unit: Yes NoY N
Date exclusive oral feeding commenced: D D M M 2 0 Y Y
If yes
Ultimate discharge from acute hospital:
Date:
Status: Alive DeadA D
D D M M 2 0 Y Y
Signature: Date completed: D D M M 2 0 Y Y
 
Note: Please obtain Retrospective consent prior to discharge
Completed by:
(print name)
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 Haemo-pneumothorax:
Start date: Start time: (24-hour clock)Severity1:
Ischaemic bowel:
Adverse event:
Hypersensitivity reaction 
(anaphylactic reaction):
Related2: 
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y YHyperosmolar syndrome:
H H : M M
2Related (to trial treatment):     0=None, 1=Unlikely, 2=Possibly, 3=Probably, 4=Definitely
1Severity:     0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Fatal
 Note: If Severity 3 or more complete the Serious Adverse Event Reporting Form and fax to ICNARC CTU
Start date: Start time: (24-hour clock)Severity1: Related2: 
D D M M 2 0 Y Y
H H : M M
H H : M M
H H : M M
H H : M M
H H : M M
H H : M M
D D M M 2 0 Y Y H H : M M
D D M M 2 0 Y Y H H : M M
Jaundice:
Hepatomegaly:
Electrolyte disturbance:
Raised liver enzymes:
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
H H : M M
H H : M M
H H : M M
H H : M M
Nausea requiring treatment:
Abdominal pain:
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
Abdominal distension:
H H : M M
H H : M M
H H : M M
H H : M M
D D M M 2 0 Y Y H H : M M
D D M M 2 0 Y Y H H : M M
Signature: Date completed: D D M M 2 0 Y Y
Hypoglycaemia:
D D M M 2 0 Y Y H H : M M
Vomiting:
D D M M 2 0 Y Y H H : M M
Pneumothorax:
Regurgitation/aspiration:
D D M M 2 0 Y Y H H : M M
Vascular catheter related 
infection:
Completed by:
(print name)
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 Regained mental capacity:
Retrospective consent:
Date:
Yes NoY N
D D M M 2 0 Y Y
Obtained
Part-obtained
O
P
Refused
Not sought
R
N
If part-obtained/not sought
Signature: Date completed: D D M M 2 0 Y Y
Details:
 
Completed by:
(print name)
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 Date of death: D D M M 2 0 Y Y
Signature: Date completed: D D M M 2 0 Y Y
If completed, return to ICNARC CTU
By fax: 
By email: 
By post: 
  
  
 
Completed by:
(print name)
DOI: 10.3310/hta20280 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 28
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Harvey et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
127
 Reason (if available):
Date of withdrawal: D D M M 2 0 Y Y
Signature: Date completed: D D M M 2 0 Y Y
If completed, return to ICNARC CTU
By fax: 
By email: 
By post: 
  
  
Consent withdrawn by: Patient 1
Personal Consultee 2
Professional Consultee 3
 
Completed by:
(print name)
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Appendix 3 Severity of illness scores
Acute Physiology and Chronic Health Evaluation version II
The APACHE II Acute Physiology score consists of weightings for 12 physiological parameters to give
a total score ranging from 0 to 60, with higher scores indicating greater severity of illness.34 The
12 physiological parameters are as follows:
l temperature
l mean arterial pressure
l heart rate
l respiratory rate
l alveolar–arterial gradient (if FiO2 ≥ 0.5) or PaO2 (if FiO2 < 0.5)
l arterial pH (or serum bicarbonate if no arterial blood gas recorded)
l serum sodium
l serum potassium
l serum creatinine (with double weighting for acute renal failure)
l haematocrit (estimated from haemoglobin)
l white blood cell count, and
l GCS score (assumed to be normal for patients sedated or paralysed).
The APACHE II Score comprises the Acute Physiology score plus additional weightings for age and severe
comorbidities in the past medical history to give a total score ranging from 0 to 71. Severe comorbidities
must have been present and documented in the past medical history within the 6 months prior to
presentation at hospital and are defined as follows:
l Severe liver condition – presence of portal hypertension, biopsy-proven cirrhosis or
hepatic encephalopathy.
l Severe cardiovascular condition – presence of fatigue, claudication, dyspnoea or angina at rest
(New York Heart Association Functional Class IV).
l Severe respiratory condition – presence of permanent shortness of breath with light activity as a result
of pulmonary disease, or on home ventilation.
l Severe renal condition – receiving chronic renal replacement therapy (haemodialysis, haemofiltration or
peritoneal dialysis) for irreversible end-stage renal disease.
l Immunological condition – receiving chemotherapy, radiotherapy or daily high-dose steroid treatment
(0.3 mg/kg, or greater, prednisolone or equivalent) for 6 months, or diagnosis of human
immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), lymphoma, acute or chronic
myelogenous/lymphocytic leukaemia, multiple myeloma or active metastatic disease.
The APACHE II predicted risk of death combines the APACHE II Score with additional weightings
for admission following emergency surgery and for diagnostic categories from the primary reason for
admission to the critical care unit to estimate the predicted risk of death before ultimate discharge from
an acute hospital.
The APACHE II severity of illness scores and predicted risk of mortality were calculated from raw data using
standardised computer algorithms. Severity of illness scores were based on the most extreme (highest
or lowest) values of physiological parameters recorded during the first 24 hours following admission to the
critical care unit. Coefficients for the APACHE II risk prediction model were taken from the most recent
(2013) UK recalibration of the model, based on 242,450 admissions to 207 UK ICUs participating in the
Case Mix Programme between 1 January 2011 and 31 December 2012.
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Intensive Care National Audit & Research Centre model
The ICNARC Physiology Score consists of objectively defined weightings for 12 physiological parameters
to give a total score ranging from 0 to 100, with higher scores indicating greater severity of illness.35
The 12 physiological parameters are as follows:
l heart rate
l systolic blood pressure
l temperature
l respiratory rate
l PaO2/FiO2 ratio (weighted differently, depending on whether the patient was ventilated at any time
during the first 24 hours in the unit, or the entire stay if < 24 hours)
l arterial pH
l serum urea
l serum creatinine
l serum sodium
l urine output
l white blood cell count, and
l GCS score (plus additional weightings for patients sedated or paralysed and sedated for the whole of
the first 24 hours in the unit, or the entire stay if < 24 hours).
The ICNARC model predicted risk of death combines the ICNARC Physiology Score with additional
weightings for age, cardiopulmonary resuscitation within 24 hours prior to admission to the critical care
unit, location prior to admission to the critical care unit, urgency of surgery (for admissions from theatre),
primary reason for admission to the critical care unit, and interactions between the Physiology Score and
primary reason for admission to estimate the predicted risk of death before ultimate discharge from an
acute hospital.
The ICNARC Physiology Score and predicted risk of mortality were calculated from raw data using
standardised computer algorithms. The Physiology Score was based on the most extreme (highest or
lowest) values of physiological parameters recorded during the first 24 hours following admission to the
critical care unit. Coefficients for the ICNARC risk prediction model were taken from the most recent
(2013) UK recalibration of the model based on 242,450 admissions to 207 UK ICUs participating in the
Case Mix Programme between 1 January 2011 and 31 December 2012.
Sequential Organ Failure Assessment
The SOFA score consists of weightings for six organ systems to give a total score ranging from 0 to 24,
with higher scores indicating a greater degree of organ failure.33 The organ failure assessments are
as follows:
l respiratory dysfunction, based on lowest PaO2/FiO2
l cardiovascular dysfunction, based on vasopressor use and lowest mean arterial pressure
l renal dysfunction, based on highest creatinine
l neurological dysfunction, based on lowest (or last pre-sedation) GCS score
l hepatic dysfunction, based on highest bilirubin, and
l coagulation dysfunction, based on lowest platelet count.
The SOFA score was calculated from raw physiology and treatment data from the 24 hours prior
to randomisation.
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
Appendix 4 Critical Care Minimum Dataset
Definitions
Duration of organ support in the critical care unit was defined as the number of days alive and free from
support of each of the following organ systems, as defined by the UK Department of Health CCMDS
during the first 30 days following randomisation.36 Patients who died within the first 30 days were
assigned zero days alive and free from organ support. Organ support definitions were as follows:
l Advanced respiratory – indicated by one or more of invasive mechanical ventilatory support through a
translaryngeal tube or tracheostomy; bilevel positive airway pressure through a translaryngeal tube or
tracheostomy; continuous positive airway pressure through a translaryngeal tube; or extracorporeal
respiratory support.
l Advanced cardiovascular – indicated by one or more of receipt of multiple intravenous and/or rhythm
controlling drugs (of which at least one must be vasoactive) when used simultaneously to support or
control arterial pressure, cardiac output or organ/tissue perfusion; continuous observation of cardiac
output and derived indices; an intra-aortic balloon pump or other assist device; or temporary
cardiac pacemaker.
l Renal – indicated by receipt of acute renal replacement therapy (e.g. haemodialysis, hemofiltration,
etc.); or receipt of renal replacement therapy for chronic renal failure when other acute organ support
is received.
l Neurological – indicated by one or more of central nervous system depression that was sufficient to
prejudice the airway and protective reflexes (except when caused by sedation prescribed to facilitate
mechanical ventilation or by poisoning, e.g. deliberate or accidental self-administered overdose,
alcohol, drugs, etc.); receipt of invasive neurological monitoring or treatment (e.g. intracranial pressure
monitoring, jugular bulb sampling, external ventricular drain, etc.); receipt of continuous intravenous
medication to control seizures and/or for continuous cerebral monitoring; or receipt of therapeutic
hypothermia using cooling protocols or devices.
l Gastrointestinal – indicated by receipt of PN or EN (i.e. any method of feeding other than normal
oral intake).
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Appendix 5 Patient follow-up cover letter
 
<TITLE FIRSTNAME SURNAME> 
<ADDRESS 1> 
<ADDRESS 2> 
<ADDRESS 3> 
<POSTCODE> 
DATE 
 
 
Dear <TITLE> <SURNAME> 
 
Re: CALORIES: a study evaluating the clinical and cost-effectiveness of early nutritional 
support in critically ill patients via the parenteral versus the enteral route 
 
When you were treated at <NAME OF HOSPITAL> in <MONTH, YEAR>, you may remember that 
you agreed to take part in a research study called CALORIES, which is comparing two different 
methods of feeding patients.  A Patient Newsletter is enclosed which contains further information 
about CALORIES. 
 
As part of the study, we are contacting patients <THREE MONTHS/ONE YEAR> after they were 
admitted to hospital to find out about their general health and well-being.  We would be very grateful 
if you would complete the enclosed questionnaire – this should only take about 15 minutes of your 
time.  A stamped, self-addressed envelope is provided for ease of return. 
 
 
 
 
 
 
 
 
The CALORIES Study, coordinated by the Intensive Care National Audit & Research Centre 
(ICNARC), is being conducted in 28 NHS hospitals and general information about the trial is 
available at the following website: www.icnarc.org.  If you have any questions, or would like help 
completing the questionnaire, please contact the CALORIES Team at ICNARC (contact details 
above). 
 
Thank you very much for your time.  If you do not wish to fill in the questionnaire, please tick the 
relevant box on the questionnaire and return to us in the stamped self-addressed envelope 
provided. 
 
Yours sincerely 
 
Chief Investigator, CALORIES 
 
Encs: 
 
Version 2.1 23/10/2013  Patient Trial number: <NUMBER> 
 
If you are the carer for the person to whom this letter is addressed and they are unable to 
read it, we would be very grateful if you could take the time to read this letter and the Patient 
Information Sheet on their behalf.  If you feel that they would like to participate, please complete 
the questionnaire either with them or on their behalf. By better understanding the recovery of the 
person you care for, we hope to improve the care of future patients admitted to critical care units. 
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Appendix 6 Patient follow-up questionnaire
 
Trial Number: «Patient_trial_ID» 
 
 
CALORIES: a multicentre, randomised controlled trial comparing the clinical and cost-effectiveness of 
early nutritional support in critically ill patients via the parenteral versus the enteral route 
 
 
 
We would be grateful if you would complete this questionnaire. The CALORIES trial aims to improve 
the care of critically ill patients. 
 
A pen is provided and a FREEPOST envelope for return of the questionnaire. Please answer multiple 
choice questions by putting a    in ONE BOX for each question. 
 
Please complete today’s date below: 
 
 /  /  
Day  Month  Year 
 
Please also let us know whether you completed this questionnaire: 
 
 Alone 
 With help 
 Or it was completed by someone who cares for you 
 
 
NOW PLEASE TURN THE PAGE TO START THE QUESTIONNAIRE     
  
If you do not wish to complete this questionnaire, please tick the box and return the unanswered 
questionnaire in the stamped self-addressed envelope provided.  
 
I do not wish to complete this questionnaire             
 
Your current and future care will not be affected whether you decide to, or not to, fill in this 
questionnaire. 
 
 
Health Questionnaire, Version 2.0, 21/11/11 
HEALTH QUESTIONNAIRE 
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We would like to understand how your health is since you left the critical care unit.  
There are no right or wrong answers. We have found that the best way to answer the questions is to 
go with your first instinct, whatever you think is the correct response for you.  
 
Under each heading, please tick the ONE box that best describes your health TODAY  
 
MOBILITY 
I have no problems in walking about       
I have slight problems in walking about       
I have moderate problems in walking about      
I have severe problems in walking about      
I am unable to walk about         
 
SELF-CARE 
I have no problems washing or dressing myself     
I have slight problems washing or dressing myself     
I have moderate problems washing or dressing myself    
I have severe problems washing or dressing myself     
I am unable to wash or dress myself       
 
USUAL ACTIVITIES (e.g. work, study, housework,  
family or leisure activities) 
I have no problems doing my usual activities      
I have slight problems doing my usual activities     
I have moderate problems doing my usual activities     
I have severe problems doing my usual activities     
I am unable to do my usual activities       
 
PAIN / DISCOMFORT 
I have no pain or discomfort        
I have slight pain or discomfort        
I have moderate pain or discomfort       
I have severe pain or discomfort        
I have extreme pain or discomfort       
 
ANXIETY / DEPRESSION 
I am not anxious or depressed        
I am slightly anxious or depressed       
I am moderately anxious or depressed       
I am severely anxious or depressed       
I am extremely anxious or depressed       
YOUR HEALTH 
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• We would like to know how good or bad your health is  
TODAY. 
• This scale is numbered from 0 to 100. 
• 100 means the best health you can imagine. 
0 means the worst health you can imagine. 
• Mark an X on the scale to indicate how your health is TODAY.  
• Now, please write the number you marked on the scale in the box 
below.  
                     
 
 
 
YOUR HEALTH TODAY  = 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
0 
20 
30 
40 
50 
60 
80 
70 
90 
100 
5 
15 
25 
35 
45 
55 
75 
65 
85 
95 
The best health     
 you can imagine 
The worst health   
 you can imagine 
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Please think of all the things you do and experience in relation to food and meals (e.g. planning meals, 
shopping, preparing meals, eating meals) and then, using the 1 (disagree) – 7 (agree) scale, indicate 
your agreement with each item below. 
 
 
 
              Please score 1 - 7 
 
Food and meals are positive elements in my life    
 
 
I am generally pleased with my food     
 
 
Food and meals give me satisfaction in daily life    
  
 
My life in relation to food and meals is close to my ideal    
 
 
With regard to food, the conditions of my life are excellent  
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We would be grateful if you would complete this questionnaire. It will help us understand the care you 
needed after leaving hospital.  
 
The questions refer to ALL health services that you have used since leaving the hospital on 
<Discharge date>, and before <Three months/one year>. 
 
 
 
 
A Since you left hospital on <Discharge date> have you stayed overnight in hospital for any 
reason? 
      No  - Go to Part 2 
      Yes - Please give details about the number of stays below 
 
B For EACH TIME you stayed in hospital please answer the following 
     
 
Number of 
nights 
 
1-3 
nights 
4-10 
nights 
11 or more 
nights 
Did you spend any part of 
your stay in critical care? 
1st Stay  or      
2nd Stay  or      
3rd Stay  or      
4th Stay*  or      
 
*If you have stayed in hospital overnight more than 4 times, please could you provide information on 
these further hospital stays in Part 6 of the questionnaire. 
Part 1. Hospital Stay 
HEALTH SERVICES 
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Outpatient visits are when a patient comes to the hospital to see a specialist (e.g. consultant) but 
does not stay overnight. 
 
A Since you left hospital on <Discharge date> have you visited hospital outpatients about 
ANY ASPECT of your health? 
      No  - Go to Part 3 
      Yes - Please give details about the number of outpatients visit(s) below 
 
B 
 
Number of  
visits 
 1-3 
visits 
4-10 
visits 
11 or more 
visits 
 
 
or     
  
 
 
 
 
 
A Since you left hospital on <Discharge date> have you visited any of the health care 
providers listed below? 
      No  - Go to Part 4 
      Yes - Please give details about your visits below 
 
B For EACH PROVIDER please answer the following 
     
Did you visit this provider? 
Number of 
visits 
 
1-3 
visits 
4-10 
visits 
11 or more  
visits 
GP   or     
Nurse at your 
GP clinic 
  or     
Nurse at hospital 
or elsewhere 
  or     
Health visitor   or     
Part 2.  Hospital outpatient visits 
Part 3. Visits to health care providers   
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A Since you left hospital on <Discharge date> have you had home visits from any the 
following health care providers about ANY ASPECT of your health? 
      No  - Go to Part 5 
      Yes - Please give details about your visits below 
B For EACH HOME VISIT please answer the following 
 
Were you visited at home  
by this provider? 
Number of 
visits 
 
1-3 
visits 
4-10 
visits 
11 or more  
visits 
GP   or     
Nurse from your 
GP clinic   or     
Occupational 
Therapist   or     
Health visitor or 
District nurse   or     
 
 
 
 
A Since you left hospital on <Discharge date> please indicate whether you have had contact 
(either visits to the provider or home visits) with any of the following service providers about 
any aspect of your health? 
      No  - Go to Part 6 
      Yes - Please give details below 
 
B For EACH PROVIDER please answer the following 
 
Have you had contact with any of 
these providers? 
Number of 
visits 
 
1-3 
visits 
4-10 
visits 
11 or more  
visits 
Occupational therapist  
 
or     
Psychologist  
 
or     
Speech and Language 
therapist 
 
 
or     
Physiotherapist  
 
or     
Dietician  
 
or     
Part 4.  Visits to your home by health care providers 
Part 5. Visits to other service providers 
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A Since you left hospital on <Discharge date> have you had further hospital stays or used 
ANY OTHER health care services for any aspect of your health that you haven’t included 
above? 
      No  - Go to Part 7 
      Yes - Please give details below 
 
B For EACH PROVIDER please answer the following 
 
Type of service provider Number of visits Reason 
   
   
   
   
Part 6. Other services not listed so far 
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Your views are important to us.  Please feel free to provide any other comments you 
have in the box below. 
 
 
 
Thank you for help 
 
If you would like to ask us any questions about completing the questionnaire please 
email or call: 
 
CALORIES Team        
                                                  
  
Part 7.  Comments 
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